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1. Introduction 
Ceramics can be described as “solid compounds that are formed by the application of heat, and 
sometimes heat and pressure, comprising at least one metal and a nonmetallic elemental solid or a 
nonmetal, a combination of at least two nonmetallic elemental solids, or a combination of at least two 
nonmetallic elemental solids and a nonmetal”(1). Ceramics comprised of calcium phosphates, silica, 
alumina, zirconia and titanium dioxide are nowadays used for various medical applications due to their 
positive interactions with human tissues. Examples can be found in the field of dentistry(2) where 
calcium phosphate and calcium hydroxide-based materials are used as endodontic filling materials and 
metal-ceramic alloys are applied for crowns. Also in the field of orthopedics(3-6) (invertebral disks, 
joints) and plastic surgery(7) (cranial defects) ceramics are frequently employed. Characteristics of 
these ceramic materials are often a high mechanical strength, a good body-response and a low or non-
existing biodegradability.  
Due to the slow degradability, for tissue engineering purposes these materials don’t appear to be very 
attractive. However, in the field of bone tissue engineering most scaffolds are ceramic or ceramic-
derivatives. Especially hydroxyapatite-based calcium phosphate compounds(8,9) and bioactive glass(10) 
are regarded as high-potential scaffolds due to their osteoconductive properties. To improve the 
biodegradability of these implants, porosity is introduced(11) which also gives rise to bone ingrowth, 
though pore sizes must be large enough. This porosity is sometimes also called macroporosity while 
the ceramic implants can have a micro or nanoporosity of their own. A parameter that is important 
here for tissue engineered bone constructs is the so-called “interconnectivity” of the pores. It implies 
that the pores introduced into these scaffolds overlap each other, and instead of separate cavities, lanes 
of interconnected pores are generated. Figure 1 gives an overview of typical ceramic 3D-structures.  
Next to the scaffold material, in bone tissue engineering cells and growth factors are also introduced to 
speed-up tissue ingrowth. In most ceramic scaffolds, however, difficulties arise when cells are added, 
most probably due to a limited supply of nutrition at the inside of the implant or less than optimal cell-
cell interactions.  
Growth factors like bone morphogenic protein-2 (BMP-2), transforming growth factor (TGF-β), basic 
fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are commonly 
introduced into these scaffolds due to their osteoinductive properties and vascularization(12-14). Though 
ceramics like hydroxyapatite are known for their positive interaction with bone morphogenic proteins 
(BMP’s), high amounts of these growth-factors are added in in vivo studies to guarantee a positive 
tissue response. A reason for this phenomenon is that ceramics can bind strongly to the growth-
factors/proteins, or give a release pattern that is less than optimal. This increases the clinical relevant 
amount high above normal values inside the human body and increases the cost of a single implant 
substantially, therefore decreasing a possible use of the material. Alternatives for the use of growth 
factors are for example the use of ceramics with osteoinductive properties, as described for biphasic 
_________________________________________________________________________General introduction 
 11
calcium phosphate (BCP)(15), a composite of hydroxyapatite (HA) and β-tricalcium phosphate (β-
TCP).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Ceramic 3d-structures; A = non-porous, B = microporous, C = macroporous (spherical), D = 
macroporous (spherical) + micropores, E = macroporous (3d-printing), F = macroporous (3d-printing) + 
micropores 
 
Another possibility is the use of other materials like (bio)polymers that are physically or chemically 
mixed with a ceramic compound. Examples of polymers that are commonly used in combination with 
ceramics are the polylactic acid-based polymers(16) and biopolymers like chitosan(17) and collagen(18). 
Nowadays, these composite materials of organic/inorganic origin are studied extensively because they 
can combine the tailored degradability and high release efficiencies of the polymer with the 
osteoconductivity and delayed/sustained release characteristics of the ceramic material. Next to that, 
also mechanical and physical properties of the polymer can compromise the brittleness of the ceramic 
material or give better handling properties to calcium phosphate (CaP) cement.  
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Overall, the characteristics of an ideal ceramic composite for bone tissue engineering should comply to 
the following parameters: 
1. A biodegradability that is  enabling bone remodeling 
2. A macroporosity that enables cell ingrowth into the composite 
3. Mechanical stability/ease of handling 
4. Osteoconductivity to guide bone around/inside the implant 
5. Carrier for growth factors/cells 
 
In the next paragraphs, ceramics and ceramic/organic composites are summarized that are studied in 
the last decades and their use for bone tissue engineering and drug release will be discussed according 
to the ideal scaffold characteristics. 
 
2. Ceramic composites 
As mentioned in the introduction, ceramic composites are nowadays commonly used in a wide variety 
of medical applications. In this section, ceramic composites without the addition of organic 
components are reviewed. An overview of some commercially available ceramics, cements and 
bioactive glass is given in Table 1. An index of abbreviations of CaP-compounds with corresponding 
chemical formula and Ca/P-ratio is given in Table 2. 
 
2.1. Calcium phosphate ceramics 
Due to their similarity to human bone, calcium phosphate ceramics were and still are very popular 
implant materials for diverse clinical applications since the last 30 years. Different types of CaP-
ceramics are available, though they can be classified as either hydroxyapatite (HA), beta-tricalcium 
phosphate (β-TCP), biphasic calcium phosphate (BCP), amorphous calcium phosphate (ACP), 
carbonated apatite (CA) or calcium deficient HA (CDHA).  
The use of these materials for tissue engineering purposes is still explored. Most researchers are aware 
that the low resorbability of sintered CaP-ceramics, and in particular HA or CA forms a problem. The 
use of highly porous implants induces bone formation inside the implant and increases degradation. 
Complete resorption in most cases is very difficult due to the crystalline architecture. Porosity in these 
ceramics can be introduced by different techniques where in most cases a structure of interconnected 
(spherical) pores is produced. This can be accomplished by leaching and sintering out of salt crystals 
or polymeric microparticles/mold after which the ceramic remains. Mastrogiacomo et al.(19) for 
example used a cellulose matrix to serve as mold for a HA-paste, after which the cellulose was 
removed by pyrolysis and after sintering an open porous HA matrix remained. A similar technique is 
based on rapid prototyping(20). Here, a HA scaffold with controllable shape/size and porosity is 
produced after casting the calcium phosphate onto a negative mold, produced by rapid prototyping, 
and burning out the mold.  
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Table 1. Commercially available ceramics, cements and bioactive glass 
Ceramic/ 
cement 
Consistancy Endproduct Setting time Com.Strength 
(MPa) 
Porosity 
Biosorb β-TCP Granules  
Ca/P = 1.49-1.51 
- 15-150 MPa 5-45% 
macro+micro 
Calcibon Calcium deficient CA granules - 4-7 MPa micro+macro 
Ceraform 65% HA 
35% TCP 
granules - 50MPa <10% 
Chronos  β-TCP granules - 7.5 MPa 60-80% 
macro 
Endobon Bovine HA granules - 2.5-16 MPa high 
Interpore HA (coral) granules - high 35% 
Pro-Osteon HA (coral) granules - 2-4 Mpa 65% 
Triosite 60% HA 
40% β-TCP 
granules,  
Ca/P = 1.6 
- >10 MPa 70% 
macro+micro 
Vitoss β-TCP granules - low 88-92% macro 
Biobon  
(α-BSM) 
ACP 
DCPD 
Poorly cristalline 
HA, Ca/P = 1.45 
15-20min  
(37°C) 
12 MPa 50-60% 
micro 
Biopex 75% α-TCP 
18% TTCP 
5% DCPD 
2% HA 
HA 8min ± 80MPa micro 
Bone Source TTCP 
DCPD 
HA, Ca/P =1.67 10-15 min 
(37°C) 
36 MPa micro 
Calcibon 61% α-TCP 
26% DCPA 
10% CaCO3 
3% pHA 
Calcium deficient 
CA 
Ca/P = 1.53 
2-4min  
(37°C) 
60-70MPa 44% 
micro 
Cementek α-TCP 
TTCP 
Ca(OH)2 
HA, Ca/P = 1.64 40 min 20MPa 50% 
micro 
Chronos 
inject 
42% β-TCP 
21% MCPM 
31% β-TCP granules 
5% MgHPO4*3H2O 
Brushite (DCPD) 12 min 3 MPa micro 
Mimix α-TCP 
TTCP 
citric acid 
HA 2-4 min 
(37°C) 
22 MPa micro 
Norian-SRS MCPM 
α-TCP 
CaCO3 
Dahlite (CA) 
Ca/P = 1.67 
 
12 hr 28-55 MPa very low 
Bioglass 
45S5 
45% SiO2 
24.5% Na2O 
24.5% CaO 
6% P2O5 
Different 
shapes/films 
- - low 
 
Also surfactant (foaming methods) can be used to produce spherical porosity inside the CaP-ceramic. 
Almiral et al.(21) used H2O2 as a foaming agent. In this study O2-gas was produced by reaction of the 
hydrogen peroxide, which formed the foam and porosity inside the ceramic. Some ceramics are nature 
derived and have a distinct porous structure of their own, like the coralline hydroxyapatite derived 
ceramics (Interpore®, Pro-Osteon®) and the bovine derived ceramics (Endobon®). These materials are 
very similar in structure as human bone; however, a drawback of these commercially available 
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ceramics is that the porosity/mechanical strength has a fixed shape and value and therefore cannot be 
tailored for a specific purpose. 
Next to the macroporosity that enables cell ingrowth, in some cases the CaP-ceramic also has a 
micro/nanoporosity. Because of the limited pore size, this porosity seems not of interest for tissue 
engineering, however, the microporosity improves fluid flow though the ceramic, thereby providing 
nutrition for cells inside the scaffold. 
 
Table 2. Abbreviations of CaP-compounds with corresponding chemical formula and Ca/P-ratio 
Abbreviation Name Formula Ca/P-ratio 
ACP Amorphous calcium phosphate - 1.25<x<1.55 
BCP Biphasic calcium phosphate Ca3(PO4)2 + Ca10(PO4)6(OH)2 1.50<x<1.67 
CA Carbonated apatite, dahlite Ca5(PO4,CO3)3 1.67 
CDHA Calcium deficient hydroxyapatite Ca10-x(HPO4)x(PO4)6-x(OH)2-x 1.50<x<1.67 
DCPA Dicalcium phosphate anhydrous, Monetite CaHPO4 1.00 
DCPD Dicalcium phosphate dihydrate, Brushite CaHPO4*2H2O 1.00 
HA Hydroxyapatite Ca10(PO4)6(OH)2 1.67 
MCPM Monocalcium phosphate monohydrate Ca(H2PO4)2*H2O 0.50 
OCP Octacalcium phosphate Ca8H2(PO4)6*5H2O 1.33 
pHA Precipitated hydroxyapatite Ca10-x(HPO4)x(PO4)6-x(OH)2-x 1.50<x<1.67 
α-TCP α-Tricalcium phosphate, Whitlockite α-Ca3(PO4)2 1.50 
β-TCP β-Tricalcium phosphate, Whitlockite β-Ca3(PO4)2 1.50 
TTCP Tetracalcium phosphate, Hilgenstockite CaO*Ca3(PO4)2 2.00 
 
Because of the positive influence of ceramics on cell differentiation/proliferation, it is not surprising 
that bone forming cells are often introduced into these ceramics to speed-up tissue ingrowth. The 
surface of sintered ceramics is chemically stable and therefore a good substrate for seeding cells. 
Adding cells to tissue engineered scaffolds is often called a necessity, conversely, even inside the 
100% interconnected macroporous scaffolds there is high cell morbidity and cell survival is restricted 
to the surface layer. Kruyt et al.(22) applied a multiple-condition model consisting of polyacetal 
cassettes in which different CaP-ceramics were placed consisting of BCP, β-TCP and HA. In these 
scaffolds bone marrow stromal cells (BMSC’s) were loaded and the effect on bone ingrowth was 
investigated. The effect of added BMSC’s was visible especially with BCP and β-TCP, which overall 
exhibited better bone ingrowth than HA. Furthermore, the BMSC’s showed a more pronounced effect 
in an ectopic site when compared to a bony environment, which was explained by a better 
vascularization and therefore lower cell morbidity at the ectopic site.  
Adding osteo-inductive growth factors/drugs to CaP ceramics is very convenient. Due to the high 
affinity of the ceramics for drugs/proteins, one can load these scaffolds just by absorption of a growth-
factor containing fluid onto the ceramic. As discussed earlier, the high affinity of CaP ceramics for 
proteins/growth factors can also result in retention of a high percentage of this material. The release 
pattern of most loaded ceramics seems to consist of an initial burst release (elution of not bound 
protein) followed by a specific release dependent on material/drug. Stallman et al.(23) added 
gentamycin to different calcium phosphate granules and observed a similar release pattern for all 
_________________________________________________________________________General introduction 
 15
granules with only a very low sustained release. Release efficiencies reached to 30-62% after 17 days, 
indicating that the ceramic retained a substantial amount of the gentamycin. Guicheux et al.(24) added 
5µg of human growth hormone onto a macroporous BCP ceramic and observed a rapid release within 
the first 48h, followed by a slow sustained release exponentially decreasing until day 11. Though this 
was a less than optimal release pattern, 100% of the human growth hormone was released and showed 
structural integrity and biological activity. To achieve a more sustained release, Kimakhe et al.(25) 
applied dynamic compaction to a CDHA scaffold loaded with polymyxin B. The release pattern 
observed was indeed more sustained following Higushi’s law(13); however, the dynamic compaction 
decreased the biological activity of the drug. 
Degradation of growth factors in time also can occur as Ziegler et al.(26) observed with rxBMP-4, rh-
bFGF and rhVEGF loaded α-TCP ceramics, neutralized glass ceramics, a glass ceramic/PLGA 
composite and dehydrated human bone. Here, different release curves and efficiencies were obtained 
depending on the type of growth factor and comparing the ceramics. Looking at the materials, 
dehydrated human bone showed the weakest loading capacity, releasing 70-95% of the loaded drug 
within three days. A comparison between the growth factors showed a looser binding of VEGF to the 
α-TCP ceramic, and an upregulation of BMP-4 after 3 days with all synthetic scaffolds.  Surprising 
was that within most groups molecular weight of the growth factor decreased dramatically after 3-5 
days in release medium, especially with BMP-4 and bFGF. This result indicates that degradation of 
protein structures can occur when incorporated inside ceramics/release media for a longer period. The 
upregulation of BMP-4 after 3 days therefore was also discussed to be the result of degradation. 
Bioactivity of the released fractions was not recorded, though it would be interesting to see if these 
degraded protein structures still have a bioactivity.  
Next to the introduction of growth factors, another possibility is to use a scaffold that has an 
osteoinductive potential of itself. Research by many authors show that calcium phosphate materials, 
especially biphasic calcium phosphate (BCP) and HA have some osteoinductivy of themselves when 
implanted in muscle tissue(15,27). About the process of osteoinductivity there is still a lot of speculation, 
though the presence of macro and microporosity seems to be essential(28). Whether ceramics alone can 
induce enough bone to make growth factors/cells obsolete is debatable, though it would make the final 
application much easier in use and lower in cost. 
 
2.2. Calcium phosphate cements 
Next to calcium phosphate ceramics, calcium phosphate cements are of interest for bone tissue 
engineering purposes. Calcium phosphate cements consist of a powder phase of calcium and/or 
phosphate salts that together with an aqueous phase react at room/body temperature and form a 
calcium phosphate precipitate that sets by the entanglement of crystals. Due to the low processing 
temperature, they don’t comply with the original definition of ceramics, though the powder phase 
contains sintered CaP-material (α-TCP, HA). The main difference between cements when compared to 
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ceramics is the injectability and in-situ hardening of the cement which makes it a material that is easy 
to handle from a clinical point of view(29, 30). A ceramic has to be shaped to the defect site during 
operation which makes it very labor intensive, and often a less than optimal tissue-to-implant contact 
is obtained. Since CaP-cements were invented by Chow et al.(31), a lot of different formulations have 
been investigated with variable success. In general there are two types of CaP cement: apatite cements 
that set into HA, CA or CDHA and brushite cements that have DCPD (brushite) as end product. 
Without going too far into the literature about the two cement types one can say that microporous 
apatite cement is slow degrading and has a good mechanical stability. Brushite cement overall has a 
lower mechanical strength but a faster biodegradability than the apatite cement. Both types of cement 
can be applied for tissue engineering purposes. Comparable to CaP-ceramics, introduction of 
macroporosity into the material is a necessity. Unlike most sintered CaP-ceramics, CaP-cements also 
have a high nano/sub-micron-sized porosity. This porosity enables fluid flow inside the composite; 
however, it is too small for tissue ingrowth. Macroporosity can be introduced using different methods, 
rendering a highly porous system. Examples are the use of water-soluble crystals that after injection 
just dissolve, or degradable polymer microspheres that will be discussed in a following chapter. Xu et 
al.(32) used mannitol crystals that were mixed with the CaP cement powder, after which the set cement 
was immersed in water. These particles generate macroporosity but should be present in a high 
percentage to assure interconnectivity. Another method is to introduce a foaming agent inside the 
material that generates gas-bubbles in the cement. Del Real et al.(33, 34) used sodium bicarbonate to 
generate these bubbles inside an apatite cement. The pores that were formed were irregularly shaped 
and quite large. As a consequence, compressive strength decreased to very low values when compared 
to the original cement. In vivo resorption was significantly accelerated, though the cement was not 
injectable anymore. Recently, Ginebra et al.(35) developed an injectable macroporous CaP-cement with 
the use of albumin as porogen. These cements have a more regular and interconnected macroporosity 
and still retain or even increase their injectability. Due to the smaller pore size generated, the 
compressive strength is slightly higher than the cement produced by the gas bubble method. 
Adding cells to cement scaffolds is difficult due to the chemically unstable environment and the 
mixing process. Link et al.(36) observed that a commercially available apatite cement (Calcibon®) 
showed in vitro cytotoxicity though in vivo an excellent biocompatibility is observed. The cytotoxic 
reaction here is caused by dissolution of one of the cement components that releases acidic products. 
In in vivo studies, the cement experiences a more dynamical flow that neutralizes the acid.  
Growth factors/drugs can be added to the cement just by adding the growth factor/drug to the liquid 
hardener, thereby distributing it equally through the cement. As the setting process can be influenced 
by the addition of proteins to the liquid phase, the addition of high amounts delays cement setting and 
therefore forms difficulties for clinical use. Growth factors like BMP-2/TGF-beta that are commonly 
used for tissue engineering purposes are only added in small amounts, and therefore the influence of 
these growth-factors on cement setting can be regarded as insignificant. Carrier proteins, like bovine 
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serum albumin (BSA), are present in much larger amounts and therefore have a higher ability to 
influence the setting reaction. On the other hand, Blom et al.(37) added rhTGF-β in BSA carrier 
solution (2 mg/ml) to an apatite-based cement, but observed no increase in setting time. The addition 
of albumin to cement even can be beneficial for release properties. A study of Ruhé et al.(38) showed a 
higher in vitro release of rhBMP-2 out of an albumin containing macroporous scaffold, though in vivo 
no difference was observed. The albumin here serves as a buffer between the cement and the growth 
factor, providing a weaker bond.  
Release characteristics from calcium phosphate cement are well-studied and in many cases consist of a 
cement dissolution initial stage (during cement setting), followed by a diffusion-dependent release that 
is influenced by material characteristics(13). When compared to ceramics, the occurrence of a high burst 
release is very rare, mostly due to the different administration of the drug. Release of drug due to the 
(in vivo) resorption of the material is much more complicated though has be to taken into account with 
high resorbable porous or brushite cements. Also the type of drug influences the release rates when 
these drugs are incorporated inside the cement. Stallman et al.(23, 39) determined the release properties 
of gentamycin and human lactoferrin 1-11 (hLF1-11) from different commercially available 
microporous CaP cements in different studies but under similar conditions. The release of gentamycin 
after 7 days was between 36-85%, while with hLF-11 the total release only reached to 1.9-33.8%, 
indicating a much higher retention. The high spread in release percentage here is caused by the 
difference in cement type which was divided into low and high retention cements. Next to that, the 
release curves of hLF-11 almost showed no initial burst release, while with the gentamycin loaded 
cements this occurred in most of the formulations. A concentration dependency on the drug release % 
is also possible, though the protein absorbing ability of CaP-cements is very high and release patterns 
in most cases look similar.  In vivo studies using TGF-β and BMP-2 inside macroporous/microporous 
scaffolds show positive bone response on the introduction of these growth factors, proving that the 
released material is still active(12, 14, 40-43). Seeherman et al.(40) observed accelerated healing in a 
nonhuman primate fibular osteotomy model using a single percutaneous injection of rhBMP-2 in 
macroporous CaP-cement. For this model a concentration of 1.5 mg/ml (0.75 µg/injection) was 
optimal which was fully released within 6 weeks. Also Ruhé et al.(41, 42) observed increased bone 
healing and osteoinductive properties of rhBMP-2 loaded macroporous CaP-cement scaffolds when 
implanted in cranial defects and at ectopic sites in rabbits. The amount of growth factor used here was 
10µg/implant, where in vivo release studies show a 60% release of rhBMP-2 after 4 weeks(38). Blom et 
al.(43) used TGF-β-loaded microporous CaP-cement to fill bone defects in the skull of rats. They 
applied 10 or 20 ng TGF-β to the cement and observed an increase in bone healing when compared to 
the non-loaded scaffolds, although the effect was minimal. Because of the high costs of the growth-
factor and looking at the wide range of amounts of growth factor applied in in vivo research, it is 
important to use as little as possible regarding the final application. Drug release efficiencies therefore 
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should be optimized, though they are strongly dependent on the type of growth factor / carrier and 
implant site.   
 
2.3. Bioactive glass 
Bioactive glass is the name of a range of glass compositions that have the ability to bind to bone and 
other tissues as was discovered by Hench in 1969(44). It is produced like conventional glass in which 
the basic components are SiO2, Na2O, CaO and P2O5, and is commercially available as Bioglass®. 
More recently, bioactive glasses are also made using the sol-gel route which results in finer porous 
structures with a higher bioactivity than the conventional glasses with the same composition(45). Each 
component has its own contribution to the bioactivity of the bioactive glass, but CaO or Na2O can be 
substituted without significantly affecting bone bonding. Even P2O5-free glasses are bioactive, where it 
was first assumed that this was a required component. The bone bonding ability is based on the 
chemical reactivity of the bioactive glass in which silicon bonds are broken and finally a CaP-rich 
layer is deposited on top of the glass which crystallizes to hydroxycarbonate apatite (HCA). 
Mechanical properties of bioactive glass are not optimal, and therefore other ceramic components are 
sometimes added to the bioactive glass for reinforcement. These materials are also referred to as glass-
ceramic composites(46, 47). 
For tissue engineering purposes, next to the bioactivity, the bioactive glass should be degradable and 
porous. The methods for preparing porous bioactive glass are similar to porous CaP ceramics. Yuan et 
al.(48) used a H2O2-foaming method to obtain a macroporous bioactive glass with pore sizes ranging 
from 100-600µm. Chen et al.(49) was able to prepare a 86-93% porous bioactive glass by use of a 
polyurethane template which was immersed in a glass slurry. The glass adhered to the polymer, excess 
was removed, and the polymer was burned out after which the scaffold was sintered. Kaufmann et 
al.(50) used PEG-glycol particles of different sizes and amounts to retrieve a porous bioactive glass 
substrate after sintering. Degradability of bioactive glass is mainly a dissolution based procedure. 
Dissolution rates can be influenced by the particle size, glass type and type of medium(51, 52). However, 
overall the biodegradation of these materials is very low.  
Drug loading of bioactive glasses is possible using the sol-gel method. Santos et al.(53) added trypsin 
inhibitor to the bioactive glass by absorbing it to the sols in a protein content of 0.6, 1.6 and 3.3% by 
weight. To measure the release of the trypsin inhibitor, samples were crushed into granules and release 
was measured in buffer solution. The cumulative release after 4 weeks was 21.2-43.4%. The release 
pattern was characterized by an initial stage of slow release, followed by a second stage in which the 
release had a linear relationship against the square root of time. Domingues et al.(54) introduced 
tetracycline and tetracyline/β-cyclodextrin into a bioactive glass and observed an initial burst of 12%, 
followed by a sustained release over 80 days and a total release of 22-25%. Also, growth factors were 
added to a neutralized bioactive glass ceramic(26). Here an initial release of 10% was seen, followed by 
a delayed boost between day 3 and 8, depending on the type of growth factor. Efficiencies of 80% 
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were obtained, though only the growth factor released during the initial burst showed structural 
stability. 
 
3. Ceramic/polymer composites 
Next to the studies in which the tissue engineered scaffold only exists of the ceramic material, 
nowadays there is a lot of research ongoing on so-called ceramic/polymer scaffolds. From the previous 
three paragraphs it can be concluded that ceramic scaffolds alone can be a suitable implant material for 
bone tissue engineering while macro/microporosity can be introduced, they can form a suitable 
scaffold for cells and serve as a delivery vehicle of osteoinductive drugs. On the other hand there are 
some problems that are very difficult to solve with the ceramic scaffold alone, like poor degradability 
of the material and mechanical properties, i.e. tensile strength and brittleness. The addition of 
biodegradable polymers can improve the degradability of the ceramics/cements and alter their 
mechanical/ physical properties. Also, drug release profiles can be altered because there is a wide 
range of different polymers that can be selected, which show different degradation rates and 
mechanisms. In the next paragraphs especially two types of ceramic/polymer composites are reviewed: 
cement with added polymers and ceramic particles into a (porous) polymer carrier. An overview of the 
various polymers discussed in this section is given in Table 3. 
 
Table 3. Summary of polymers used in combination with ceramics, categorized in groups 
Group Polymers 
Polylactic/polyglycolic acid polylactid acid (PLA, PLLA, PDLLA), polyglycolic acid (PGA), 
poly(lactic-co-glycolic acid) (PLGA), poly-ε-caprolactone (PCL) 
Proteins collagen, gelatin, fibrin, casein, peptides 
Carbohydrates chitin, chitosan, cellulose, starch, alginate, hyaluronan, 
hydroxymethylpropylcellulose (HPMC), amylopectin 
Other polymers poly(propylene fumarate) (PPF), polycarbonate, polyalkanoates, poly(1,8-
octanediol-citrate) (POC), poly(ethylene glycol) (PEG), poly (ethylene imine) 
(PEI), poly(ethylene oxide) PEO, prolypropylene (PP), nylon, aramide, 
poly(allylamine hydrochloride) (PAH) 
 
3.1. Polylactic/polyglycolic acid-based polymer/ceramic composites 
Polylactic/polyglycolic acid derived polymers are well studied and many types have already been 
investigated. Members of this ester-backbone polymer group are polylactic acid (PLA, PLLA), 
polyglycolic acid (PGA), poly-(d/l-lactic-co-glycolic) acid (PLGA) and poly-ε-caprolactone (PCL). 
The polylactic/glycolic acid group is interesting due to its biocompatibility and degradation properties 
that can be tailored by changing different parameters, for example the molecular weight, tacticity and 
L/G-ratio in the case of PLGA. The degradation mechanism is a hydrolysis reaction in which the 
glycolic acid residue degrades faster than the polylactic acid while the cleavage site of PLA is 
sterically hindered. Overall the degradation rate is in the following order: PGA > PLGA > PLA > 
PCL. Because of the tailored degradability, a scaffold can be formulated in which the degradation 
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properties are adapted to the final application. Most polylactic/ceramic scaffolds therefore exploit 
these degradation properties by using the polymer as the scaffold material.  
Ceramic particles are added to the polymer to make it (more) osteoconductive and/or to increase 
mechanical properties. These scaffolds can be either porous or dense of structure using bioactive glass, 
HA, ACP and BCP as ceramic component in a PLLA, PLGA or PCL matrix. For tissue engineering 
purposes, a porous structure is preferred, though dense scaffolds are also frequently investigated. 
Navarro et al.(55) made a glass-ceramic particle/PLA scaffold by homogeneous mixing of the glass-
ceramic into a PLA solution after which H2O-solvable NaCl particles were added to create 
macroporosity in the scaffold. Mechanical properties of the PLA increased after adding up to 40% of 
glass-ceramic particles, still compressive strength was very low. Conversely, Niemela et al.(56) 
observed a decrease in bending strength/modulus as well as shear, compression and torsion strength 
when bioactive glass was added to a poly-L,DL-lactide (70/30) carrier by twin-screw extrusion. 
Despite the unfavorable mechanical properties, bioactive glass increases the bioactivity of the polymer 
carrier, as was observed by Yao et al.(57) where the addition of bioactive glass particles promoted 
osteoblastic differentiation of marrow stromal cells.  
Zhang et al.(58) prepared highly porous composites (85.1-95.6%) of HA and PLLA/PLGA by solid-
liquid phase separation and solvent sublimation of a polymer/HAP mixture in dioxane/water. These 
composites showed reinforcement when compared to pure PLLA. Shikinami et al.(59) even  made 
reinforced dense composites of sintered HA inside a PLLA matrix and obtained mechanical properties 
equivalent/higher than cortical bone. Degradation of these materials, however, is slow, and complete 
resorption will take many years(60).  
A porous composite of PCL with 10/20% CaP particles was investigated by Mondrinos et al.(61). 
Compared to pure PCL, the compressive strength of these porous scaffolds produced by a 3d printing 
method, increased dramatically. Human embryonic palatal mesenchymal cells were added to these 
composites, which showed an increased proliferation in the 20% CaP composites. Next to the usual 
ceramic particles/polymer matrix, other ceramic/polylactic composites have also been formulated(62, 63). 
For example, Ambrioso et al.(63) prepared a macroporous scaffolds by sintering composite CaP/PLGA 
microspheres where the CaP-phase was trapped inside the microspheres.  
The addition of cells to porous polylactic acid-based composites normally does not provide 
difficulties, especially when slow degrading PCL or PLLA is used. Faster degrading polymers, like 
low molecular weight PLGA or PLA, can give a cytotoxic reaction due to the production of acidic 
degradation products. This is not only visible when cells are implanted but also in vivo studies with 
these polymer/ceramic composites without the addition of cells can show a cytotoxic reaction. Ignatius 
et al.(64) observed a strong inflammatory response after 24 months in sheep when composites of PLA 
and α-TCP or a glass ceramic were implanted. This inflammatory response occurred concomitantly 
with a strong reduction of the PLA and mechanical strength. 
_________________________________________________________________________General introduction 
 21
Polylactic/polyglycolic acid-ceramic implants can also be used as scaffolds for drug release where the 
drug can be incorporated into the polymer(65) or absorbed onto the composite(26). Soriano et al.(65) added 
gentamycin to calcium phosphate/PLA blends and release curves showed a burst release followed by a 
slower sustained release, typical for PLA polymers. After coating the implants with PLA, the burst 
release was reduced and a sustained release over a period of 10 weeks was observed. As discussed in 
the ceramics paragraph, growth factors were also added to these composites(26). 
Polylactic/glycolic acid-CaP cement composites can be formulated by the introduction of PLA/PGA 
microspheres. While CaP-cements are processed at room temperature, polymer microspheres can be 
added as a porogen forming pores after in vivo / in vitro degradation and as a possible carrier of 
growth factors. Drug release from degradable PLLA/PLGA microspheres is studied extensively and 
has proven to be useful for the release of proteins/drugs. Preparation methods for these microspheres 
are diverse and microspheres of different sizes and morphology can be prepared using a either a 
double-emulsion method(66) or spray drying(67). 
 
Figure 2. PLGA microsphere/CaP cement 
composites; close-up PLGA microspheres 
inside cement scaffold (above, original 
magnification 300x), 20% PLGA 
microsphere/CaP cement scaffold after 12 
weeks in vitro degradation (below, original 
magnification 50x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introducing PLGA microspheres inside calcium phosphate cement was first done by Simon Jr. et 
al.(68). Microspheres with a diameter of 180-360 µm were added to calcium phosphate cement 
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consisting of tetracalcium phosphate (TTCP), and after hardening cells were cultured on it. The 
resulting paste was moldable and showed good biocompatibility.  
Ruhé et al.(69) and Habraken et al.(70) put PLGA microspheres with an average size of 20-40 µm inside 
an injectable CaP cement so that a macroporous scaffold could be formed after microsphere 
degradation while still having sufficient setting properties. In vitro experiments showed that the 
introduction of 20% PLGA microspheres in the CaP scaffold decreased the compression strength, 
injectability and increased cement setting time, but within manageable ranges(70). Bulk erosion of the 
microspheres in the scaffolds was also observed, corresponding to a sudden decrease in mechanical 
strength. SEM-micrographs of these PLGA microsphere/CaP cement scaffolds before and after 
degradation are shown in Figure 2. Compared to the microporous cement, an extra pH decrease 
occurred due to PLGA hydrolysis that showed to increase cement resorption around the microspheres. 
Apparently, this pH decrease does not hamper in vivo applications, because subcutaneous implantation 
of these scaffolds showed no adverse tissue reaction during microsphere degradation(71) and also in 
cranial defects even bone ingrowth was observed(72, 73). 
In vitro release characteristics with rhBMP-2(69) showed a sustained, but small release (5-10%) after 4 
weeks in medium, though in vivo release characteristics(74) with low and high molecular weight PLGA 
microspheres showed higher release efficiencies (25-50%). Next to that, the low molecular weight 
PLGA microsphere composites showed the highest release after 28 days, indicating that the drug in 
this formulation exhibited less interaction with the surrounding cement. The discrepancy between in 
vitro and in vivo results could be due to a more dynamic flow and the occurrence of high amounts of 
salts and proteins like albumin in vivo that positively influenced the release properties.  
Comparable cement composites were prepared by Schnieders et al.(75). Scaffolds containing up to 20 
wt% of microspheres were loaded with gentamycin (10-30 wt%) and showed a sustained in vitro 
release pattern, while the release pattern from separate microspheres exhibited a typical burst release. 
In this study mechanical properties/setting time were not affected as much due to the use of smaller 
microspheres.  
Overall, these PLGA microsphere/calcium phosphate cement composites form a suitable macroporous 
scaffold with good physical/mechanical properties, a good body response and sustained release 
properties. 
 
3.2. Protein-based polymer/ceramic composites 
Composites of CaP-ceramics and cements with protein-based polymers are investigated extensively 
because they can produce organic-inorganic composites with mechanical/physical and biological 
characteristics that are similar to human bone. Well-known examples of this group of biopolymers are 
collagen and gelatin. 
Because collagen is one of the most abundant protein components inside the human body, it is not 
surprising that a lot of research has been done using collagen in a tissue-engineered construct. Next to 
_________________________________________________________________________General introduction 
 23
its high abundancy, there exist a lot of collagen types and forms that are usually retrieved by 
processing different animal tissues. Gelatin is a cheap and commercially available biomaterial that 
next to its household use gains more interest in general medicine. Gelatin is a processed form of 
collagen that is usually derived from pig-skin with an acidic process (type A) or from bovine origin 
with a basic (lime cured) process (type B). Both gelatin and collagen are degradable biopolymers 
which are solely degraded by proteolysis (collagenase, gelatinase). Degradation rates here are tailored 
by chemical crosslinking of the proteins, which makes the gelatin/collagen less accessible for 
proteolytic degradation. Introducing these biopolymers into a ceramic scaffold or introducing ceramics 
into a collagen/gelatin scaffold gives a composite with tailored degradation rates, and combines the 
biological- and mechanical/physical properties of both materials.  
Porous gelatin/collagen scaffolds with ceramic particles are formulated by different authors(76-78), 
especially so-called gelatin sponges that are prepared by freeze-drying a gelatin/calcium phosphate 
mixture. The mechanical properties of these porous scaffolds are poor and often the gelatin/collagen is 
highly crosslinked for a better (biological) stability, though this can also decrease biocompatibility 
while crosslinking agents like glutaraldehyde can give a cytotoxic reaction(79). Shibata et al.(78) 
therefore prepared a colloidal β-TCP/collagen composite that does not need any extra treatment. Du et 
al.(80) used collagen I as matrix for CaP mineralization to obtain a collagen/CaP composite. Here the 
biomimetic properties of the collagen were exploited and 60-70% CaP composites were produced with 
a high tensile strength. A different ceramic/gelatin porous scaffold was prepared by Tampieri et al.(81). 
In this study a macroporous HA ceramic was soaked in gelatin solution, and a 10% gelatin composite 
was formed in which the gelatin penetrated in the bulk of the ceramic. Also crosslinker was used to 
slow down diffusion of gelatin out of the scaffold, however, a low concentration was applied that 
assured biocompatibility. 
For the release of growth factors, these CaP particle/biopolymer composites have not been used too 
often, though the release properties of especially gelatin is well investigated and relies on an 
electrostatic interaction between a positively/negatively charged gelatin and a drug of the opposite 
charge(82). Takahashi et al.(76) investigated gelatin sponges containing β-TCP particles that were loaded 
with BMP-2. These sponges were prepared by chemical crosslinking of the gelatin in the presence of 
different amounts of β-TCP granules; BMP-2 loading was done by simply dropping a solution of the 
growth-factor to freeze-dried sponges. Release was followed in vivo by labeling the BMP-2 with 125I, 
which was observed to be similar for all composites and showed a high initial release followed by a 
more sustained release. Bone formation was also observed with all types of composites, though high 
amounts of β-TCP granules made the sponge collapse during degradation leading to denser structures 
and less bone formation. Kim et al.(77) added gentamycin to a HA-particle containing gelatin sponge 
and investigated the in vitro drug entrapment and release as a function of crosslinking density of the 
gelatin, amount of HA in the sponge and drug loading. Results show that increasing the crosslinking 
density leads to a higher drug entrapment, a decreasing initial drug release and a more sustained 
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release pattern. An increase in the % of HA particles decreased the % drug entrapment, though release 
here is also more sustained. In vivo studies using a collagen scaffold with HA nanoparticles and 
rhBMP-2 were also performed; here a positive influence of the added drug was observed in a loaded 
implant model in dogs(83, 84). 
Composites of gelatin/collagen with calcium phosphate cements are formulated to obtain better 
handling properties and to improve biological response. Bigi et al.(85-87) introduced 18% of gelatin 
inside calcium phosphate cement (α-TCP) and studied the biological response as well as the properties 
of the composite. They found an acceleration of the cement setting reaction as well as an increase in 
compression strength due to the high density of the gelatin. Furthermore an excellent biological 
response was observed with an improvement of osteoblast activity and differentiation. Fujishiro et 
al.(88) prepared a porous composite of a 5% and 20% gelatin containing α-TCP-based cement. Pores of 
20-100 µm were prepared by mixing a gelatin gel with α-TCP powder. Results showed an increase in 
mechanical properties over time with the 5% composites when compared to the original cement, 
though with 20% gelatin the compressive strength was lower. The good biological response and 
increase in mechanical strength is mostly due to the biomimetic abilities of gelatin that functions as a 
nucleation point of CaP-crystal growth(89). Next to gelatin, also the addition of collagen to a CaP-
cement is investigated. Rammelt et al.(90) added 3% of collagen I to a nanocrystalline hydroxy-apatite 
cement which lead to an increased bone remodeling in rat tibia defects. Knepper-Nicolai et al.(91) added 
1-2.5% collagen I to a commercial apatite cement and also observed mechanical and physical changes 
of the cement especially when osteocalcin was added. Hempel et al.(92) investigated the behavior of 
osteoblasts cultered on the same 2.5% collagen containing cement and observed that changes in the 
local microenvironment like the pH greatly influenced cell differentiation and proliferation on these 
composites.  
Release properties of these collagen/cement composites were investigated by Lode et al.(93). They 
studied the release of VEGF from a collagen containing apatite cement and compared it to the release 
pattern/VEGF activity of the normal cement. Cumulative release (25%) and burst release from the 
collagen cement was higher than from plain cement indicating a looser binding of the VEGF to the 
collagen. Additionally, the introduction of phospherine and sodium citrate to the collagen containing 
cement showed a positive impact on VEGF activity. This was determined by analyzing the 
proliferation of endothelial cells after exposing them to the diluted release medium. 
Next to gelatin and collagen also other protein structures are used as composite material for CaP-
ceramics and cements. Fibrin, and especially fibrin glue was applied for the introduction of ceramic 
particles(94, 95), or mixed together with calcium phosphate cement(96). Studies have been performed 
introducing alumina and TCP-particles in a casein and soybean protein scaffold(97), and polypeptides 
into CaP-cement(98). Again, main reasons for the use of these proteins were biodegradability, 
biomimetic properties and mechanical reinforcement. 
 
_________________________________________________________________________General introduction 
 25
3.3. Carbohydrate-based polymer/ceramic composites 
Next to protein based biopolymers, a different group of biodegradable polymers are of interest for 
general medicine and tissue engineering purposes, i.e. carbohydrate-based biopolymers. Most well-
known are probably chitin and chitosan, a derivative of chitin, but also alginate, hyaluronan and 
cellulose are members of this group. 
Of these polymers, chitosan is often applied together with CaP-cement or CaP-particles because it is 
biodegradable by lyctic enzymes and it gives a good match to natural bone with respect to mechanical 
properties. Regarding CaP-cement, chitosan can improve the mechanical/ physical properties as well 
as influence cement setting, though the compression strength of the ceramic is superior to chitosan. 
Chitosan can be added to a CaP-cement as adjuvant to make the cement more injectable as was 
observed by Leroux et al.(99) without substantially modifying the setting reaction. Similar results were 
observed by Takagi et al.(100), who concluded that CPC-chitosan composites exhibited a better 
cohesion in water than regular tetracalcium phosphate (TTCP) cement. Xu et al.(101) observed a 
reinforcement of a TTCP-cement by the addition of chitosan lactate. An increase in flexural strength, 
work of fracture and strain-at-peak load was observed, which was explained by the difference in 
microstructure of the chitosan composite. Also macroporosity was added to the composite by addition 
of mannitol crystals(102). This led to a dramatic decrease of the elastic modulus and flexural strength, 
though macroporosities up to 65% were obtained and cells show infiltration into the scaffolds. 
The CPC-chitosan composites can also be applied for drug release. Takechi et al.(103) added flomoxef 
sodium to the liquid phase of the TTCP-cement/chitosan composite and measured release from preset 
disks for 3 days. Results showed a release pattern that was characterized by an initial burst, followed 
by a more sustained release. The total % of drug released in 24 hrs was 24-35%, where the addition of 
chitosan in different amounts did not influence total release after 72hrs. Even more, the release from 
these chitosan enriched cements did not differ significantly from the normal TTCP cement, though the 
maximum amount of chitosan used was 1.0%. 
Similar to other polymer-ceramic composites, the opposite construction with ceramic particles in a 
porous chitosan composite is also formulated. Lee et al.(104) added TCP particles to chitosan sponges 
by freeze-drying and crosslinking a mixture of a chitosan solution and TCP. Zhang et al.(105) added HA 
and calcium phosphate invert glass to a chitosan sponge using a similar procedure. The added ceramic 
particles gave both scaffolds an extra osteogenic potential while the composite materials showed 
enhanced osteoblast proliferation and differentiation. Next to that, E-modulus and yield strength were 
reported to improve when introducing invert glass and β-TCP particles(106). These scaffolds were also 
loaded with gentamycin by immersing them in gentamycin-containing PBS solutions. Release patterns 
showed a high burst release that was diminished by addition of the ceramic particles and a total release 
of > 90% after 3 weeks in release medium. A more sustained release from the particle-containing 
composite was observed, which was suggested to occur due to a higher extend of chitosan 
crosslinking. Lee et al.(107) also introduced platelet-derived growth factor (PDGF) to the chitosan-TCP 
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scaffolds and measured in vitro release by 125I-labelled PDGF and in vivo bone regeneration in 
calvarial defects in rats. The release test showed an initial burst that was followed by a slower 
maintained release. In vivo, the addition of PDGF further enhanced bone formation.  
Next to chitosan, hydroxypropylmethylcellulose (HPMC, a cellulose derivative) is another 
carbohydrate applied in combination with ceramic particles or as an addition to calcium phosphate 
cement. Daculsi et al.(108) developed an injectable bone substitute comprised of BCP particles in a 
HPMC carrier. The materials showed to poses poor mechanical properties but a fast in vivo dissolution 
followed by replacement with newly formed bone. Crosslinking the HPMC by silanol groups (si-
HPMC) renders a more stable scaffold with a comparable in vivo performance(109). Burguera et al.(110) 
added HPMC as a gelling agent to a conventional and DCPD containing cement. Here a dramatic 
increase in injectability was observed after adding the HPMC, which was due to the high 
compressibility of the polymer.  
Comparable injectable pastes comprised of amylopectin with β-TCP granules were prepared by 
Ongpipattanakul et al.(111). These pastes were loaded with rhTGF-β by absorbing the growth factor on 
the granules and in vitro results showed a release of 80% after 24h incubation in serum. When 
implanted in a rabbit unilateral segmental defect model a positive bone response of the added TGF-β 
was observed after 56 days. In vivo release data showed a half life of the TGF-β at the implant site of 
4-6 days, next to that the growth factor also remained intact for more than 21 days in vivo as was 
observed in SDS-page. 
Composites of bioactive glass and starch/cellulose acetate and a mixture of methylmethacrylate/acrylic 
acid have been investigated by Boesel et al.(112). Different amounts of bioactive glass were added up to 
30%, which resulted in a significant improvement in E-modulus and yield strength of the material. In 
general no bioactivity was observed due to the inhibiting effect of the acrylic acid. Only with the 
highly reactive Bioglass®, calcium phosphate precipitation occurred.  
Hyaluronan is another attractive carbohydrate-based polymer for tissue engineering that is present in 
the human body and proteolytically degradable by hyaluronidases. Bone grafts consisting of HA 
granules in a hyaluronan carrier were investigated by Liljensten et al.(113) who also investigated 
HA/phospholipid scaffolds. Comparison of these materials to HA granules without carrier material 
showed a significant increase in newly formed bone when implanted in circular defects in rabbit tibia.  
The use of alginate in inorganic-organic scaffolds for bone tissue engineering is limited due to the poor 
biodegradation, though recently attempts have been made to make the alginate more biodegradable by 
shortening the chains and by chemical modifications(114). Alginate has been added as a cohesion 
promoter for calcium phosphate cements because these materials have the tendency to disintegrate 
upon contact with blood/fluid. Also chitosan, as discussed before, and other hydrocarbonate 
biopolymers have the ability to improve cement cohesion. Khairoun et al.(115) therefore investigated the 
cohesion properties of a commercial HA-cement after the addition of a wide range of these polymers 
i.e.: hydroxyethyl starch, starch, sodium dextran sulphate, α/β/λ-cyclodextrine, alginic acid, 
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hyaluronic acid and chondroitine sulphate. Results for all biopolymer/cement composites show a 
reduced cohesion time and small changes in setting time and mechanical properties when compared to 
the original cement. 
 
3.4. Other polymer/ceramic composites 
Next to the polymer/ceramic composites already discussed in the last three sections, composites of 
ceramics with different types of polymers were also formulated. Especially synthetic polyesters, other 
than polylactic/glycolic acid discussed previously, can be suitable carrier materials for ceramic 
particles. In this paragraph the characteristics of these and other polymer composites as well as their 
use for tissue engineering will be discussed briefly.  
A composite comprised of 25% β-TCP particles in a poly(propylene fumarate) (PPF) carrier was 
formulated by Peter et al.(116). PPF is a slow biodegradable and crosslinkable unsaturated linear 
polyester that is injectable and can provide a good mechanical support for (bone) defects. β-TCP 
particles were introduced for their osteoconductive properties, thereby making the PPF a more suitable 
material for bone tissue engineering. 
A different group of ester-backbone biodegradable polymers that can be applied for bone tissue 
engineering purposes is the polycarbonate group. These polymers degrade hydrolytically or 
proteolytically by lipase, though, because it is a synthetic polymer, molecular weight and therefore 
degradation characteristics can be varied. Besides, there is also a wide choice of polycarbonate 
compounds ranging from very elastic polymers to more stiff materials. A composite of a 
poly(desaminotyrosyl tyrosine ethyl esther carbonate) (poly(DTE carbonate)) and CaP glass fibers 
(CaO-P2O5-Fe2O3) was formulated by Charvet et al.(117). They installed short fibers of 2-3 mm length 
into a mould after which a solution of polycarbonate in methylene chloride was added. After that, the 
samples were heat processed and compression molded. Results showed that addition of the fibers 
doubles the stiffness of the composites; additional plasma coating of the fibers even improved the 
mechanical properties further due to a better matrix/fiber bonding.  
Polyhydroxyalkanoates (PHA) form another group of biodegradable aliphatic polyesters that have 
their applications in a broad field of medicine. Biodegradation of these polymers can be tailored by 
changing the polymer length and distance between ester groups. Different polymers of these group are 
formulated, ranging from a stiff and brittle material (poly(3-hydroxybutyrate), poly(3HB)) to more 
flexible structures (poly(3-hydroxybutyrate-co-hydroxyvalerate)(poly(3HB-co-3HV)) and poly(3-
hydroxybutyrate-co-hydroxyhexaoate) poly(3HB-co-3HHx)). Ceramic particles of β-TCP, HA and 
Bioglass® were added to these polymers(118), which in case of poly(3HB) and poly(3HB-co-3HV) led 
to an increase in mechanical properties and bioactivity. With the addition of hydroxyapatite particles 
to poly(3HB-co-3HHx) polymer an adverse effect was obtained, probably due to aggregations of HA 
particles that affected the mechanical strength and osteoblast interaction. 
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Poly(diol citrate)-HA microparticle composites were prepared and characterized by Qui et al.(119). 
Poly(diol citrate) is an elastic polyester that is biodegradable (hydrolysis) with a degradation time 
ranging from a few months to a year. Composites up to 65% of HA were prepared in which an 
increase in HA content led to better mechanical properties (denser), a slower degradation and 
improved mineralization in vitro.  
Mickiewicz et al.(120) added a range of water-soluble polymers comprising of different polyelectrolytes, 
poly(ethylene oxide) and bovine serum albumin (BSA) during cement setting of a brushite cement. 
Addition of the polycations poly(ethylenimine) and poly(allylamine hydrochloride) as well as BSA 
improved the mechanical properties of the cement due to a denser microstructure. For tissue 
engineering applications these materials can be useful due to their strengthening abilities and 
dissolvability, however, they should not give an adverse tissue response. The use of BSA, as already 
discussed in the paragraph about cements, also can be beneficial for drug release especially in low 
releasing calcium phosphate cements. 
A composite comprised of an α-TCP based apatite cement and reinforced with polypropylene, nylon 
and carbon fibers was investigated by dos Santos et al.(121). Although compressive strength decreased 
by addition of these fibers, an increase in toughness and tensile strength was observed. Also Xu et 
al.(122) added fibers consisting of either aramide, carbon, Epoxy-glass or polyglactin to a calcium 
phosphate cement and found an increase in tensile strength, work-of-fracture and elastic modulus. 
Most of these polymers, however, are not biodegradable and therefore not applicable for tissue 
engineering purposes.  
 
4. Concluding remarks 
From this review it can be concluded that there is a wide interest in the use of ceramics for bone tissue 
engineering purposes, whether it comprises a 100% ceramic composite, a composite of polymer with 
ceramic particles or addition of polymeric additives/porogens to calcium phosphate cement. The ideal 
scaffold parameters that were stated in the introduction therefore can be obtained using a broad range 
of materials and techniques. Scaffolds made of solely osteoconductive bioceramics can be feasible for 
tissue engineering purposes when porosity is introduced because they will allow bone ingrowth. The 
porosity also will increase the resorption rates, however, can decrease mechanical properties. Although 
tailorable within certain ranges, complete resorption of the ceramic remains difficult. Another 
challenge is the brittleness of the ceramic, which makes implantation for load-bearing applications 
complex. CaP cements/ ceramics can be applied as carriers for drugs in which release patterns and 
efficiencies strongly depend on the type of ceramic/cement used. In general, ceramics show a higher 
initial release than cements that have a more sustained release pattern. Also bioactive glass prepared 
by sol-gel can be used as a carrier for drugs.   
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The formulation of polymer/ceramic composites can compensate for the brittleness as well as improve 
the biodegradation and drug release of the original ceramic but compression strength and biological 
activity of the added polymers are often inferior. 
Biopolymers like chitosan, gelatin and collagen are frequently introduced into calcium phosphate 
cement to improve the in vivo cohesion and injection properties of the cement. Occasionally these 
polymers are applied to mechanically reinforce the cement, which is a result of the compact 
microstructure that is formed after mixing both inorganic-organic materials. The degradation 
properties and porosity of cement can be altered by adding polymer microspheres/particles that 
degrade in vivo as was observed with PLGA-microspheres. Furthermore, PLGA microsphere and 
collagen containing cements have shown to be promising materials for drug release/entrapment. 
Ceramic particles can also be added to a polymeric carrier to improve or introduce osteogenic 
properties. Scaffolds comprised of a ceramic in a polylactic, protein or carbohydrate carrier overall 
show higher degradation rates than pure ceramics. In addition, degradation rates can be tailored by 
changing the molecular weight or crosslinking density of the polymer. Compression strength of these 
scaffolds is less than of 100% ceramic composites; on the other hand, these polymer-based materials 
are not as brittle. Release patterns from drug-loaded scaffolds overall show a high initial release. The 
addition of higher amounts of ceramic particles to for e.g. chitosan composites or increased 
crosslinking of the gelatin chains decreases the initial burst release and provides a more sustained 
release of drugs/growth factors. 
 
5. Objective of this thesis 
In view of the above mentioned, the objective of this thesis was to synthesize a calcium phosphate 
cement that is suitable for tissue engineering purposes. Therefore, biodegradable microspheres were 
incorporated into the cement, which introduced macroporosity after in situ degradation and at the same 
time can be used as drug delivery vehicle for osteoinductive growth factors. The hypothesis behind 
this model is that during degradation of the microspheres, bone ingrowth compensates for the loss of 
mechanical strength and increases osteoclastic resorption of the cement. Furthermore, after 
introduction of the microspheres, physical and mechanical properties of the cement composites still 
should be sufficient for clinical application. 
The research as described in this thesis deals with the development of such microsphere/calcium 
phosphate cement composites with respect to physical/chemical analysis, degradation and drug 
release. The subaims of this thesis are: 
1) To formulate injectable PLGA microsphere/calcium phosphate cement composites and to 
investigate their in vitro degradation characteristics 
2) To investigate the combined degradation and release mechanism of a PLGA 
microsphere/calcium phosphate cement composite 
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3) To formulate calcium phosphate cement composites with incorporated gelatin microspheres 
and to investigate their in vitro degradation characteristics 
4) To formulate a porcine gelatin microsphere/calcium phosphate cement composite and to 
investigate its combined degradation and release mechanism. 
5) To investigate the in vitro growth factor release from various gelatin microsphere/calcium 
phosphate cement composites 
6) To formulate calcium phosphate cement composites with incorporated PTMC microspheres 
and to investigate their in vitro degradation characteristics 
7) To evaluate the in vivo performance of calcium phosphate cements with incorporated PLGA, 
gelatin or PTMC microspheres 
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1. Introduction 
Calcium phosphate (CaP) compounds are widely used as a bone substitute in the field of dentistry, 
orthopedic and reconstructive surgery. Especially the hydroxyapatite (HA) based compounds have an 
excellent biocompatibility and show some osteoconductive characteristics(1). They are usually applied 
in the form of blocks or granules. Unfortunately, there are difficulties shaping these CaP blocks during 
surgery while they have to fit in the bone defect. In granulate form, shaping of CaP ceramics is easier, 
but a disadvantage is the migration of the ceramic particles. Calcium phosphate cements seem to 
overcome these problems(2). These materials are composed of a powder component that is mixed with 
a fluid (hardener). They are injectable and can be molded in situ. Further, they set at body temperature 
and can even be shaped before complete setting. Besides the clinical advantage, CaP cements can be 
extremely biocompatible. Despite this, the resorption rate of these CaP cements is too low and the 
cement might take years to fully disappear. 
To increase degradation rates, macroporosity can be introduced to the cement. In literature some 
methods are described to introduce macroporosity to a CaP cement like the introduction of water-
soluble mannitol crystals(3-4), and a CO2-gas bubble method(5-6). In vivo experiments with pre-
fabricated scaffolds using this last method showed high resorption rates, however, the cement paste 
obtained was not injectable. Another method to introduce macroporosity into a calcium phosphate 
cement is the application of biodegradable polymer microspheres(7-8). When these microspheres are 
eroded a porous scaffold is obtained. Many types of polymer can be used for the production of the 
microspheres(9-14). PLGA (poly(D,L-lactic-co-glycolic) acid) has gained most interest for microsphere 
use as it can provide sustained drug delivery and has a long clinical history. PLGA degrades by means 
of hydrolysis. Here the diffusion of the aqeous phase in the PLGA is faster than the degradation of the 
polymer chains and mass loss occurs instantaniously through the PLGA, which is also called bulk 
erosion(15). An in vitro study with PLGA implants showed 90% polymer degradation within four to six 
weeks and complete erosion within eight weeks, depending on the porosity of the PLGA implant(16). 
PLGA degradation is influenced by various factors like the polymer chain length, lactic to glycolic 
(L/G) ratio and characteristics of the surrounding medium(17).  
The goal of this initial study was to investigate some PLGA microsphere/CaP formulations for their 
injectability and setting/cohesion properties. Also a degradation study was done in which the polymer 
and cement degradation/erosion was followed by means of a pH, mass and molecular weight assay and 
visualized by scanning electron microscopy. Mechanical properties of the PLGA/CaP samples like the 
compression strength and E-modulus were determined. 
 
2. Materials and Methods 
2.1. Materials 
PDLLGA (Purasorb®, Purac, Gorinchem, Netherlands) prepared by a stannous octoate (Sn(Oct)2) 
initiating system with a molecular weight (Mw) of 48.0 ± 1.6 kg/mol and a lactic to glycolic acid ratio 
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of  50:50 was used for the microsphere synthesis. The polydispersity index (PI) of the polymer was 
2.34 ± 0.07. Poly vinylic alcohol (PVA, 88% hydrolyzed, MW 22000, Acros Organics, Geel, Belgium) 
was used as stabilizer during the microsphere preparation. The calcium phosphate cement (Calcibon®, 
Biomet Merck, Darmstadt, Germany) consisted of 61% α-TCP, 26% CaHPO4, 10% CaCO3 and 3% 
precipitated HA. The cement liquid applied was a 1% aqueous solution of Na2HPO4. 
 
2.2. Methods 
2.2.1. Preparation PLGA microspheres 
PLGA microspheres were prepared using a water-in-oil-in-water (w/o/w)-double emulsion solvent 
evaporation technique. 1.0 g of PLGA was solved in 4 ml of dichloromethane (DCM) inside a 50 ml 
PP tube. 500µl of demineralized water (ddH2O) was added while vortexing vigorously for 1 min, 
subsequently 6 ml of a 0.3% PVA solution was added and vortexing was continued for another 1 min. 
The content of the 50 ml tube was transferred to a stirred 1000 ml beaker and another 394 ml of 0.3% 
PVA was added slowly. This was directly followed by adding 400 ml of a 2% isopropylic alcohol 
(IPA) solution. The suspension was stirred for 1 hr. The spheres were allowed to settle for 15 min and 
the solution was decanted. The suspension left was centrifuged, and the clear solution at the top was 
decanted. 5 ml of ddH2O was added, the spheres were washed, centrifuged and the solution was 
aspirated. Finally the spheres were frozen, freeze-dryed for 24 hr and stored under argon at   -20°C. 
 
2.2.2. Preparation of PLGA/CaP samples 
Samples were made by adding the PLGA microspheres to the CaP cement powder inside a 2 ml plastic 
syringe, subsequently adding the 1% Na2HPO4 to the mixture and stirring the contents vigorously for 
30 sec (Silamat® mixing apparatus, Vivadent, Schaan, Liechtenstein). Subsequently the mixture was 
injected inside a teflon mould (cylinders 4.5 x 9 mm). The amounts of the constituents for the different 
formulations, as well as for the microporous cement, are given in Table 1. A liquid/powder (L/P) ratio 
of 0.32 was applied, except for the 20/80 composites were a higher amount of liquid was used. From 
each syringe 4-5 samples were obtained. These samples were dried in a furnace at 40°C for 1 hr, and 
stored at room temperature.  
 
Table 1. Ingredients for the different PLGA/CaP formulations 
 CaP (mg) PLGA mp’s (mg) 1% Na2HPO4 (µl) 
Microporous cement 1000 0 320 
10/90 PLGA/CaP 900 100 290 
20/80 PLGA/CaP 800 200 300 
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2.2.3. Morphology analysis 
The morphology of the samples was determined by observation on a scanning electron microscope 
(SEM) (JEOL 6400-LINK AN 10000 at 10 kV). The samples were mounted on aluminium stubs using 
Carbon tape and sputter-coated with gold-palladium prior to examination.  
 
2.2.4. Size distribution 
The size distribution of the PLGA microspheres was determined via image analysis. Spheres were 
suspended in H2O and pictures were taken with an optical microscope (Leica/Leitz DM RBE 
Microscope system, Leica Microsystems AG, Wetzlar, GER), after which the size distribution was 
determined using digital image software (Leica Qwin®, Leica Microsystems AG, Wetzlar, GER). 
 
2.2.5. Injectability 
Injectability tests were done on the different PLGA/CaP samples according to Khairoun et al(18). 
Briefly, after mixing the microspheres with the cement/liquid, the syringe, with an orifice diameter of 
1.7 mm, was fitted vertically in a fixture and put under the platen of a tensile bench set in tension 
mode (Fig.1). 25 seconds after mixing the cement, compressive force was applied to the syringe and 
recorded as a function of the plunger travel length. All tests were performed in threefold. 
 
Figure 1. Injectability test 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.6. Setting time 
The initial and final setting time of the various cement formulations was assessed using custom 
available Gillmore needles (ASTM C266(19)). For this a bronze block was used as mould containing 6 
holes (6 mm in diameter, 12 mm in height). The mould was placed in a water bath at body temperature 
_Injectable PLGA microsphere/calcium phosphate cements: physical properties and degradation characteristics 
 43
(37˚C). Samples of each formulation were mixed and injected into the mould in a retrograde fashion, 
after which the initial and final setting time was determined. Tests were done in threefold. 
For the determination of the cohesive properties of the different formulations, samples were injected 
into Ringer’s solution at 37°C. During the cement setting time it was inspected whether the 
cement/composite retained its original configuration. Any anomalies were recorded. 
 
2.2.7. Porosity 
Of the different cement formulations the (macro)porosity was determined. In this experiment 
macroporosity can be regarded as the porosity of the cement formulations in which the pores are 
caused by (the erosion of) the PLGA microspheres. The PLGA/CaP samples therefore were weighed 
before they were placed in a furnace at 650°C for 2 h. After that they were weighed again, in which the 
difference in weight is the polymer mass content of the samples. The test was performed in threefold. 
Equation 1 and 2 were derived for the calculation of the total porosity and the macroporosity. 
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burnt
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m−=ε        Equation 2 
Legend 
εtot  = total porosity (%) 
εmacro  = macroporosity (%) 
mburnt  = average mass sample (after burning out polymer) (g, n=3) 
mmicroporous = average mass microporous sample (g, n=3) 
V  = volume sample (cm3) 
ρHAP  = density hydroxy apatite (g/cm3) 
 
2.2.8. Degradation study 
For the degradation study, PLGA/CaP and microporous cement samples were prepared as described 
earlier. The samples were placed in 3 ml of phosphate-buffered saline (PBS, pH 7.4) and incubated at 
37˚C in a water bath on a shaker table (70 rpm) for twelve weeks. At week 2, 4, 6, 9 and 12, 5 
specimens of each cement formulation were subjected to analysis. For the compression test and E-
modulus 3 specimens were tested and samples after 3 days in Ringer’s solution were taken as a 
reference. 
pH measurements  
Directly after removal of the samples from the waterbath, the pH of the PBS medium was measured. 
Mass loss quantification  
The samples were vacuum dried overnight before measuring the mass. The mass loss of the samples 
was calculated using Equation 3. The mass loss of the PLGA microspheres inside the samples was also 
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determined using Equation 4, which is a derivation of Equation 3 under the assumption of an equal 
cement degradation in both microporous/composite samples. 
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Legend 
RL  = Mass loss sample on t = n (%) 
RL,Pol  = Mass loss polymer on t = n (%) 
M0  = Mass sample on t = 0 (g) 
Mn  = Mass sample on t = n (g) 
Mcomp,0  = Mass composite sample on t = 0 (g) 
Mmicro,0  = Mass microporous cement on t = 0 (g) 
Lcomp,n  = Mass loss composite sample on t = n (g) 
Lmicro,n  = Mass loss microporous cement on t = n (g) 
a  = Mass fraction polymer on t=0 
b  = Mass fraction microporous cement on t=0 
 
Molecular weight analysis 
The molecular weight of the PLGA polymer inside the PLGA/CaP samples was monitored using gel 
permeation chromatography (GPC). The system comprises of a Hitachi L2130 HPLC pump, a Hitachi 
L-2400 UV detector and a Merck/Hitachi L-2490 RI Detector (Hitachi corp., Tokyo, JPN). The GPC 
column used was a 4.6*300 mm Waters Styragel® HR 4E column with a Waters 4.6*30 mm Styragel® 
guard colum (Waters Corp., Milford, MA, USA). Tetrahydrofuran (THF) was used as eluent at a flow 
rate of 0.35 ml/min. Polystyrene (PS) standards (SM-105, Shodex corp., Tokyo, JPN) were used to 
obtain a primairy calibration curve. For the calculation of the Mw of the PLGA, Mark-Houwink 
constants of PLGA 50:50 (a = 0.761, K = 1.07*10-2, THF, 22.5°C)(20) and PS (a = 0.717, K = 1.17*10-
2, THF, 25°C) were used. To extract the PLGA, 100 mg of the samples was grinded and put in a 
sample flask together with 3 ml of THF. The suspension was put on a shaker table for 2 h and was 
purified using Waters 13 mm GHP 0.2µm Acrodisk® filters (Waters Corp., Milford, MA, USA). 
Mechanical characteristics  
Samples were placed in a testing bench (858 MiniBionixII®, MTS Corp., Eden Prairie, MN, USA) and 
compressive strength and E-modulus in the longitudinal direction (parallel to the long axis) of the 
specimens was measured at 0.5 mm/min crosshead speed.  
Morphology 
The morphology of the different cement formulations was determined using SEM. For this purpose 3 
intersections were used that were parallel to the long axis of the samples. These samples were obtained 
from the compression test. Degradation behaviour of the PLGA microspheres inside the samples was 
visualized at higher magnifications.  
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2.2.9. Statistical analysis 
Data were arranged as mean ± standard deviation. Significant differences were determined using 
analysis of variance (ANOVA). Results were considered significant if p<0.05. Calculations were 
performed using GraphPad Instat® (GraphPad Software Inc., San Diego, CA, USA). 
 
3. Results 
3.1. Characterisation PLGA microspheres 
Figure 2 shows a SEM-micrograph and size distribution of microspheres synthesized using the w/o/w 
double emulsion method. The spheres have a spherical and smooth appearance, and do not 
agglomerate. The average size of the microspheres is 33µm ± 17µm.  
 
Figure 2. Scanning electron micrograph of the PLGA microspheres prepared by the upscaled double-emulsion 
technique (original magnification 80x) and size distribution graph of the PLGA microspheres (group size = 268) 
 
3.2. Injectability 
In Figure 3 injectability graphs of different cement formulations are given. The force, subjected to the 
syringe, is expressed as a function of time. Injection time is the time span in which the paste can be 
injected after mixing the cement with the liquid component. This characteristic can be determined 
while after a certain time point pressure increases which corresponds to the hardening of the cement in 
the syringe. The left figure shows that with an increasing percentage of hardener in the liquid phase 
injection time decreased from 110 s (0.5%) to 90 s (1.0%) and 60 s (2.0%) for the microporous 
cement. 
For the injectability tests of the PLGA/CaP samples a percentage of hardener was chosen of 1.0%. 
When adding PLGA microspheres to the cement, the injection time decreased from 90 s to about 75 s 
(10/90) and 60 s (20/80). Also the force experienced during application of the paste was higher when 
more microspheres were added.  
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Figure 3. Injectability graphs of microporous cement at 0.5 % Na2HPO4 (∆), 1% Na2HPO4 (), 2 % Na2HPO4 
(◊) (left) and of microporous cement (∆), 10/90 PLGA/CaP(),20/80 PLGA/CaP(◊) at 1% Na2HPO4.(right) 
 
3.3. Setting time and cohesion 
Figure 4 shows the initial and final setting time of the different pastes. When microspheres were added 
to the CaP cement, initial setting time increased slightly but significant in both cases. Final setting time 
showed a non-significant increase with the 10/90 formulation and a significant increase with the 20/80 
formulation. 
 
 
Figure 4. Initial and final 
setting time of micropo-
rous cement, 10/90 
PLGA/CaP and 20/80 
PLGA/CaP 
 
 
 
 
 
 
 
The result of the cohesion test is given in Table 2. After injecting the paste in Ringer’s solution the 
cement stayed in the desired shape during setting in all cases. In one case, using the 20/80 formulation, 
emission of cement particles was observed during injection. 
 
Table 2. Cohesion properties of the different cement formulations 
 Microporous 
cement 
10/90 PLGA/CaP 20/80 PLGA/CaP 
Cohesion  ++ ++ + 
Comments - - Little amounts of dust after injection 
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3.4. Porosity 
In Table 3 the porosity and macroporosity of the samples is given. The microporous CaP samples had 
a porosity of 41%. With the PLGA/CaP samples a higher porosity of 60% (10/90) and 69% (20/80) 
was obtained. The macro porosity that was introduced by the PLGA microspheres reached to 33% 
(10/90) and 48% (20/80) respectively.  
 
Table 3. Results porosity measurement 
 Average Mass (g) Density (g/cm3) Porosity (%) Macro porosity (%) 
Microporous 
cement 
0.2627±0.0061 1.835±0.039 40.80±1.26 - 
10/90 
PLGA/CaP 
0.1766±0.0029 1.234±0.019 60.20±0.53 32.77±1.88 
20/80 
PLGA/CaP 
0.1362±0.0019 0.951±0.012 69.31±0.39 48.18±1.38 
 
3.5. Degradation study 
pH measurements 
The left graph of Figure 5 shows the pH of the PBS solution in which the samples were situated. After 
week 4 significant differences were observed. The 20/80 formulation showed the highest decrease in 
pH, reaching to 4.0 at week 12. The same trend was seen with the 10/90 samples reaching to a pH of 
4.4 and the microporous CaP samples reaching an ultimate pH of 5.5. 
 
 
Figure 5. pH of the surrounding PBS (left) and  percentage of initial mass (right) of the microporous cement, 
10/90 PLGA/CaP and 20/80 PLGA/CaP as a function of the degradation time 
 
Mass loss quantification 
The development of the mass loss in time of the samples is given in the right graph of Figure 5. The 
microporous CaP as well as the other cement formulations, showed a mass loss of 5% at week 2 and 4. 
At week 6 a significant difference was measured between the microporous cement and the 20/80 
formulation indicating PLGA erosion. Week 9 and 12 showed significant differences between all the 
samples, with the microporous cement remaining at 90% of its initial mass, the 10/90 samples 
decreasing to 82% and the 20/80 samples decreasing to 68%. Using Equation 4 the decrease in mass of 
the PLGA polymer inside the samples was derived (Figure 6, left). In this graph little mass loss was 
visible in week 2 and 4. Week 6 showed an average mass loss of 18%, which in the case of the 20/80 
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formulation was significantly higher than week 2 and 4. Week 9 showed a significant polymer loss 
reaching to 75-80%. At week 12 almost all of the PLGA had disappeared and surpassed 100% with the 
20/80 formulation. No significant difference in polymer erosion rate was observed between the 10/90 
and 20/80 samples. 
 
 
Figure 6. Percentage mas loss using Equation 4 (left) and weight average molecular weight (Mw)(right) of the 
10/90 and 20/80 PLGA/CaP samples  as a function of the degradation time. 
 
Molecular weight 
The Mw of the PLGA polymer inside the 10/90 and 20/80 samples as a function of the degradation 
time is given in the right graph of Figure 6. In this graph a linear decrease of the molecular weight was 
observed till t=6 weeks where the Mw of both samples was less than 20% of the initial value. Also a 
small, but significant difference was seen in Mw between the 10/90 and 20/80 samples at t=9 weeks 
indicating faster degradation of the PLGA inside the 20/80 formulation at this time point. 
Mechanical characteristics 
In Figure 7 the compression strength and E-modulus of the samples is given as a function of the 
degradation time. At t = 3 days a significant difference in compression strength was observed between 
the microporous CaP and the 10/90 and 20/80 PLGA/CaP samples. When proceeding in time the 
strength of the microporous cement remained constant while the compression strength of the 
microsphere containing samples decreased significantly to 12.2 MPa (10/90) and 4.3 MPa (20/80) at 
day 12.  
With the E-modulus the same trend was observed. At day 3 there was a significant difference between 
the microporous cement and both microsphere containing samples. The E-modulus of the microporous 
cement remained unchanged over time. The same was observed with the 10/90 PLGA/CaP samples 
although here a small but insignificant decrease was shown at week 12. The 20/80 formulation showed 
a significant decrease from 1300 MPa at day 3 to 170 MPa at week 12. 
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Figure 7. Compression strength (left) and E-modulus (right) of microporous cement, 10/90 and 20/80 
PLGA/CaP samples as a function of the degradation time 
 
Morphology 
Figure 8 and 9 show SEM micrographs of the microspheres inside the 10/90 and 20/80 PLGA/CaP 
samples. On both samples the spheres at day 3, week 2 and 4 looked quite dense, and little erosion was 
observed. At week 6, bulk erosion(21) was visible resulting in flattened particles that had lost their 
sphericity. At week 9 the particles were almost completely eroded and thin shells of PLGA covered 
the inside of the holes in the cement. Finally at week 12 a structure of spherical pores was observed in 
which some traces of PLGA could be found. With the 20/80 formulation it was visible that the newly 
formed pores showed some interconnections. Also the cement showed signs of erosion at the edges of 
the macropores.  
 
4. Discussion 
In this study the applicability was investigated of PLGA microsphere/CaP cement as injectable bone 
filler. The mechanical and physical characteristics of the different samples as well as the 
degradation/erosion behaviour of the scaffolds in vitro was investigated and compared with a 
microporous CaP scaffold. Important for bone tissue engineering applications is that macroporosity is 
obtained during degradation, though the scaffold must retain some mechanical strength. 
Regarding the mechanical/physical characteristics of the cement paste, the pattern observed for the 
injectability graphs showed that the addition of PLGA microspheres results in a higher stress at the tip 
of the syringe, increasing the initial injection pressure. The injection time also decreased with a higher 
amount of microspheres. The reason for this feature is that next to the cement, also the microspheres 
absorb some of the hardener, increasing the viscosity of the paste. In fact, for the 20/80 formulation 
already extra liquid phase was introduced, otherwise the paste was not injectable(22).  Consequently, 
the higher amount of hardener resulted in a significant higher final setting time for this formulation. 
Extremely important with these multiple-component cements therefore is to find an optimum L/P ratio 
that gives cement pastes that are injectable and in the same time have a sufficient setting time for 
clinical use. In addition to that, too high L/P ratio’s decrease the compression strength of the cement(2). 
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Figure 8. SEM-micrographs of PLGA microspheres in the 10/90 PLGA/CaP formulation: t = 3 days (upper left), 
t = 2 weeks (upper right), t = 4 weeks (middle left), t = 6 weeks (middle right), t = 9 weeks (lower left) and t = 12 
weeks (lower right)(original magnification 300x) 
 
Further, cement properties are influenced by the size and distribution of the microspheres. Spheres 
with a larger diameter overall provoke increased difficulties with clogging at the syringe opening. 
Consequently, in the current research relatively small microspheres were chosen. These smaller 
spheres have a less than optimal pore diameter for bone ingrowth as confirmed by literature(23). Still, it 
has to be noticed that other more recent literature(24-25) showed already effective bone ingrowth with 
pore sizes starting from 50µm.  
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Figure 9. SEM-micrographs of PLGA microspheres in the 20/80 PLGA/CaP formulation: t = 3 days (upper left), 
t = 2 weeks (upper right), t = 4 weeks (middle left), t = 6 weeks (middle right), t = 9 weeks (lower left) and t = 12 
weeks (lower right)(original magnification 300x) 
 
In this research we used a broad particle size distribution. The particle size distribution is an important 
factor, while it determines the packing of the spheres. Spheres of different sizes, preferentially a 
bimodal distribution of larger and smaller sized spheres, can create a closer packing in which little 
spheres serve as interstitials between the higher sized spheres.   
The porosity of the microspheres, which is determined by the (double-emulsion) process parameters(9), 
influences the injectability by creating more stiff or flexible spheres. The double-emulsion technique 
normally produces very porous structures with honeycomb morphology(17). From cross-sections of our 
microspheres imbedded in epoxy-resin, the same honeycomb morphology was observed.  
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After cement setting, both PLGA/CaP formulations formed a scaffold in which intact PLGA 
microspheres were equally distributed. In literature(26) spheres in a solid matrix become interconnected 
when the volume fraction surpasses 0.4. According to this, the 20/80 formulation (48%) should posses 
an interconnective structure, while the 10/90 formulation (33%) lacks interconnectivity. SEM-
micrographs of the degradation assay (Figure 8 and 9) indeed showed interconnectivity between the 
spheres in the 20/80 samples, while in the 10/90 samples spheres were more isolated. An open porous 
structure of macropores(27) was not obtained and in most cases a thin shell of HA between two 
neighbouring spheres could be observed by SEM. Though the presence of these shells initially forms a 
barrier, they are very susceptible for degradation. This is due to a local high acid concentration caused 
by PLGA hydrolysis and increased porosity after the PLGA has disappeared. Figure 6 gives evidence 
of this mechanism because PLGA erosion of the 20/80 sample surpassed 100% at t = 12 weeks. To be 
able to calculate the PLGA erosion with equation 4, the erosion of the CaP inside the PLGA/CaP 
samples was assumed to be equal to the microporous CaP samples. A PLGA erosion that surpasses 
100% then automatically means that this assumption is false at this time point and that CaP erosion is 
higher than in the microporous cement. SEM-micrographs of this sample also showed signs of cement 
dissolution at these thin HA shells.  
The in vitro degradation test showed that the overall pH of the medium of the 10/90 and 20/80 samples 
gave a pattern in which a significant higher decrease than the microporous CaP was observed, starting 
from week 6 and stabilizing around 10 weeks. This pH decrease was caused by the PLGA degradation 
products and exceeded the buffer capacity of the PBS buffer. A linear decrease of the pH in time was 
observed by Agrawal et al(28) when PLGA was mixed with HA. The graph obtained in this research 
showed a more exponential decrease that is similar to the the curve of normal PLGA with an overal 
smaller decrease in pH and a delay in onset.  
Significant differences in mass loss were also visible starting from week 6 (day 42). At this time point 
the PLGA was already eroding, as is shown in Figure 6 (left) and is also evident in the SEM-
micrographs (Figures 8 and 9). With the 10/90 and 20/80 samples it lasted more than 9 weeks and less 
than 12 weeks before the PLGA mass was reduced to zero. Under similar conditions complete PLGA-
mass loss was observed after 8-9 weeks of degradation in literature(16,28). The present structure in 
which the microspheres are surrounded by HA delays PLGA erosion due to the buffering effect of the 
HA and to the rigid structure of the cement that immobilizes the particles and prevents PLGA 
degradation products from reaching the outside medium. However, accumulations of these by-
products locally decrease the pH resulting in an accelerated degradation/structural deformation of the 
microspheres. This result is in contrast to degradation experiments of separate spheres in which a 
gradual degradation is observed(29-30). Reduction in molecular weight of the PLGA started at day 0 and 
was 80% at week 6 when bulk erosion was visible. A linear decrease was seen until this time point. 
After 6 weeks, due to erosion, less polymer was present and PLGA degradation showed a more 
exponential decrease. 
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The results observed with the compression strength assay and E-modulus showed that the PLGA 
microspheres provided an extra initial strength to the composite, while during/after erosion of the 
PLGA microspheres the compression strength significantly decreased. With the 20/80 formulation the 
compression strength decreased to values slightly higher than other porous cements(3-6). The porous 
CaP implants by Del Real et al(6) have already shown to be biodegradable in a relative short time span 
(81% in 10 weeks) using a goat model. The total porosity of the implant material Del Real used was 
59%. This is (slightly) lower than the porosity of the 10/90 and 20/80 samples, while the compressive 
strength of our samples after 12 weeks of degradation is higher (12.2 MPa and 4.3 MPa compared to 
1.3 MPa). Therefore the compressive strength is most likely to be dependent on the size and 
rearrangement of the pores inside the cement. So the equal distribution of relatively small and 
polydisperse microspheres, used in this experiment, seems to be favourable with respect to the strength 
of the implant.  
 
5. Conclusion 
From the results it can be concluded that the 10/90 PLGA/CaP cement is easy to handle (injectability, 
initial and final setting time, cohesive properties) with the limitation that the pores left after PLGA 
degradation are not interconnected. The 20/80 PLGA/CaP formulation showed signs of 
interconnectivity, but exhibited less handling properties, though still within workable boundaries. In 
vitro PLGA degradation in both implants was comparable and lasted 9-12 weeks. The higher amount 
of microspheres in the 20/80 composite resulted in a higher pH decrease due to PLGA hydrolysis. 
Signs of CaP degradation were also found with this formulation. The compression strength of the 
PLGA/CaP formulations before and after 12 weeks of degradation was higher than most porous 
implants, though the overall porosity was comparable or even higher.  
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1. Introduction 
Tissue engineering is an interdisciplinary field of science in which biological substitutes are developed 
that are intended to restore, maintain or improve tissue function for a whole organ(1). In general, bone 
tissue engineering methods apply a mechanically stable and biodegradable scaffold material 
containing cells (osteoblasts) and/or growth factors (bone morphogenic protein-2 (BMP-2), 
transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF))(2-3). Calcium 
phosphate cements (CPCs), though brittle, can be a suitable scaffold material for bone tissue 
engineering because of their osteoconductivity and perfect fit with the surrounding tissue when 
injected in situ(4). To allow bone ingrowth into these materials, in a former experiment, macroporosity 
was introduced into a CPC by use of poly(lactic-co-glycolic acid) (PLGA) microspheres(5). This 
rendered composites that had manageable handling properties and resulted, after PLGA erosion, in a 
highly porous scaffold.  
Next to the formation of macroporosity, PLGA microspheres also can be used to obtain a controlled 
release of osteoinductive growth factors/drugs(6-10). When compared to a conventional cement(11-13), 
introduction of these drug loaded PLGA microspheres into CPC can alter release patterns and 
efficiencies as well as shield the drug from chemical reactions during cement setting(14). Ruhé et al(15-16) 
used PLGA microsphere CPC scaffolds for the in vitro and in vivo release of recombinant human bone 
morphogenic protein-2 (rhBMP-2). Main conclusion of both studies was that the introduction of drug-
loaded PLGA microspheres into the cement scaffold resulted in a sustained rhBMP-2 release within 4 
weeks. In the in vivo study(16), drug release could be tailored within certain ranges by changing the 
molecular weight of the PLGA and loading method. Results showed that composites where the drug 
was incorporated inside low molecular weight PLGA microspheres (Mw ≈ 5.000 g/mol) revealed a 
higher release rate than the other groups, i.e. high molecular weight PLGA (Mw ≈ 50.000 g/mol) and 
adsorption of drug onto microspheres. It was suggested that a faster degradation of the low molecular 
weight PLGA resulted in a higher release, and while the drug was incorporated in the PLGA less 
interaction with the surrounding cement occurred.  
The goal of this study was to elucidate the release mechanism of a PLGA microsphere/ calcium 
phosphate cement composite (PLGA/CPC). Therefore, microspheres with a molecular weight of 
approximately 5000 g/mol were loaded with a model protein (bovine serum albumin, BSA) using two 
loading methods. In vitro BSA release from PLGA/CPC, CPC and PLGA microspheres into an 
aqueous solution was investigated by reversed-phase high performance liquid chromatography (RP-
HPLC). Furthermore, similar to a previous performed degradation experiment(5), physical and 
mechanical properties of the PLGA/CPC were determined and an in vitro degradation study was 
performed in phosphate buffered saline (PBS).  
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2. Materials and Methods 
2.1. Materials 
Poly(lactic-co-glycolic acid) (PLGA, Mn = 2838 ± 3 g/mol, Mw = 4547 ± 32 g/mol, PDI = 1.60 ± 0.01, 
L/G = 52/48, Purasorb®, Purac, Gorinchem, Netherlands) was used for the preparation of the 
microspheres. Poly(vinyl alcohol) (PVA, 88% hydrolyzed, Mw = 22000 g/mol, Acros Organics, Geel, 
Belgium) was used as stabilizer during microsphere preparation. The calcium phosphate cement 
(Calcibon®, Biomet Merck, Darmstadt, Germany) consisted of 61% α-tricalcium phosphate (α-TCP), 
26% CaHPO4, 10% CaCO3 and 3% precipitated hydroxyapatite (HA). The cement liquid was a 1% 
w/v Na2HPO4 in demineralized water (ddH2O). 
 
2.2. Methods 
2.2.1. Preparation PLGA microspheres 
PLGA microspheres were prepared using a (w/o/w) double emulsion solvent evaporation technique 
described in a previous experiment(5). Briefly, 1.4 g of PLGA was dissolved in 2 ml of 
dichloromethane (DCM) inside a 50 ml glass tube. 500µl of demineralized water (ddH2O) was added 
to the polymer solution while vortexing vigorously for 1 min. Subsequently 6 ml of a 0.3% w/v PVA 
solution in ddH2O was added and vortexing was continued for another 1 min. The content of the 50 ml 
tube was transferred to a stirred 1000 ml beaker and another 394 ml of 0.3% w/v PVA solution was 
added slowly. This was directly followed by slowly adding 400 ml of a 2% v/v isopropylic alcohol 
(IPA) solution in ddH2O. The suspension was stirred for 1 h. Spheres were allowed to settle for 15 min 
and the clear solution on top was decanted. Finally, spheres were washed with ddH2O, freeze-dried for 
24 h and stored under argon at -20°C. Morphology of the microspheres was analyzed by scanning 
electron microscopy (SEM) (JEOL 6400-LINK AN 10000 at 10 kV). For this, samples were mounted 
on aluminium stubs and sputtered with gold-palladium prior to examination. From the SEM-
micrographs, average size of the microspheres was determined (n = 200) using digital image software 
(Leica Qwin®, Leica Microsystems AG, Wetzlar, Germany). 
 
2.2.2. Preparation PLGA/CPC 
20% w/w PLGA microsphere/CPC composite samples for the degradation or release test were made 
by adding 200 mg PLGA microspheres to 800 mg CPC powder inside a 2 ml plastic syringe, after 
which the contents were stirred vigorously for 15 s to achieve a good distribution of spheres inside the 
cement (Silamat® mixing apparatus, Vivadent, Schaan, Liechtenstein). Subsequently, 350 µl 1% w/v 
Na2HPO4 in ddH2O was added to the mixture and the contents were stirred again for 15 s. The 
resulting paste was injected into a Teflon mould (cylinders 4.5 x 9 mm) where it was allowed to 
harden at room temperature overnight. 
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2.2.3. Physical/Mechanical properties PLGA/CPC 
Initial and final setting time, total/macroporosity and compression strength/E-modulus of the 
PLGA/CPC was determined(5). In brief, the microsphere composites were subjected to the following 
analyses. 
Setting time 
Initial and final setting time was assessed using custom available Gillmore needles (ASTM C266). For 
this, a bronze block containing 6 holes (6 mm in diameter, 12 mm in height) was used as a mould and 
placed in a water bath at body temperature (37˚C). Samples were mixed and injected into the mould in 
a retrograde fashion, after which the initial and final setting time was determined. Tests were done in 
triplicate. 
Porosity 
Total- and macroporosity of preset samples was determined. Macroporosity is the porosity generated 
by the degradation of PLGA microspheres and corresponds to the volume percentage of microspheres 
initially. The total porosity is the macroporosity plus the original microporosity of the cement. For this, 
both PLGA/CPC samples and CPC samples of a known volume were placed in an oven at 650°C for 2 
h. After burning out the PLGA/moisture, samples were weighed and equation 1 and 2 were used for 
the derivation of the total porosity and the macroporosity. 
%100*)
*
1( /
HAP
micromacro
tot V
m
ρε −=         Equation 1 
%100*)1(
micro
macro
macro m
m−=ε         Equation 2 
Legend: εtot = total porosity (%), εmacro = macroporosity (%), mmacro = average mass of macroporous sample (after 
burning out gelatin) (g, n = 3), mmicro = average mass of CPC sample (g, n = 3), V = volume sample (cm3), ρHAP = 
density of hydroxyapatite (g/cm3) 
 
Mechanical characteristics  
Preset PLGA/CPC samples were soaked in Ringer’s solution for 3 days. Thereafter, they were placed 
in a tensile bench (858 MiniBionixII®, MTS Corp., Eden Prairie, MN, USA) and compression strength 
and E-modulus along the height of the specimens was measured at 0.5 mm/min crosshead speed. 
 
2.2.4. Degradation study 
For the degradation study, preset PLGA/CPC and CPC samples were placed in 3 ml phosphate 
buffered saline (PBS, pH = 7.4) and incubated at 37˚C in a water bath on a shaker table (70 rpm) for 
12 weeks. Sample medium was refreshed every week and 5 specimens were subjected to analysis at 
day 14, 28, 42, 63 and 84 of incubation.  
pH measurement  
Directly after removal of the samples from the water bath, pH of the PBS medium was measured. 
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Mass loss quantification  
The samples were vacuum dried overnight before measuring the mass. Mass change of the samples 
was calculated using Equation 3.  
%100*
0
0
m
mm
R nC
−=         Equation 3 
Legend:  RC = mass change of sample on t = n (%), m0 = mass sample on t = 0 (g), mn = mass sample on t = n (g) 
 
Molecular weight analysis 
The molecular weight of the PLGA polymer inside the PLGA/CPC was monitored using gel 
permeation chromatography (GPC). The system comprises of a L2130 HPLC pump, a L-2400 UV 
detector and a L-2490 RI Detector (Hitachi corp., Tokyo, JPN). The GPC column used was a 4.6*300 
mm Styragel® HR 4E column with a 4.6*30 mm Styragel® guard column (Waters Corp., Milford, MA, 
USA). Tetrahydrofuran (THF) was applied as eluent at a flow rate of 0.35 ml/min. Polystyrene 
standards (SM-105, Shodex corp., Tokyo, JPN) were used to obtain a primary calibration curve. For 
the calculation of the number average molecular weight (Mn) or weight average molecular weight 
(Mw) of the PLGA, Mark-Houwink constants of PLGA 50:50 (a = 0.761, K = 1.07*10-2, THF, 
22.5°C)(17) and PS (a = 0.717, K = 1.17*10-2, THF, 25°C) were used. To extract the PLGA, 100 mg of 
the samples was grinded and put in a sample flask together with 3 ml of THF. The suspension was put 
on a shaker table for 2 h and was purified using 13 mm GHP 0.2µm Acrodisk® filters (Waters). 
Mechanical characteristics  
Compression strength of the samples after incubation was measured using a tensile bench as described 
in “Physical/Mechanical properties PLGA/CPC”. 
Morphology 
Morphology of the different cement formulations was analyzed using SEM. Degradation behavior of 
the PLGA microspheres was visualized at a magnification of 250x. 
 
2.2.4. BSA Release test 
Preparation BSA loaded microspheres and PLGA/CPC 
PLGA/CPC as well as PLGA microspheres and CPC controls were loaded with bovine serum albumin 
(BSA) as presented in Table 1. With CPC, 20 µl of a 8.0% w/v BSA solution in ddH2O was added and 
disks were dried at room temperature. With the PLGA/CPC and PLGA microspheres, BSA was 
incorporated (BSA(I)) into as well as adsorbed (BSA(A)) onto the microspheres(16). For the BSA(I) 
samples, a BSA solution (11.2% w/v BSA in ddH2O) was added to the initial water phase during 
microsphere preparation. The BSA(A) samples were prepared by adding 800µl of a 5.0% w/v BSA 
solution in ddH2O to 1.0 g of microspheres, after which the BSA was freeze-dried onto the spheres. 
After loading the spheres, PLGA/CPC was prepared as described in “Preparation PLGA/CPC”. 
Entrapment efficiency of the microspheres was determined by dissolving a known amount of spheres 
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in sodium hydroxide (NaOH) after which the solution was neutralized with hydrochloric acid (HCl). 
BSA concentration in the resulting solution was measured by high performance liquid chromatography 
(HPLC) using a reversed-phase (RP)-HPLC column (Atlantis®, Waters corp., Milford, MA, USA) and 
the same HPLC system as was applied with GPC with the UV detector at 280nm. A 40/60 mixture of 
acetonitril/water was used as mobile phase containing 10% v/v 0.1M formic acid. Before each analysis 
samples were filtered using Acrodisk® filters (Waters).  
 
Table 1. Loading of BSA per implant 
 Sample 
dimensions  
Theoretical 
loading (mg) 
Entrapment 
efficiency (EE,%) 
Actual Loading 
(mg) 
CPC 7.7*2.0 1.6 - - 
PLGA/CPC                           (radius*height,mm) 
BSA (A) 4.5*9.0 1.5 - - 
BSA (I) 4.5*9.0 1.5 - - 
PLGA Microspheres            (amount, mg) 
BSA (A) 37 1.5 85.7 ± 2.8 1.29 ± 0.04 
BSA (I) 37 1.5 73.4 ± 4.1 1.10 ± 0.06 
 
Release assay 
During the release test, 3 samples of each formulation were incubated in demineralized water (ddH2O). 
Initially, 1.6 ml of ddH2O was added after which samples of 200 µl were taken at t = 0.5, 1, 2 and 24 
h. Thereafter, the sample medium was kept at 1 ml and samples were taken at t = 2, 3, 4, 7 days and 
accordingly every week until 42 days. Starting from 1 day, sample medium was refreshed every time a 
sample was taken. Samples were analyzed by RP-HPLC, and taken in triplicate (n=3). 
 
2.2.5. Statistical analysis 
Data were presented as mean ± standard deviation. Significant differences were determined using 
analysis of variance (ANOVA). Results were considered significant if p<0.05. Calculations were 
performed using GraphPad Instat® (GraphPad Software Inc., San Diego, CA, USA). 
 
3. Results 
3.1. Preparation microspheres/cement  
The prepared PLGA microspheres showed a slightly deformed spherical structure after freeze-drying 
as is visible in Figure 1. Also some empty microsphere shells were observed as well as the inclusion of 
smaller microspheres inside larger ones. The average size of the microspheres was 28.67 µm (Table 2). 
Cement properties of the PLGA/CPC showed a total porosity of 75.1% and macroporosity of 57.1%. 
Compression strength (11.6 MPa) was markedly lower than the CPC. The PLGA/CPC also 
demonstrated a higher initial setting time than the CPC (p<0.001). Final setting time of the 
PLGA/CPC was longer than 20 min, though was reached within 24 h. 
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Figure 1. SEM-
micrograph of PLGA 
microspheres after 
freeze-drying where the 
arrowheads point out 
inclusion of small spheres 
into larger ones (original 
magnification 100x) 
 
 
 
 
 
 
 
 
 
 
Table 2. Characteristics of PLGA/CPC and CPC 
 PLGA/CPC CPC 
Particle size (µm) 28.67 ± 25.65 - 
Sample weight (mg) 176.4 ± 9.0 262.7 ± 6.1 
Porosity (%) 75.1 ± 2.2 40.8 ± 1.3 
Macroporosity (%) 57.9 ± 2.0 0 
Compression strength (MPa) 11.6 ± 4.7 64.4 ± 16.6 
E-modulus (MPa) 748.9 ± 239.0 5435.6 ± 1331.9 
Initial setting time (s) 210 ± 0  108 ± 6 
Final setting time (s) > 1200* 265 ± 31 
* Final setting time reached within 24 h 
 
3.2. Degradation test 
The results of the pH test are given in Figure 2. The medium of the PLGA/CPC showed a fast pH 
decrease in the beginning but stabilized after 42 days at a pH of 4.5. This was significantly lower than 
the CPC control where pH stabilized at 5.8. The development of the mass of the PLGA/CPC and CPC 
is given in Figure 3. The PLGA/CPC demonstrated a significant decrease in mass (p<0.01) already 
after 14 days, whereas the CPC samples showed a 2% increase in mass. The mass of the PLGA/CPC 
decreased further to a total loss of 22%, slightly higher than the weight % of microspheres inside the 
composite. The molecular weight of the PLGA microspheres (Figure 4) showed a significant decrease 
to Mn ≈ 1800 g/mol, Mw ≈ 2300 g/mol after 28 days incubation time. At t = 42 days and at later time 
points the PLGA was completely degraded. Compression strength of the samples (Figure 5) also 
revealed a significant decrease from 13.8 MPa at t = 3 days to 4.6 MPa after 84 days. SEM-
micrographs of the PLGA/CPC at the different time points are shown in Figure 6. Directly after 
mixing, few microspheres were visible and the cement appeared to be dense. At 14 days, a structure of 
Chapter 3__________________________________________________________________________________ 
 64 
degraded polymer inside microsphere cavities was observed. No PLGA polymer was observed after 4 
weeks and small, spherical structures were present inside the pores. Furthermore, after 63 and 84 days 
the calcium phosphate matrix showed a structural deformation and pores became less spherical. 
 
Figure 2. pH change of 
the medium of  the 
PLGA/CPC and CPC 
during the degradation 
test, ** = p<0.01 
 
 
 
 
 
 
 
 
Figure 3. Mass development 
of the PLGA/CPC and CPC 
during the degradation test, 
*** = p<0.001 
 
 
 
 
 
 
 
 
3.3. Release test 
Entrapment efficiency of the microspheres is given in Table 1. Efficiency of the PLGA microspheres 
reached 87% with the BSA(A) samples, whereas with the BSA(I) microspheres (73%) it was 
significantly lower (p<0.05). Entrapment efficiency of the PLGA/CPC and CPC could not be 
measured. 
Figure 7 depicts the result of the release assay with the PLGA/CPC, microspheres and CPC control. 
All PLGA microspheres exhibited a high burst release, but compared to the BSA(A) microspheres, 
inclusion of the BSA (BSA(I)) resulted in a lower burst. With both groups a small sustained release up 
to 42 days was present that was slightly enhanced with the BSA(I) microspheres. When expressed as 
percentage of actual loaded BSA, release efficiency after 42 days reached approximately 80% with the 
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BSA(I) groups and 100% with the BSA(A) groups. The release patterns of the PLGA/CPC or CPC 
samples were different from the PLGA microspheres.  
Figure 4. Molecular weight of 
PLGA during the degradation 
test, A = Number average 
molecular weight (Mn), B = 
weight average molecular 
weight (Mw), ***= p<0.001 
(+=fully degraded PLGA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Compression strength of  
the PLGA/CPC and CPC during the 
degradation test, **=p<0.01 
 
 
 
 
 
 
 
 
 
Within all groups the total amount of BSA released after 42 days was less than 20%, and virtually no 
burst release was obtained. The PLGA/CPC samples overall followed a similar release pattern as the 
CPC, and showed a release of 4.5-6.4% within the first week followed by virtually no sustained BSA 
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release. With the BSA(A) samples, release after 7 days even was significantly less (p<0.05) than the 
CPC.  
 
 
Figure 6. SEM-micrographs of the PLGA/CPC during the degradation test (original magnification 250x) 
 
4. Discussion 
To elucidate the release mechanism of PLGA microsphere/CaP cement composites, in this study a low 
molecular weight PLGA/CPC was investigated for in vitro degradation and drug release characteristics 
using BSA as a model protein. Because drug release from PLGA/CPCs is hypothesized to be the result 
of PLGA microsphere degradation, both degradation and release data should be investigated.  
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Figure 7. BSA release from the PLGA microspheres, PLGA/CPC and CPC expressed as percentage (%) of the 
theoretical loaded BSA 
 
Degradation characteristics and mechanical/physical properties of the PLGA/CPC were determined 
according to an earlier performed study with higher molecular weight PLGA microspheres (Mw = 
50.000 g/mol)(5). In vitro release characteristics were assessed by measuring the concentration of BSA 
in the release medium by RP-HPLC. Loading was performed by inclusion of BSA inside the 
microspheres during the double emulsion process or adsorption of BSA onto the microspheres by 
freeze-drying. BSA-loaded CPC and PLGA microspheres were taken as reference materials. 
Results from the degradation test showed a fast degradation of the PLGA microspheres, which resulted 
in a structure of spherical and interconnected pores inside the cement already after 4 weeks. Because 
of this fast degradation, also the pH (hydrolysis) and compression strength decreased quite 
dramatically. The CPC showed a much smaller pH decrease that was caused by cement reorganization 
into apatite or dissolution of one of the cement starting components (monetite)(18). Compared to a 
PLGA/CPC with PLGA of Mw ≈ 50.000 g/mol(5), degradation was significantly enhanced. Degradation 
rates of these composites therefore can be increased by decreasing the molecular weight of the PLGA. 
Improved degradation of the PLGA microspheres can be beneficial for in vivo conditions but the pH 
decrease should not induce inflammation(19) and mechanical stability should be sufficient to provide 
the porous structure.  
Besides fast microsphere degradation, also signs of cement degradation were observed. Results of the 
PLGA/CPC showed a higher mass loss than the percentage of microspheres added initially, whereas 
the CPC only showed an increase in mass that was caused by precipitate from the PBS solution(20). 
SEM pictures of the samples showed loss of structural stability after 9 and 12 weeks that could be 
related to cement degradation and an increase in the microporosity of the cement. Explanations for 
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improved cement degradation are acidic dissolution by PLGA hydrolysis or the higher porosity of the 
composites after PLGA degradation. SEM investigation revealed also the formation of spherical 
structures inside the macropores. These structures were calcium phosphate shells that precipitated onto 
small PLGA microspheres, which were trapped inside the original microspheres. Such a microsphere 
structure was seen with SEM (Fig.1) and is proof of the formation of microcapsules(21) which also 
involves the encapsulation of smaller spheres by larger ones during the double emulsion technique as a 
result of suboptimal process parameters. These process parameters also explain the difference in 
entrapment efficiency that was observed for BSA(I) (73%) and BSA(A) (87%) microspheres. During 
double-emulsion, BSA can diffuse through the microsphere shell to the surrounding medium resulting 
in decreased entrapment efficiencies(22). Unfortunately, entrapment efficiencies of the PLGA/CPC and 
CPC controls could not be determined using the same method as a result of electrostatic interactions 
between the BSA and the cement. 
From the in vitro release test, multiple observations were made. First of all, the introduction of PLGA 
microspheres inside the cement minimized the burst release that was observed with separate PLGA 
microspheres. Burst release from the PLGA microspheres occurs when loosely bonded proteins near or 
onto the surface dissolve directly after exposing them to the medium. With the BSA(A) microspheres, 
almost all of the BSA was released within 1 day, indicating that freeze-drying the BSA onto the 
spheres does not result in a strong physical bond. Furthermore, a small sustained release with both 
BSA(A) and BSA(I) microspheres was observed. This sustained release is a result of the degradation 
of the microspheres or, with the BSA(I) samples, diffusion of the BSA through the particle surface(23). 
The release curve that was observed with the PLGA/CPC was quite different from the separate 
microspheres and comparable to the CPC. It consisted of a low initial release within 1 week that was 
followed by a period of no release. The introduction of PLGA microspheres in these formulations 
therefore did not markedly improve the release efficiency or altered the release pattern from the 
cement. A plausible explanation for the release pattern observed for both PLGA/CPCs is binding of 
BSA to the cement after release from the (degraded) PLGA microspheres. Furthermore, during cement 
mixing loosely bonded BSA can dissolve into the liquid hardener thereby distributing the BSA evenly 
through the cement.  
With the BSA(A) PLGA/CPC initial release was even less than the CPC control. From the degradation 
experiment we observed that compared to CPC, with PLGA/CPC a stronger pH decrease occurred 
within the first weeks as a result of microsphere degradation. Such a pH changes the state of the 
cement surface, which in the release study resulted in a stronger electrostatic bond with the BSA. In 
more detail, physical bonds between the cement and proteins occur because the surface of the cement 
is covered by negatively charged phosphate groups and positively charged calcium groups. The state 
of the phosphate groups is pH dependent, and can shift from HPO42- to H2PO4-  when pH decreases, 
thereby changing the overall charge of the cement surface. For HA, the point of zero charge (pzc), 
comparable to the isoelectric point of proteins, lies around pH = 6.5-7.3(24-25). This indicates that at an 
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acidic pH the surface of HA, the end product of our cement, is positively charged. Negatively charged 
proteins, like BSA (pI = 5.0), therefore will experience a stronger physical attraction with the cement 
when pH decreases from a neutral to a mild acidic pH as was present initially with the PLGA/CPC but 
also in a lesser extent with the CPC. This phenomenon was also described by Hughes Wassell et al(26), 
who observed a 1.3 times increase of adsorbed BSA onto HA powder when pH dropped from 7.15 to 
5.15. We performed a similar experiment with our cement where BSA loaded microspheres and 
cement powder were added to 3 ml of medium at pH =7.4 (PBS) and medium of pH = 3.35 (citric 
acid). Results after 1 day are listed in Table 3 and show an approximately 3 times decrease in %BSA 
released with the acidic buffer for both BSA(A) and BSA(I) microspheres, indicating a strong pH 
dependency. Alternatively, basic proteins can experience a weaker binding with the cement at an 
acidic pH. This mechanism explains the slightly improved in vitro BMP-2 (pI =8.5) release from a 
PLGA/CPC in acidic buffer (pH = 4.0) that was observed by Ruhé et al(15). 
In an in vivo situation, local pH inside a calcium phosphate implant can also decrease leading to a 
similar phenomenon. Overall, in vivo BMP-2 release from a comparable PLGA/CPC(16) showed a 
better release efficiency and higher sustained release after 4 weeks than an in vitro BMP-2 release 
study using the same composites(15). Under the in vivo conditions, absorption of proteins from the 
surrounding body fluid will influence drug release as they can compete with protein binding sites at 
the cement interface. Alternatively, a higher volume of the body fluid and/or a better flow inside the 
composites neutralizes the acidic degradation products more effectively.  
After PLGA microsphere degradation, the amount of acidic degradation products decreases. As the 
state of the cement surface changes back in neutral conditions, it is hypothesized that adsorbed 
proteins like BSA will experience a weaker interaction with the cement, resulting in a delayed release. 
Also the increase in cement surface area after microsphere degradation can improve drug release from 
the cement. Such a release pattern can explain the enhanced release that was observed with lower 
molecular weight PLGA/CPC (Mw ≈ 5.000) in the earlier described 4 weeks in vivo release study by 
Ruhé et al(16). Within this time period these microspheres should be completely degraded whereas the 
higher molecular weight PLGA microspheres (Mw ≈ 50.000) are still present(5). With our in vitro 
release study we did not observe this feature after 6 weeks, which could be the result of the small 
volume and low buffering capacity of the medium. 
Next to the release pattern, structural integrity of the drug is also an important issue as the drug should 
be active upon release into the surrounding medium. When drugs are released from PLGA 
microspheres, in most cases there is some evidence of structure loss and degradation(27-29). Even during 
the encapsulation of drugs in the w/o/w double-emulsion process, loss of tertiary structure and 
degradation occurs(30). Furthermore, if drug is dispersed into the cement upon mixing, the harsh 
chemical conditions during cement setting possibly can degrade it(14). The end product of our cement, 
hydroxyapatite(HA), is not likely to harm the protein structure as it is known for its stabilizing effect 
on drugs/proteins(31). However, in literature(32), structural degradation of growth factors like BMP-4 
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and bFGF is observed after release from various ceramic scaffolds. Unlike previous studies performed 
with 125I-labelled growth factor(16), the used analysis method (RP-HPLC) in our study gives some 
information about the structure and stability of the released BSA. However, to get a more precise 
impression of the BSA structure, i.e. molecular weight, in our release experiment a pilot study was 
performed in which sample medium of the PLGA/CPC and microspheres at different time points was 
investigated by sodium dodecyl sulphate poly(acryl amide) gel electroforesis (SDS-PAGE)(32) and 
matrix assisted laser dissorption ionization-time of flight mass spectrometry (MALDI-TOF MS)(33). 
Corresponding to the high burst in the release study, results from SDS-PAGE (Figure 8) showed a 
strong signal at the height of BSA for the PLGA microspheres at day 1 of incubation whereas no 
signal was measured with the PLGA/CPC. Further investigation of the release medium of the 
PLGA/CPC with MALDI-TOF MS (Figure 9) showed some peaks in the range 2,000-14,000 g/mol 
with the sample that was taken after 1 week, whereas after 4 weeks almost no signal was observed. 
Degradation of the BSA therefore seems to occur for the PLGA/CPC, but only a very low 
concentration of these degradation products was found.   
 
 
Figure 8. SDS-PAGE chromatogram of BSA released from PLGA microspheres and PLGA/CPC after 1 day 
incubation in release medium; ST=standard, MS = microspheres, COM = PLGA/CPC composites, A = BSA 
adsorbed onto PLGA microspheres, I = BSA incorporated into PLGA microspheres 
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Figure 9. MALDI-TOF MS spectrum within a molecular weight range of 2000-10000 g/mol featuring products 
released from the PLGA/CPC after 7 and 28 days of incubation in release medium 
 
 
5. Conclusion 
By changing the molecular weight of the PLGA, in situ degradation rates of incorporated microspheres 
and concomitant formation of macroporosity can be tailored. In vitro BSA release until 6 weeks from 
PLGA/CPC was marginal and not improved when compared to BSA loaded CPC. Separate PLGA 
microspheres showed high release efficiencies and a release pattern that consisted of a high initial 
burst. Furthermore, structural stability of the released BSA was observed with separate PLGA 
microspheres but not with the PLGA/CPC. From both degradation and release data we can conclude 
that with PLGA/CPC, BSA readsorbed to the cement surface after being released from the (degraded) 
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microspheres. This process was mediated by the pH decrease that occurs as a result of PLGA 
microsphere degradation. 
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1. Introduction 
Bone defects caused by trauma or tumor resection and age related loss of bone mass induce a high 
demand for bone filling materials. Most synthetic alloplasts are not suitable for these types of 
applications because their mechanical/physical or biological properties are not sufficient, so in most 
cases autogenous bone is still used(1-2). On the other hand, calcium phosphate compounds appear to be 
an attractive alternative, as they are osteoconductive and can reach to compression strengths that are 
comparable to bone(3). Especially calcium phosphate cement (CPC) is a good candidate since it can be 
shaped to the defect site after injection and renders an optimal contact between bone and material(4). 
Despite this, the in vivo resorption and tissue ingrowth of most CPCs is slow(5). In previous studies(6-8) 
poly(DL-lactic-co-glycolic acid) (PLGA) microspheres were added to improve the properties of a CPC 
for tissue engineering purposes. These microspheres introduced macroporosity into the cement and 
were also applied for the delivery of growth factors. In vitro degradation tests(6) showed a slow 
degradation of the PLGA microspheres that was accompanied by a pH decrease of the surrounding 
medium. Compressive strength of the microsphere composites decreased concomitantly as the PLGA 
eroded, rendering highly macroporous scaffolds. 
Next to PLGA also other polymers can be applied for the production of microspheres. Especially 
natural polymers like chitosan(9), collagen(10-11) and gelatin are interesting candidates that demonstrate 
enzymatic degradation. Of these polymers, gelatin would be the preferred material because it does not 
express antigenicity in physiological conditions and is completely resorbable in vivo, unlike 
collagen(12). Gelatin microspheres have been used by different authors for the sustained release of 
growth factors(13-14). Here, the loading of growth factor relies on an ion-binding interaction between an 
acidic or basic gelatin and a positively/negatively charged protein(15). To stabilize gelatin microspheres 
in an aqueous environment a crosslinker(16-18) is used. Degradation characteristics of the microspheres 
can be tailored by changing the crosslinking density. Gelatin can be derived from different animal 
sources, though porcine (type A, basic) and bovine (type B, acidic) gelatin cover 95% of both 
household and industrial use. Food grade (FG) gelatin consists mostly of type A gelatin (80%) and less 
of type B (15%). 
The goal of this study was to characterize the gelatin microsphere CPC on mechanical/ physical 
properties and degradation characteristics. For this purpose, food-grade (FG) gelatin microspheres 
with different crosslinking densities were incorporated into the cement. Injectability and 
setting/cohesive properties of the composites were determined. Furthermore, a 12-week in vitro 
degradation test in proteolytic medium was performed using preset scaffolds. Samples were assayed 
on mass loss, compressive strength, E-modulus and morphology. In addition to the in vitro degradation 
test, a degradation study with gelatin microspheres was performed to investigate the influence of 
physical conditions inside the cement like pH and calcium concentration on microsphere stability. 
Also degradation characteristics of type A and type B gelatin microspheres were compared to the 
food-grade gelatin.  
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2. Materials and Methods 
2.1. Materials 
Gelatin (food-grade (FG), Granules, pH = 3.8-7.6, bloom number = 80-120, Merck, Darmstadt, 
Germany; type A (pI = 7.0-9.0, bloom number = 300) / type B (pI = 4.7-5.2, bloom number = 225), 
cell culture tested, Sigma-Aldrich, St. Louis, MO, USA) was used for the preparation of the 
microspheres. Olive oil (Acros Organics, Geel, Belgium) and acetone (HPLC grade, Labscan ltd., 
Dublin, Ireland) were used as substrate during microsphere preparation. Glutaraldehyde (25wt% 
solution, EM-grade, Merck, Darmstadt, Germany) was applied as crosslinker. The calcium phosphate 
cement (Calcibon®, Biomet Merck, Darmstadt, Germany) was composed of 61% α-TCP, 26% 
CaHPO4, 10% CaCO3 and 3% precipitated HA. The cement liquid applied was a 1% aqueous solution 
of Na2HPO4.  
 
2.2. Methods 
2.2.1. Preparation gelatin microspheres 
2.5 g of gelatin was dissolved in 25 ml ddH2O for 30 min at 60°C. While stirring at 500 rpm using a 
Teflon upper stirrer, the resulting clear solution was added slowly (10 ml pipette) to a 250 ml three-
necked round bottom flask containing 125 ml olive oil. During stirring, the round bottom flask was put 
in an ice bath. After 30 min, 50 ml of chilled acetone (4°C) and glutaraldehyde (0.5 ml = 6.25 mM) 
was added slowly. The solution was stirred for another 1h (GEL1) or 2h (GEL2) to produce 
microspheres with a higher extent of crosslinking. Microspheres were collected by filtration (D3, 
Schott Duran, Mainz, Germany) and washed several times with acetone (approx. 1 l) to remove 
residual olive oil. Following this, microspheres were dried over night in a vacuum stove. For the 
enhanced degradation test all microspheres were crosslinked for 1h. 
 
2.2.2. Preparation of gelatin microsphere CPC 
Gelatin microspheres were swollen before cement powder or liquid hardener was added to obtain a 
good distribution of microspheres inside the cement. Therefore, 50 mg of dried GEL1/GEL2 
microspheres were put in a 2 ml plastic syringe, subsequently adding 300 µl/250 µl demineralized 
water (ddH2O) after which the syringe was stirred vigorously for 15 s using a mixing device (Silamat® 
mixing apparatus, Vivadent, Schaan, Liechtenstein). Subsequently, 950 mg cement powder was added 
to the swollen microspheres and the resulting mixture was stirred for another 15 s. Then 300 µl of 
hardener solution (1% Na2HPO4) was added and the content was stirred again for 15 s. The resulting 
cement paste was injected into a Teflon mould (6 cylinders, 4.5 x 10 mm), after which samples were 
left to set at room temperature for 24 hr and stored in a vacuum stove. 
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2.2.3. Morphology analysis 
The morphology of the gelatin microspheres and gelatin microsphere CPC was evaluated by scanning 
electron microscopy (SEM) (JEOL 6400-LINK AN 10000 at 10 kV). The samples were mounted on 
aluminum stubs using carbon tape and sputter-coated with gold-palladium prior to examination.  
 
2.2.4. Size distribution 
The particle size distribution of the gelatin microspheres was determined by image analysis. Dry 
microspheres were visualized by SEM, while swollen microspheres were characterized with an optical 
microscope (Leica) after suspension in ddH2O. The size distribution of both dry and swollen spheres 
was determined using digital image software (Leica Qwin). 
 
2.2.5. Injectability 
After mixing, the syringe, with an orifice diameter of 1.7 mm, was fitted vertically in a fixture and put 
under the platen of a tensile bench set (858 MiniBionixII®, MTS Corp., Eden Prairie, MN, USA) in 
tension mode(6). The cement composites were compressed until approximately 1 cc was present inside 
the syringes, which was used as starting point. 25 seconds after mixing the cement (for 15s), a 
compressive force was applied to the syringe with a constant velocity of 10 mm/min. The compressive 
force was recorded as a function of the plunger travel length(19) after which it was converted into time. 
The time from mixing the paste until pressure reaches 60N, is referred to as the injection time. If all 
the paste is injected before pressure increase, the paste is regarded as fully injectable. All tests were 
performed threefold (n = 3). 
 
2.2.6. Setting time 
The initial and final setting times were assessed using custom available Gillmore needles (ASTM 
C266). A bronze block was used as mould containing 6 holes (6 mm in diameter, 12 mm in height). 
The mould was placed in a water bath to simulate body temperature (37˚C). Samples were mixed and 
injected into the mould in a retrograde fashion, after which the initial and final setting time of the 
samples was determined (n = 3). 
For determination of the cohesive properties of the gelatin microsphere CPC, samples were injected 
into Ringer’s solution at 37°C. During the cement setting time it was observed whether the paste 
retained its original configuration or powder formation/disintegration occurred. Every anomaly was 
recorded. 
 
2.2.7. Porosity 
The macro- and total porosity of preset gelatin microsphere CPC samples was determined. The 
macroporosity is the porosity in which the pores are created by the degradation of gelatin 
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microspheres. The total porosity is the macroporosity plus the original microporosity of the cement. 
When the gelatin microspheres are not degraded, the macroporosity corresponds to the vol% of 
microspheres initially present inside the cement. 
To measure these parameters, both gelatin microsphere CPC samples and microporous CPC samples 
of a known volume were placed in an oven at 650°C for 2 h. After burning out the gelatin/moisture, 
samples were weighed and Equation 1 and 2 were used for the derivation of the total porosity and the 
macroporosity. Tests were performed threefold (n = 3). 
%100*)
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m
ρε −=         Equation 1 
%100*)1(
micro
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m−=ε         Equation 2 
Legend: εtot = total porosity (%), εmacro = macroporosity (%), mmacro = average mass macroporous sample (after 
burning out gelatin) (g, n=3), mmicro = average mass microporous sample (g, n=3), V = volume sample (cm3), 
ρHAP = density hydroxy apatite (g/cm3) 
 
2.2.8. Degradation assay 
For the degradation assay gelatin microsphere CPC samples were prepared as described before. 
Samples were placed in 3 ml of phosphate-buffered saline (PBS, pH 7.4) containing 50 µg/ml 
gentamycin and 373 ng/ml collagenase 1A(Sigma)(13) and incubated at 37˚C in a water bath on a 
shaker table (70 rpm) for 12 weeks. Every 3-4 days sample buffer was refreshed. At days 1, 3, 7, 14, 
28, 42 and 84, specimens were subjected to analysis according to the descriptions summarized below. 
Samples were taken fivefold (n = 5). Gelatin microspheres (8-9 mg, dry spheres) and microporous 
cement scaffolds were used as a control.  
pH measurements 
After removal of the samples from the water bath the pH of the PBS medium was measured.  
Mass loss quantification 
Samples were freeze-dried overnight before measuring the mass. The mass loss of the samples was 
calculated using Equation 3. 
%100*
0
0
M
MM
R nL
−=         Equation 3 
Legend: RL = mass loss sample at t = n (%), M0 = mass sample at t = 0 (g), Mn = mass sample at t = n (g) 
 
Morphology 
The morphology of the samples was determined using SEM. To visualize composite degradation and 
increase in (macro)porosity, overview pictures were taken at a magnification of 100x. Also, pictures 
were taken at higher magnifications to visualize the microsphere degradation. Next to that, energy 
dispersive X-Ray spectrometry (EDS) was performed for further material analysis. 
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Mechanical characteristics  
Samples were placed in a mechanical testing bench (858 MiniBionixII®, MTS Corp., Eden Prairie, 
MN, USA) and both compressive strength and E-modulus along the height of the specimens were 
measured at a crosshead speed of 0.5 mm/min.  
 
2.2.9. Supplementary microsphere degradation study 
In addition to the 12 weeks degradation study, a degradation study using gelatin microspheres was 
performed to investigate the influence of physical conditions inside the cement like pH and calcium 
concentration on microsphere stability. Also the degradation characteristics of FG gelatin 
microspheres were compared to microspheres of type A and type B gelatin. In this study the 
degradation of the microspheres was enhanced by applying a high concentration of gelatin-degrading 
enzyme, which enabled us to compare the degradation characteristics of these microspheres within a 
short time period. For this purpose 10 mg of 1h crosslinked gelatin microspheres of either type A, B or 
FG were put in 3 ml PBS containing 10µg/ml collagenase 1A at 37°C. Applying these conditions, a 
pilot study showed that FG microspheres were fully degraded within 3 days. Because an exponential 
degradation profile was observed in this pilot, a time period of 1 day was chosen for the degradation 
study. To mimic the conditions inside the gelatin microsphere CPCs, gelatin microspheres were 
pretreated for 1 day in PBS containing 0.1M CaCl2 (pH = 5.72) before they were exposed to the 
enhanced degradation medium. PBS (pH = 7.4) and acidic PBS (pH = 5.72) were taken as a control. 
Samples were assayed on mass loss and morphology (n = 3). 
 
2.2.10. Statistical analysis 
Data were arranged as mean ± standard deviation. Significant differences were determined using 
analysis of variance (ANOVA). Results were considered significant if p<0.05. Calculations were 
performed using GraphPad Instat®. 
 
3. Results 
3.1. Preparation microspheres 
SEM-micrographs of the prepared microspheres are shown in Figure 1A-B. Dry microspheres were 
partially agglomerated and imprints of the interconnections between the spheres were visible at the 
surface. In an aqueous environment, the GEL1 and GEL2 microspheres showed an approximately 1.5 
times increase in diameter (Table 1) during which the interconnections were broken. The size 
distribution (Figure 1C) showed that most unswollen microspheres were below 10 µm in diameter and 
an increase in sphere size higher than 30µm was observed after swelling. Overall, a slightly higher 
percentage of larger spheres was observed in the GEL1 group. 
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Figure 1. SEM image of the morphology of GEL1 microspheres (A), GEL2 microspheres (B) and size distribu-
tion of dry and swollen microspheres (C), group size: n=171/166 (dry microspheres), n=201/222 (swollen micro-
spheres) 
 
Table 1. Physical parameters cement/microsphere formulations 
 Microporous(6) GEL1 CPC GEL2 CPC 
Average microsphere size (µm) - 9.70 (dry) 
14.79 (swollen) 
8.64 (dry) 
13.76 (swollen) 
Initial setting time (s) 108.3 ± 5.8 165.0 ± 15.0 145.0 ± 8.7 
Injection time (s) 108 128 120 
Mass (mg) 262.7 ± 6.1 166.0 ± 5.3 174.2 ± 5.5 
Porosity * 45.52± 1.26 69.67 ± 1.29 69.21 ± 0.36 
Macro porosity * - 44.32 43.49 
* = after removing gelatin microspheres 
 
3.2. Preparation & clinical handling properties gelatin microsphere CPC 
A SEM-micrograph of the microspheres inside the cement is given in Figure 2A, which is 
representative for both GEL1 and GEL2 microsphere CPCs. A substantial percentage of the spheres 
was broken, showing an eggshell structure. Furthermore, an equal distribution of microspheres inside 
the cement was obtained.  The injectability graph of the gelatin microsphere CPCs (Figure 2B) showed 
that the pressure on the syringe increased at a later time point than the microporous cement(6), 
indicating that the composite cement was easier to inject. When comparing both gelatin microsphere 
CPCs, the GEL1 composite showed a longer injection time, i.e. better injectability than the GEL2 
composite. The setting time (Table 1) of both gelatin microsphere CPCs was comparable to each other 
and slightly higher than the microporous cement (p<0.01). No final setting time was measured due to 
the high water content of the gelatin microspheres. Cohesion tests revealed no powder formation or 
disintegration when injecting the samples in an aqueous environment. The macroporosity of both 
GEL1 and GEL2 microsphere CPCs was 43-44%, with a total porosity of 69-70%.  
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Figure 2. Morphology gelatin microsphere CPC (A) and injectability graph of GEL1/GEL2 microsphere CPC 
and microporous CPC(6) (B) 
 
3.3. Degradation assay 
In Figure 3A the cumulative pH of the PBS medium is given as a function of the degradation time. The 
medium of both gelatin microsphere CPCs showed an initial pH increase, followed by a decrease and 
stabilized at a pH of 6.1 at t = 40 days. The release medium of both GEL1 and GEL2 microspheres 
showed a small decrease to a pH of 7.1. The development of the mass in time is shown in Figure 3B. 
For both gelatin microsphere CPCs an initial increase of 2% was followed by a slow decrease in mass. 
After 12 weeks a maximum decrease of 2% was observed. The microporous cement only showed an 
increase in mass of 3% that appeared to decrease after 12 weeks. Significant differences in mass loss 
between the microporous cement and gelatin microsphere CPCs were observed (p<0.05 at t = 4, 8 
weeks), though only the GEL1 microsphere CPC showed a significant decrease in mass at t = 12 
weeks (p<0.01). The gelatin microspheres showed an initial increase in mass that was higher than the 
increase of the gelatin microsphere CPCs, but decreased very rapidly after 3 days. Significant 
differences between the GEL1 and GEL2 microspheres were observed at day 1 and 14 (p<0.05), 
although the trend was similar.  
The development of the compression strength of the gelatin microsphere CPCs over time is given in 
Figure 4A. An initial increase was observed over 7 days, after which the compression strength 
remained almost constant for 12 weeks. The final compression strength of both gelatin microsphere 
CPCs was 30 MPa, which was significantly lower than the microporous cement (p<0.001). The E-
modulus (Figure 4B) showed a comparable trend with respect to the compression strength with an 
increase till day 7 after which it remained stable at ± 2000 MPa. Also here the microporous cement 
was significantly higher (p<0.05) and no significant differences were observed between the GEL1 and 
GEL2 composites. 
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Figure 3. pH decrease of surrounding medium (A) and mass loss (B) as a function of degradation time of the 
GEL1/GEL2 microsphere CPC, microspheres and microporous cement 
 
The morphology of the gelatin microsphere CPCs and gelatin microspheres separately are given in 
Figure 5-6. For both gelatin microsphere CPCs small differences in morphology were observed 
between samples from day 1 to week 12. Microsphere structures were still visible after 12 weeks and 
no increase in macroporosity was observed during the degradation test. In contrast, comparison of 
samples taken at day 1 with samples taken at later time points showed even a clear densification of the 
material. At higher magnifications (Figure 7), the presence of crystals onto/inside the gelatin 
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microspheres was observed. EDS analysis revealed that these crystals consisted of calcium and 
phosphate which indicated a recristallization of the cement at these sites.  
 
 
Figure 4. Compression strength (A) and E-modulus (B) as a function of degradation time of the GEL1/GEL2 
microsphere CPC and microporous cement 
 
The separate gelatin microspheres showed already deformations at day 1, slowly losing their spherical 
shape and fusing into a network of gelatin particles at week 4 and 6. After 12 weeks no separate 
gelatin microspheres were distinguished anymore. The structures still visible with SEM were traced to 
accumulations of PBS salts and some salts remaining from the gelatin. Differences between the GEL1 
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and GEL 2 microspheres were visible especially at 4 weeks where the remaining structures of the 
GEL2 microspheres showed a smaller, more particle-like morphology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. SEM-micrographs of GEL1 microsphere CPC(left) and GEL1 microspheres (right) at t =1 day and 4,6 
and 12 weeks (original magnification 100x), arrows indicate the presence of gelatin microsphere shells 
 
3.4. Supplementary microsphere degradation study 
Figure 8 shows the % mass left after 1 day in degradation medium using three types of gelatin and 
three different pretreatment methods. The results showed that the pretreatment method was important 
since both PBS + CaCl2 and PBS (pH = 5.72) groups degraded significantly slower than the PBS (pH 
= 7.4) group with all types of gelatin (Table 2).  
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Figure 6. SEM-micrographs of GEL2 microsphere CPC(left) and GEL2 microspheres (right) at t =1 day and 4,6 
and 12 weeks (original magnification 100x), arrows indicate the presence of gelatin microsphere shells 
 
A difference between the PBS (pH = 5.72) group and the PBS + CaCl2 group was observed with type 
B gelatin that exhibited a higher mass loss with the PBS + CaCl2 group. Furthermore it was observed 
that both type A and type B gelatin degraded significantly faster than the FG gelatin within all 
pretreatment groups.  
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Figure 7. Close-up pictures of gelatin microspheres inside the cement, showing precipitate onto/inside the 
gelatin microspheres (arrows); A = GEL1 3 days (original magnification 250x), B = GEL1 2 weeks (original 
magnification 3000x), C = GEL1 6 weeks (original magnification 1000x), D = GEL2 6 weeks (original mag-
nification 1000x) 
 
Figures 9-11 depict SEM-micrographs of gelatin type A, type B and FG microspheres before and after 
pretreatment and after 1 day in enhanced degradation medium. Before pretreatment only perfect 
spheres were present, after pretreatment the spheres were deformed within all groups. After 1 day in 
enhanced degradation medium, microparticle structure was lost in the PBS (pH=7.4) groups, while 
with the PBS+CaCl2 and PBS (pH=5.72) groups microparticles or a structure of elongated/connected 
microparticle structures were still visible. Also, morphological degradation was found to differ 
between the various types of gelatin. Microspheres prepared of FG gelatin maintained their 
microsphere structure very well, while type A gelatin microspheres showed deformations into an 
agglomerate structure within all pretreatment groups. Type B gelatin was intermediate, with the 
PBS+CaCl2-group showing a separate microparticle structure and the PBS (pH=5.72) group showing 
an agglomerate structure consisting of thin, elongated microparticles. 
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Figure 8. Mass remaining 
at t=1 day of enhanced 
degradation with Type A, 
Type B and FG gelatin 
microspheres after pre-
treatment in PBS with 
pH=7.4, 0.1M CaCl2 or 
pH=5.72 
 
 
 
 
 
Table 2. Statistical significance samples supplementary degradation study 
Parameter Samples Significance  
type A PBS (7.4) vs type A PBS+CaCl2  p < 0.001 
type A PBS (7.4) vs type A PBS (5.72) p < 0.001 
type B PBS (7.4) vs type B PBS+ CaCl2 p < 0.05 
type B PBS (7.4) vs type B PBS (5.72) p < 0.001 
type B PBS+ CaCl2 vs type B PBS (5.72) p < 0.001 
type FG PBS (7.4) vs type FG PBS + CaCl2  p < 0.001 
Pretreatment method 
type FG PBS (7.4) vs type FG PBS (5.72) p < 0.001 
type A PBS (7.4) vs type B PBS (7.4) p < 0.05 
type A PBS (7.4) vs type FG PBS (7.4) p < 0.001 
type B PBS (7.4) vs type FG PBS (7.4) p < 0.01 
type A PBS + CaCl2 vs type FG PBS+ CaCl2 p < 0.001 
type B PBS+ CaCl2 vs type FG PBS+ CaCl2 p < 0.001 
type A PBS (5.72) vs type FG PBS (5.72) p < 0.001 
Type of gelatin 
type B PBS (5.72) vs type FG PBS (5.72) p < 0.001 
 
4. Discussion 
In this study gelatin microspheres were added to a microporous calcium phosphate cement to 
investigate the possibility of these composite materials to serve as an injectable bone substitute, and 
secondly as a possible creator of macroporosity after gelatin degradation. For this purpose, food grade 
(FG) gelatin microspheres with different crosslinking density were added to the cement and subjected 
to physical/chemical characterization. An in vitro degradation study with these composites was 
performed in proteolytic degradation medium to see whether macroporosity could be created. 
Furthermore, to investigate the influence of physical conditions inside the cement like pH and calcium 
concentration on microsphere stability, a supplementary degradation study was performed. In this 
degradation study also microspheres of cell-culture-tested-gelatin type A and type B were investigated 
and compared to the FG gelatin microspheres. 
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Figure 9. SEM-micrographs of Type A gelatin microspheres before pretreatment (upper), after pretreatment in 
PBS with pH= 7.4, 0.1M CaCl2 or pH=5.72 (middle) and after t=1 day of enhanced degradation study (lower) 
(original magnification 500x) 
 
The physical characteristics of the cement with added gelatin microspheres differed significantly from 
the microporous cement. Initial setting time showed a significant increase and final setting time was 
not measurable. An explanation for this is that the gelatin microspheres were added to the cement in a 
swollen state to obtain a good distribution. The water inside these microspheres contributed to cement 
setting, leading to increased setting times(20). On the other hand, the addition of gelatin microspheres to 
the cement resulted in improved injection properties, as injection time increased for the gelatin 
microsphere CPCs when compared to microporous cement. Differences in injectability were observed 
between the GEL1 and GEL2 composite where increased crosslinking of the gelatin microspheres led 
to more stiffer structures(21). After cement setting, SEM revealed that the microspheres inside the 
gelatin microsphere CPCs showed a structure of broken, hollow spheres. It can be hypothesized that 
physical bonds between the gelatin microspheres and surrounding cement were responsible for this 
structure as shrink stresses, arisen during drying, forced the immobilized spheres to break.  
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Figure 10. SEM-micrographs of Type B gelatin microspheres before pretreatment (upper), after pretreatment in 
PBS with pH= 7.4, 0.1M CaCl2 or pH=5.72 (middle) and after t=1 day of enhanced degradation study (lower) 
(original magnification 500x) 
 
The degradation experiment showed an initial increase in mass for the gelatin microsphere CPCs at 
day 1 and 3. This increase in mass was also observed in a higher extent with the separate gelatin 
microspheres and the microporous cement. An explanation is the precipitation of PBS crystals on the 
outside of the cement samples and microspheres during the experiment. The high increase observed 
with separate gelatin microspheres was caused by a similar mechanism. Here, weight was measured 
after gently removing the medium above the microsphere gel and freeze-drying the microspheres. 
Because the swollen gelatin microspheres contained about 6 times their wt% of water, they also 
retained a PBS precipitate that contributed to the weight of the samples. Rinsing the microspheres with 
demineralized water before drying is not a solution, since this will greatly influence the mass of the 
microspheres themselves as degradation products dissolve during rinsing and microspheres will get 
lost.   
The initial decrease in pH was also observed in a previous experiment(6) and is due to the release of 
acidic products from the cement, while the microspheres themselves only show a minimal decrease in 
pH. 
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Figure 11. SEM-micrographs of Type FG gelatin microspheres before pretreatment (upper), after pretreatment in 
PBS with pH= 7.4, 0.1M CaCl2 or pH=5.72 (middle) and after t=1 day of enhanced degradation study (lower) 
(original magnification 500x) 
 
The gelatin microsphere CPCs also showed a striking increase in mechanical strength within the first 7 
days. This increase is due to the recristallization of the cement into hydroxyapatite, which is well-
described in literature(20). In addition, the clear densification of the cement observed with SEM is most 
likely also caused by cement recristallization. Because of the biomimetic properties of the gelatin(12), 
the fractured microspheres showed a shell of calcium phosphate (CaP) precipitate onto the surface 
forming a strong bond between the cement and the gelatin. Comparison of the current results with 
PLGA microsphere CPCs in a previous experiment(6), the PLGA microspheres were always present 
without a shell of CaP precipitate. At later time points (>2 weeks) even the formation of crystals inside 
the gelatin microspheres was observed, indicating that the pores formed by the microspheres can be 
filled with a precipitate.  
At the end of the degradation test, the obtained scaffold did not show an increase in macroporosity or 
increased cement resorption. A first explanation for these results is the occurrence of the discussed 
CaP precipitates onto and inside gelatin microspheres. The volume % of gelatin microspheres inside 
the composite should be sufficient to form interconnections between the microspheres. However, if 
CaP is precipitating between two contacting microspheres, no interconnection will be formed but a 
shell of crystalline hydroxyapatite (HA). Increasing the % of microspheres inside the cement, can 
solve this problem partially as the influence of the cement will be smaller and more interconnections 
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will be present. On the other hand, precipitation will still occur and the addition of more than 5wt% of 
microspheres greatly increases setting time and decreases mechanical properties(6,20). 
Secondly, the weight loss of the GEL1 and GEL2 microsphere CPCs was very small when compared 
to the microporous cement and did not exceed the 5wt% of microspheres added initially. If the gelatin 
microspheres inside the cement composite had degraded as fast as the separate gelatin microspheres, 
the composites should have shown a higher decrease in mass and distinct morphological degradation 
of the microspheres after 6-12 weeks. SEM-pictures at these time points still showed the presence of 
intact gelatin shells throughout the composite and therefore it can be concluded that the microspheres 
degraded slower inside these composites. An explanation for the delayed degradation is 
binding/deactivation of the enzyme to the CPC. Since gelatin degrades by an enzymatic route, the 
calcium phosphate matrix of the gelatin microsphere CPC can prevent the enzyme from entering the 
material. Collagenase is prone to bind to CPC, which was proven to have a protein-binding 
capacity(7,22-23). According to Kremer et al.(24) a suspension of hydroxyapatite crystals in combination 
with free Ca2+-ions (>0.5 mM) even can induce an autolytic degradation of matrix metalloprotease-1 
(MMP-1, interstitial collagenase). A decrease in pH, as observed with the gelatin microsphere CPCs, 
also could have influenced collagenase activity. However, the optimal pH range for collagenase is 6.3-
8(25) and individual pH values measured during the test never dropped below 6.8. 
From the supplementary microsphere degradation test it can be concluded that a small pH decrease as 
is present inside the microporous cement(6), delays gelatin microsphere degradation by changing the 
microsphere structure/stability. This is most likely caused by the pH-dependent crosslink reaction of 
residual aldehyde groups after subjecting the microspheres/composite to the degradation medium. In 
this experiment gelatin microspheres were crosslinked with glutaraldehyde to ensure structural 
stability of the spheres during cement mixing. The amount of glutaraldehyde used (6.25 mM) and 
crosslink time (1h minimum) were just sufficient for sphere stability because a fast degrading 
microsphere was proposed to give a superior cement composite. However, despite this low amount of 
crosslinker, with the applied crosslink method free aldehyde groups were still present after 
microsphere preparation as glutaraldehyde partially exists as oligomers with multiple aldehyde 
chains(26). In aqueous conditions, for example the degradation medium, these aldehyde chains can 
further react with free amino groups, preferentially lysine or arginine in the gelatin(27) which leads to 
the formation of new crosslinks, in particularly Schiff bases (R1R2C=N-R3, with R3= alkylic or 
arylic)(28-29). As aldehyde groups become more electrophilic at a lower pH(30), the modest pH decrease 
must have accelerated these crosslink reactions thereby stabilizing the microspheres against proteolytic 
degradation. An approach to prevent this delayed crosslink reaction is for example the addition of an 
aldehyde reagent (inhibitor) to the oil phase at the end of microsphere preparation. Glycin(13,31) is 
commonly used as it is a body-own substance. Also, the combined used of citric acid and citric 
acic/glycin(32) shows inhibition of the crosslink reaction. 
_________________________Introduction of gelatin microspheres into an injectable calcium phosphate cement  
 93
Next to covalent bonding of gelatin chains, non-covalent bonding also played a small role in the 
gelatin microsphere CPC degradation as was observed in the supplementary degradation test. Ca2+-
ions are present inside the degradation medium due to the dissolution of monetite and calcium 
carbonate. These Ca2+ ions can bind to multiple sites in proteins(33), especially electrostatic interactions 
with the carboxy groups(34) from amino acids, like aspartate and glutamate(27), can give stable bonds 
(Figure 12). An example of such a mechanism is given by Reinhardt et al.(35) who observed that Ca2+ 
binding to motifs in Fibrillin-1 (an extracellular matrix protein) stabilizes the structure against 
proteolytic degradation. In contrast to this result, in this study the addition of Ca2+-ions led to an 
increase in degradation rate as was observed with type B gelatin microspheres. Here, the microspheres 
of the PBS+CaCl2 group showed a significant higher weight loss than the PBS (pH = 5.72) group, 
whereas the pH during pretreatment of both groups was the same. An explanation is that with type B 
gelatin Ca2+ crosslinks existed that stabilized the microparticle morphology but did not hamper 
microsphere degradation. The maintained microparticle structure possibly enhanced proteolytic 
degradation due to the larger surface area of these structures. The higher amount of carboxylic groups 
of type B gelatin (100-115 mM) when compared to type A gelatin (78-80 mM)(36) was responsible for 
the difference between the gelatin types, giving type B gelatin a better Ca2+-binding capacity. 
Regarding this capacity, another explanation for the higher degradation rate is a difference in enzyme 
activity. Because Ca2+ serves as a cofactor for interstitial collagenase(37-38), different authors have 
shown a reactivation of collagenase/gelatinase in the presence of  3.7-10 mM of free Ca2+ (39-40). 
Therefore if the gelatin also released Ca2+ during proteolytic degradation it reactivated the enzyme, 
which would be more pronounced with the type B gelatin. 
 
 
Figure 12. Folding of protein chains by interaction 
with Ca2+ 
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Comparison of the three types of gelatin in the supplementary degradation test revealed that in all 
pretreatment groups type A and type B gelatin microspheres degraded significantly faster than FG 
gelatin microspheres. The main difference between the two cell-culture tested gelatins and the FG 
gelatin is the bloom number that is significantly lower with the FG gelatin. The bloom number is a 
measure of gel strength of the gelatin(36) and is proportional to the average molecular weight of the 
chains. This implies that FG gelatin has a significant lower molecular weight and produces more 
gelatin chains per unit of microsphere surface than type A or type B gelatin. It therefore can be 
hypothesized that with type A and type B gelatin microspheres, enzymatic cleavage of a single “large” 
gelatin chain has a higher impact on microsphere degradation than with the FG gelatin, which results 
in a faster degradation.  
 
5. Conclusion 
The prepared gelatin microsphere CPCs were easy to handle with an initial setting time of less than 3 
min. They possessed a compression strength of ± 30 MPa and a microsphere content of 43-44 vol%. In 
vitro degradation showed a modest pH decrease, a mechanical strength that remained constant in time 
and a small decrease in mass. SEM-investigation of the gelatin microsphere CPCs during the 
degradation test revealed little change in morphology, where separate gelatin microspheres showed 
complete degradation within the same time period. At the end of the degradation test, no increase in 
macroporosity was observed but even a clear densification of the composite. Parameters that 
contributed to this phenomenon were cement recristallization inside/onto the microspheres and a 
delayed gelatin degradation. From the supplementary microsphere degradation test it was concluded 
that the modest pH decrease present inside the cement is a factor in the delayed gelatin degradation. 
Also differences in degradation rate between different types of gelatin were observed. Overall, the 
gelatin microsphere CPC showed good handling properties, though degradation characteristics should 
be further investigated to generate a macroporous scaffold. 
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1. Introduction 
In the field of tissue engineering, gelatin microspheres are used by many researchers as a drug delivery 
system(1-3). Characteristics that make these gelatin microspheres a good candidate for drug delivery are 
a very facile and controlled method of microparticle preparation(4-5), a biodegradability that can be 
tailored by crosslinking(6-7) and the possibility of obtaining a sustained release of drug / growth factor(8-
9). This sustained release is due to electrostatic binding of the drug with the gelatin. Next to that, 
gelatin microspheres degrade proteolytically and do not produce high amounts of acidic degradation 
products, unlike the PLGA/PLLA microspheres(10).  
In a former experiment, gelatin microspheres were already introduced into an injectable calcium 
phosphate cement (CPC)(11). CPC is a biocompatible and osteoconductive material that is commonly 
applied for the usage of bone filler in the field of dentistry, orthopedic and reconstructive surgery(12-14). 
For tissue engineering applications, however, in vivo resorption of the bulk material and ingrowth of 
tissue is too slow(15). Therefore, faster degrading gelatin microspheres (food-grade (FG), 5 wt%, 45 
vol%) were introduced into the cement to produce a macroporous scaffold after proteolytic 
degradation of the microspheres. Results showed that though the mechanical and physical properties of 
the gelatin microsphere CPC were satisfactory, in vitro degradation of the composite showed no 
increase in macroporosity(11). Parameters that contributed to this phenomenon were a delayed 
microsphere degradation inside the cement that was not influenced by the microsphere crosslinking 
density and recristallization of the cement onto/inside the microspheres, hampering the formation of 
interconnections between formed pores. In addition, a supplementary degradation test with gelatin 
microspheres showed that the type of gelatin also influenced the degradation properties as both porcine 
(type A) and bovine (type B) gelatin degraded faster than the applied FG gelatin, which was caused by 
the difference in molecular weight (Bloom number)(16) of the gelatin chains. 
Because of the faster degradation, a gelatin type A microsphere CPC (GELA CPC) was formulated to 
obtain macroporosity into the cement. Also, with this gelatin a mechanically stable, injectable and 
setting 10 wt% gelatin microsphere CPC was synthesized that was hypothesized to produce a higher 
interconnectivity(17) of the spheres compared to the 5wt% FG gelatin microsphere CPC. 
To increase in vivo resorption and bone ingrowth into the material, osteoinductive growth factors can 
be introduced into CPC. Release patterns, however, often show a marginal sustained release as the 
cement has a strong interaction with the loaded drug(18-19). With a gelatin microsphere CPC, drug can 
be loaded inside the gelatin microspheres, thereby shielding the drug from the surrounding cement. To 
investigate drug/protein release from GELA CPCs, gelatin type A (GELA) microspheres (pI = 7.0-9.0) 
can be used to electrostatically bind acidic model proteins like bovine serum albumin (BSA, pI =5.0) 
in an in vitro release study(20). 
In view of the above mentioned, the goal of the current study was to investigate the effect of the 
inclusion of GELA microspheres in CPC on in vitro degradation properties and drug/protein release 
characteristics of the cement. Therefore, a 12 week degradation test was performed in proteolytic 
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medium and samples were assayed on mass, compression strength and morphology. Release 
characteristics of the composites were determined by loading the microspheres with BSA using two 
different methods, after which BSA concentration in the release medium was measured by reversed-
phase (RP)-HPLC. Finally, the structure of the released proteins was assayed using SDS-PAGE. 
 
2. Materials and Methods 
2.1. Materials 
Gelatin (Powder, type A, IEP 7.0-9.0, Acros Organics, Geel, Belgium) was used for the preparation of 
the microspheres. Olive oil (Acros Organics, Geel, Belgium) and acetone (HPLC grade, Labscan ltd., 
Dublin, Ireland) were used as substrate during microsphere preparation. Glutaraldehyde (25wt% 
solution, EM-grade, Merck, Darmstadt, Germany) was applied as crosslinker. The calcium phosphate 
cement (Calcibon®, Biomet Merck, Darmstadt, Germany) consisted of 61% α-TCP, 26% CaHPO4, 
10% CaCO3 and 3% precipitated HA. The cement liquid applied was a 1% aqueous solution of 
Na2HPO4.  
 
2.2. Methods 
2.2.1. Preparation GELA microspheres 
2.5 g of gelatin was dissolved in 25 ml ddH2O at an elevated temperature (30 min at 60°C). The 
resulting clear solution was added slowly (10 ml pipette) to a 250 ml three-necked round bottom flask 
containing 125 ml olive oil while stirring at 500 rpm (PTFE upper stirrer). After the gelatin solution 
was added to the oil, stirring was continued and the round bottom flask was put in an ice bath so that 
the temperature of the oil phase was kept at 4°C. After 30 min, 50 ml of chilled acetone (4°C) and 
glutaraldehyde (0.5 ml = 6.25 mM) was added slowly. The solution was stirred and cooled for another 
1h. Microspheres were collected by filtration (D3, Schott Duran, Mainz, Germany) and washed several 
times with acetone (approx. 1 l) to remove residual olive oil. After that, they were stored in a drying 
chamber until further use.  
 
2.2.2. Preparation GELA CPC 
10 wt% gelatin microsphere/calcium phosphate cement composites were prepared. To generate an 
equal distribution of microspheres inside the cement, GELA microspheres were swollen first before 
cement was added. Therefore, 100 mg of microspheres were put in a 2 ml plastic syringe; subsequently 
560µl ddH2O was added after which the syringe was stirred vigorously for 15 s (Silamat® mixing 
apparatus, Vivadent, Schaan, Liechtenstein). To the resulting swollen microspheres, 900 mg of cement 
was added and the mixture was stirred for 15 s. Then 260 µl 1% Na2HPO4 solution was added and the 
contents were stirred again for 15 s. The acquired paste was injected into a PTFE mould (cylinders 4.5 
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x 9 mm), after which the samples were left to set at room temperature for 24 hr and stored in a drying 
chamber. 
 
2.2.3. Morphology analysis & size distribution 
The morphology of dry GELA microspheres and GELA CPC was visualized by scanning electron 
microscopy (SEM) (JEOL 6400-LINK AN 10000 at 10 kV). Swollen spheres were suspended in 
demineralised water (ddH2O) for 1 day before pictures were taken with an optical microscope (Leica 
DMRBE microscope, Leica Microsystems AG, Wetzlar, Germany). The size distribution of dry and 
swollen spheres was determined using digital imaging software (Leica Qwin, Leica Microsystems AG, 
Wetzlar, Germany). 
 
2.2.4. Setting time & cohesion properties 
Setting time and cohesion properties of the GELA CPC were determined as described previously(21). In 
brief, initial and final setting times were assessed using custom available Gillmore needles. For this, a 
bronze block containing 6 holes (6 mm in diameter, 12 mm in height) was used as mould and placed in 
a water bath at 37˚C. Samples were mixed and injected in a retrograde fashion, after which the setting 
time was determined (n = 3). For determination of the cohesion properties, samples were injected into 
Ringer’s solution at 37°C. During cement setting it was observed whether the paste retained its 
original configuration. Every anomaly was recorded. 
 
2.2.5. Porosity 
Of the GELA CPC, the total and macroporosity was determined. Macroporosity is porosity generated 
by (the degradation of) gelatin microspheres. The total porosity is the macroporosity plus the original 
microporosity of the cement. When the gelatin microspheres are not degraded, the macroporosity 
corresponds to the volume% of microspheres present inside the cement initially. 
To measure these parameters, both GELA CPC samples and (microporous) CPC samples of a known 
volume were placed in an oven at 650°C for 2 h. After burning out the gelatin/moisture, samples were 
weighed and equation 1 and 2 were used for the derivation of the total porosity and the macroporosity. 
Samples were taken threefold (n=3). 
%100*)
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1( /
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tot V
m
ρε −=         Equation 1 
%100*)1(
micro
macro
macro m
m−=ε         Equation 2 
Legend: εtot  = total porosity (%), εmacro = macroporosity (%), mmacro = average mass macroporous sample (after 
burning out gelatin) (g, n=3), mmicro  = average mass microporous CPC sample (g, n=3), V = volume sample 
(cm3), ρHAP = density hydroxy apatite (g/cm3) 
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2.2.6. Degradation assay 
For the degradation assay GELA CPC samples were placed in 3 ml of phosphate-buffered saline (PBS, 
pH 7.4) containing 50µg/ml gentamycin and 373ng/ml collagenase 1A (Sigma-Aldrich, St. Louis, 
USA) and incubated at 37˚C in a water bath on a shaker table (70 rpm) for a total of 12 weeks (84 
days). Every 3-4 days sample buffer was renewed; at day 14, 28, 42, 63 and 84, 5 specimens of the 
different cement formulations were subjected to analysis as summarized below. CPC samples were 
used as reference.  
Mass loss quantification  
Samples were lyophilized overnight before the mass was measured. The mass loss of the samples was 
calculated using Equation 3. 
%100*
0
0
M
MM
R nL
−=         Equation 3 
Legend: RL = mass loss sample on t = n (%), M0 = mass sample on t = 0 (g), Mn = mass sample on t = n (g) 
 
Mechanical characteristics  
Samples were placed in a testing bench (858 MiniBionixII, MTS Corp., Eden Prairie, MN, USA) and 
compression strength and E-modulus along the height of the specimens was measured at 0.5 mm/min 
crosshead speed.  
Morphology 
Morphology of the samples was determined using SEM. Pictures at a magnification of 100x were 
taken to visualize composite/microsphere degradation at approximately 1 mm from the outside of the 
sample. 
 
2.2.7. Release study 
Preparation BSA-loaded gelatin microsphere CPC 
GELA CPC was loaded with BSA using two different methods. The first method, where the 
composites were made directly after adding the BSA to the microspheres, is referred to as instant 
loading. The second method, where the BSA was allowed to settle inside the microspheres, we refer to 
as prolonged loading. Prolonged loading was applied to achieve a stronger electrostatic interaction 
between the BSA and the gelatin, as is normally performed in literature(8-9). 
For both methods, samples were loaded with BSA by adding 560µl of a 2.1% BSA solution to 100mg 
of GELA microspheres inside a 2ml plastic syringe. With instant loading, the microspheres and BSA 
solution were mixed for 15s with the Silamat mixing apparatus. Then, 900 mg of cement was added 
and gelatin microsphere composites were prepared as described in “preparation GELA CPC”. With 
prolonged loading, the microspheres and the BSA solution were mixed for 15s and stored at 4°C for 24 
h. Subsequently, cement was added and composites were prepared. As 6-7 samples were extracted 
Chapter 5__________________________________________________________________________________ 
 104
from each syringe, the calculated amount of BSA per sample with both methods was 1.5 mg, which 
was based on a homogeneous distribution (wt%) of microspheres inside the composite paste. 
Furthermore; to visualize BSA loading with both loading mechanisms, in a separate experiment 
fluorochrome labeled BSA (Alexa Fluor® 488, Molecular Probes, OR, USA) was added to the BSA 
solution in a ratio of 1/1000 and loaded onto the microspheres. After BSA loading, these microspheres 
were dispersed in water and analyzed by fluorescence light microscopy (Leica DMRBE microscope, 
Leica Microsystems AG, Wetzlar, Germany) and confocal laser scanning microscopy (CLSM, MRC 
1000, Biorad, CA, USA).  
BSA release assay 
During the release test, 3 samples of each formulation were put in release medium (ddH2O + 373 
ng/ml collagenase 1A) in 2ml Eppendorf tubes and incubated in a water bath (37ºC) on a shaker table 
(70 rpm) for 9 weeks. Initially 1.8 ml of medium was added, then samples of 200µl were taken at t = 
0.5, 1.0, 2.0 and 24 h. For the following weeks, sample medium was refreshed with 1.0 ml every 3-4 
days. BSA concentration of the sample medium at the different time points was measured and 
quantified by reversed-phase high performance liquid chromatography (RP-HPLC) using an Atlantis® 
RP-HPLC column (Waters Corp., Milford, MA, USA) a L-2130 HPLC pump (Hitachi, Tokyo, Japan) 
and a L-2400 UV detector (Hitachi) which was set at 280 nm. Furthermore, during measurement a 
40/60 acetonitrile/water mixture containing 10% 0.25 M formic acid was used as mobile phase at an 
isocratic flow rate of 0.70 ml/min and column temperature of 35°C. For determination of the BSA 
concentration a primary calibration curve was prepared. GELA CPC samples without BSA were used 
as reference as despite the difference in UV absorption maximum between gelatin and BSA (gelatin = 
230 nm(22), BSA = 280 nm) and absence of a UV-absorption band at 280 nm for the CPC a pilot study 
showed some signals from the GELA CPC in HPLC (Figure 1). 
Figure 1. RP-HPLC chroma-
tograms of bovine serum 
albumin (0.05 % w/v in water) 
and products from GELA CPC 
control after 3 days incubation 
 
 
 
 
 
 
 
 
Structure analysis 
For further investigation of the BSA-release, the molecular weight of the released proteins within the 
first weeks was analyzed using sodium dodecyl sulphate poly (acryl amide) gel electroforesis (SDS-
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PAGE). In brief, 0.5 ml of the sample medium was lyophilized and concentrated (20x). After that, 
samples were separated on a 10% poly acryl amide (PAA) gel and detected using a Chroomassie-blue 
staining. As reference non-loaded scaffolds, a 0.01% BSA-solution, a gelatin solution and a broad 
range SDS standard (Biorad®, Hercules, CA, USA) were used. 
 
2.2.8. Statistical analysis 
Data were arranged as mean ± standard deviation. Significant differences were determined using 
analysis of variance (ANOVA). Results were considered significant if p<0.05. Calculations were 
performed using GraphPad Instat®. 
 
3. Results 
3.1. Preparation microspheres / handling properties 
SEM-micrographs of the prepared microspheres are depicted in Figure 2A. The microspheres showed 
a spherical appearance as well as imprints of other spheres at their surface. The size distribution graph 
(Figure 3A) showed that 51% of the dry spheres were in the range of 0-10 µm, and after swelling a 
clear shift was observed to higher microsphere sizes. The size of the swollen spheres was more than 
doubled, with an average of 37.4 µm (Table 1). Regarding the vol% of the swollen spheres (Figure 
3B), the large amount of small spheres (<10 µm) only contributed to 1% of the total volume, whereas 
the few larger spheres > 150 µm contributed to 50%.  
 
 
Figure 2. Determination morphology by SEM; A = Dry microspheres (original magnification 100x), B = 
Microspheres in cement after 1 day cement setting (original magnification 100x) 
 
Parameters of the cement / scaffold after setting are also given in Table 1. The initial setting time of 
the GELA CPC was two times the setting time of the CPC(21). No final setting time was measured due 
to the high water content and compressibility of the gelatin microspheres(11). During the cohesion test 
the GELA CPC stayed in a solid shape, though some powder was released upon injection. After 
hardening, the scaffolds exhibited compression strengths of ±19 MPa which was significant lower than 
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the CPC samples (p<0.01). The gelatin microsphere content (macroporosity) corresponded to 
57.5vol%. SEM-micrographs directly after hardening (Figure 2B) showed a tight packing of 
microspheres, where most spheres were broken and covered by a layer of calcium phosphate 
precipitate. 
 
Figure 3. Size distribu-
tion graphs of dry and 
swollen gelatin micro-
spheres; A = Number 
average distribution, B = 
Volume average distribu-
tion, group size n=200 
(dry)/n=263 (swollen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Parameters GELA CPC and CPC 
Parameter GELA CPC CPC 
15.48 ± 13.79 (dry) Average microsphere size (µm) 
37.39 ± 31.07 (swollen) 
- 
 
Initial setting time (s) ± 210 108.3 ± 5.8 
Porosity (%) 74.8 ± 0.6 45.52 ± 1.26 
Macroporosity/ microsphere content (vol%) 57.5 - 
Compression strength  (MPa) 18.5 ± 4.5 48.2 ± 7.8 
Compression E-modulus (MPa) 905.8 ± 306.2 3140.5 ± 351.8 
Weight sample, 4.5*10 mm (mg) 127.6 ± 4.3 262.7 ± 1.26 
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3.2. Degradation assay 
The results of the degradation assay are given in Figure 4-6. The mass of the GELA CPC showed an 
almost linear decrease in time. After 84 days a total mass loss of 5% was observed. CPC only showed 
an increase in mass and already after 14 days significant differences with the GELA CPC were 
observed (14d: p<0.01, 84d: p<0.001).  
 
Figure 4. Development mass 
GELA CPC and CPC as func-
tion of degradation time, 
***=p<0.001 
 
 
 
 
 
 
 
 
 
Figure 5. Mechanical pro-
perties GELA CPC and CPC 
as function of degradation 
time; A = Compression 
strength, B = E-modulus,  
** = p<0.01, * = p<0.05 
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The compression strength of the GELA CPC (Figure 5A) was constant at 19 MPa till 42 days, after 
which a significant decrease was observed to 11 MPa at 84 days. The E-modulus (Figure 5B) also 
showed a significant decrease from 900 MPa at 3 days to 500 MPa after 84 days. The compression 
strength/ E-modulus of the CPC remained constant during the degradation test. 
 
Figure 6. Morphology 
GEL A CPC with SEM at 
1 mm from the outside 
radius at t = 14, 28, 42, 
63 and 84 days (original 
magnification 100x), 
overview of samples after 
84 days (original magnifi-
cation 22x) and close-up 
picture of gelatin micro-
spheres at the inner part 
of the composite (original 
magnification 250x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SEM-micrographs of the GELA CPC at 1 mm below the surface showed a structure of broken 
microspheres inside the cement till t = 42 days (Figure 6). Starting from 42 days, less microsphere 
structures were present and a clear increase in porosity was observed. Also interconnections between 
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the pores were visible. At 84 days the gelatin spheres at this location appeared to be totally degraded. 
However, at a lower magnification, at this time point still gelatin microspheres were visible in all the 
samples at the inner part of the composite, while at the outside gelatin was completely degraded.  
 
 
Figure 7. Fluorescence microscopy (A) and stacked CLSM micrographs (B+C) of fluorochrome labeled-BSA 
loaded gelatin microspheres, C1-C3 are intersections of microspheres shown in figure C at different heights 
(original magnification 40x) 
 
3.3. Release study 
Pictures of fluorochrome labeled BSA-loaded microspheres are depicted in Figure 7. The labeled BSA 
was adsorbed by the gelatin microspheres that showed a high concentration of fluorescent label. The 
surface structure of the microspheres was clearly visible in CLSM and label intensity differed between 
the microspheres irrespective of the microsphere size. Furthermore, BSA was present at the surface 
and in the middle of the spheres, as is clear from the CLSM micrographs at different heights, but 
distribution varied greatly among the microspheres and no difference between both loading 
mechanisms was obtained. 
The % release of BSA per time interval as well as the cumulative release from the GELA CPC is given 
in Figure 8 as a function of incubation time. The cumulative release of water solvable products from 
the GELA CPC (reference samples) is also given; however, because these products cannot be 
calibrated, the release is expressed as function of the peak area. For both loading methods almost no 
initial burst of BSA was observed. Between 1-7 days a high standard deviation was obtained due to the 
concomitant release of high amounts of water-solvable products from the GELA CPC that overlapped 
with the BSA signals. However, especially with the instant loaded scaffolds a substantial release of 10-
15% of BSA was observed. In the second and the third week significant higher amounts of BSA were 
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released from the instant loaded scaffolds compared to the prolonged loaded scaffolds. After 21 days 
the prolonged loaded scaffolds showed a sustained release of 1.5-2% per week, where the instant 
loaded scaffolds showed a further decrease of released BSA. In week 8 and 9 significant higher 
amounts of BSA were released from the prolonged loaded scaffolds. The total release efficiencies after 
63 days were 42.8± 9.1% (instant) and 26.1 ± 12.6% (prolonged). 
 
Figure 8. BSA release per time interval from instant and prolonged loaded GELA CPC, cumulative BSA release 
from instant and prolonged loaded GELA CPC (inlay, left axis) and cumulative gelatin release from control sam-
ples as calculated from peak area in AU (non-loaded GELA CPC, inlay, right axis) , ** = p<0.01, * = p<0.05 
 
Results of the SDS-PAGE measurement are given in Figure 9. The chromatogram at 3 days showed 
that the medium of the instant loaded scaffolds exhibited a strong signal at the height of BSA, whereas 
with the prolonged loaded scaffolds only a very weak BSA signal was present. However, this sample 
did show some extra bands at higher molecular weight that were also visible with both 
instant/prolonged loaded scaffolds at day 7. At 17 days the same signals were still present with the 
instant loaded scaffolds, while only low molecular weight products were observed with the prolonged 
loaded scaffolds. The GELA CPC control samples did not show specific signals at a certain molecular 
weight but a continuous band from high to low molecular weight at t = 3 and 7 days, which was also 
visible with the BSA loaded samples and can be appointed to gelatin degradation products. At t = 17 
days the chromatogram of the control samples corresponded with the prolonged loaded scaffolds and 
some signal was observed at molecular weights < 21.5 kDa. 
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Figure 9. SDS-PAGE chromatograms of BSA loaded GELA CPC at t = 3, 7 and 17 days. Legend: ST = stan-
dard, GEL = gelatin control, CON = control (non-loaded GELA CPC), INS = instant loaded GELA CPC, PRO = 
prolonged loaded GELA CPC. 
 
4. Discussion  
The aim of this experiment was to synthesize a gelatin type A microsphere / calcium phosphate cement 
composite (GELA CPC) for bone tissue engineering purposes. The addition of gelatin microspheres 
was hypothesized to introduce macroporosity into the CPC, increase biodegradability and optimize the 
release of growth factors that are often applied for bone remodeling. To test this hypothesis, the 
composite was subjected to a degradation test in proteolytic medium to investigate the degradation 
properties/mechanism and formation of macroporosity by gelatin microsphere erosion. Secondly, 
protein/drug release properties of the GELA CPC were investigated by adding a model protein (BSA) 
to the microspheres using two different loading methods.  
As mentioned in the introduction, gelatin type A was used in the current study because this material 
exhibited a faster in vitro resorption rate than the food-grade (FG) gelatin in a previous experiment(11). 
Next to that, a fully injectable and setting 10 wt% (57.5 vol%) GELA CPC was synthesized that was 
hypothesized to exhibit a better interconnectivity of the microspheres compared to the 5wt% FG 
gelatin CPC. With FG gelatin microspheres, a 5wt% composite was maximum regarding setting 
properties, whereas with GELA microspheres this was 10wt% and therefore a higher amount of 
microspheres could be introduced. The setting process of these composites, when compared to the 
original cement, is delayed by leakage of water from the swollen microspheres(23). Considering this, 
the difference between both groups can be due to the larger size of the GELA microspheres that 
exhibit a smaller interface with the surrounding cement than an identical vol% of smaller FG gelatin 
microspheres. The occurrence of a small amount of swollen microspheres > 100 µm (Figure 3) also 
could be favorable for bone ingrowth as multiple authors(17, 24-26) state that for this process pores are 
required with a minimal size of 100-200µm. However, the addition of too many of such pores can 
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decrease the mechanical properties of the composite as in literature(21,27-28) cements with large and 
irregular shaped pores show less mechanical properties than cements with smaller and regular shaped 
pores.  
From the degradation test it was concluded that the GELA CPC showed a significant decrease in mass 
and compression strength after 84 days in proteolytic medium, whereas CPC was mechanically stable 
and experienced an increase in mass that was caused by PBS precipitation(11). SEM-investigation also 
showed a clear degradation of the microspheres in time. It was observed that the microspheres first 
degraded at the outside of the implant and degradation gradually proceeded to the inner part. This 
process has to be considered as surface erosion(29), though in a previous degradation experiment 
separate microspheres degraded in a bulk erosion fashion showing gradual deformations in 
microsphere structure and higher degradation rates(11). A reason for the surface-like erosion 
mechanism is that the collagenase from the medium did not enter the middle of the composite due to 
binding of the protein to the cement(18-19) or even deactivation(30). When the microspheres degraded 
they left an interconnected structure of macropores that enabled diffusion of the enzyme into the 
composite without binding to the cement. The overall compression strength decreased while after 
gelatin degradation a weaker skeleton of calcium-deficient carbonate apatite remained. The surface-
like erosion mechanism observed in this experiment, proves that gelatin microspheres can be applied 
to produce macroporosity inside a calcium phosphate cement. Explanations for the improved 
degradation of the GELA CPC when compared to the FG gelatin CPC(11) are indeed a better 
interconnectivity of the microspheres and a faster degrading gelatin. Similar to the previous 
degradation experiment, when incorporated inside the cement, the GELA microspheres showed a layer 
of calcium phosphate precipitate on the surface(31) that could hamper interconnectivity of the pores. 
However, due to the higher vol% of microspheres inside the GELA CPC, interconnections were still 
present.  
The surface-like erosion mechanism observed for the GELA CPC is not unfavorable for bone tissue 
engineering purposes. In previous in vivo experiments with macroporous cements(32-33) it was shown 
that with these osteoconductive implants new bone ingrowth proceeded from the outside of the implant 
to the inside. So when macroporosity is first present at the superficial regions it can guide bone 
ingrowth, while in the middle of the composite strength is retained as microspheres are not degraded 
yet. Upon the addition of poly(lactic-co-glycolic) acid (PLGA) microspheres into an injectable CPC in 
a previous in vitro degradation experiment(21) bulk erosion of the microspheres was observed. This 
implicates that when the same mechanism occurs in vivo, microsphere erosion and therefore the 
decrease in compression strength occurs concomitantly though the whole composite, leaving a less 
stable implant as bone is not present in the middle. However, extrapolations of the obtained in vitro 
degradation mechanisms for both GELA CPC and PLGA CPC to in vivo behavior is complicated due 
to different conditions with respect to fluid flow, consistency of medium and sources of gelatin 
degrading enzymes(34).   
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Another advantage of GELA CPC over the PLGA microsphere containing cements is the drug loading 
mechanism. With polymers such as polylactic acid (PLA) and PLGA drugs are introduced during the 
microparticle preparation method, which leads to losses of drug and even inactivation(35). Because 
gelatin is a hydrogel, an aqueous protein/drug solution can be added to dry microspheres just before 
they are mixed with the cement and during swelling the protein/drug will be electrostatically adsorbed 
by the microspheres as was observed by CLSM. With this method almost all the protein/drug is inside 
the composite, and inactivation by chemical solvents is non-existant. However, because loading 
efficiencies of gelatin microspheres are not optimal (20) and release patterns from gelatin microspheres 
often show a high burst release(9), some protein/drug will be released into the calcium phosphate 
cement as water diffuses out of the microspheres during cement mixing. This is not beneficial because 
the cement has a strong affinity with proteins/drugs, and possibly only a small amount will be released 
when included inside the cement as was observed by multiple authors(18-19, 36). High release efficiencies 
are important while growth factors that are used for tissue engineering applications are expensive and 
can rise the costs for a future application(37).  
The release patterns that were observed with the HPLC analysis showed that instant loaded GELA 
CPC scaffolds exhibited a total BSA release of more than 40% within 21 days. This was significantly 
higher than in vitro rhBMP-2 or BSA release from PLGA microsphere CPC composites and plain CPC 
that showed a 3-15% release within 28 or 42 days(38-39). A reason for this improvement could be the 
porous structure of swollen gelatin microspheres, which is permeable for smaller molecules and 
facilitates BSA diffusion out of the scaffold. However, release efficiencies with this cement are very 
much dependent on the type of protein or drug used(28, 40) and the pH of the surrounding medium(41). 
During degradation experiments of PLGA microsphere CPC the pH was found to drop substantially in 
time during microsphere degradation(21) whereas with gelatin microspheres no additional decrease in 
pH was observed(11). Secondly, from SDS-page measurements we can conclude that in this study also a 
high release of (water-solvable) gelatin chains occurred within the first week. The signal observed for 
the GELA CPC controls in RP-HPLC (Figure 1) therefore is also likely caused by gelatin degradation 
products, although unmodified gelatin only has a very weak absorption at 280 nm(22). This concomitant 
gelatin release influenced the release of BSA. A study of Ruhé et al(42) showed that coating the cement 
with BSA increased the release efficiency of added BMP-2, which implicates that the protein binding 
capacity of the cement can be saturated at a certain concentration resulting in “weaker” protein-protein 
interactions. The bulk of gelatin chains that was released within the first days therefore possibly 
saturated the cement. After that, the remaining BSA diffused more easily out of the scaffolds rendering 
the delayed release as was observed with both loading methods at 3-7 days.  
From 7-21 days the instant loaded scaffolds showed a significantly higher BSA release than the 
prolonged loaded scaffolds. This can be explained by a weaker bonding between the gelatin and the 
BSA with the instant loaded scaffolds. In more detail, according to literature(20) proteins that are 
adsorbed to gelatin microspheres will release during degradation of the gelatin. As mentioned in the 
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materials and methods section, to achieve a strong electrostatic interaction between the protein and the 
gelatin, the protein normally is allowed to settle inside/onto the gelatin microspheres for a certain 
period before they are put in release medium(8-9). A similar procedure was done with the prolonged 
loaded scaffolds for 24h but not with the instant loaded scaffolds. Therefore with this loading method 
electrostatic interactions between the BSA and the gelatin were weaker and the BSA diffused faster 
out of the GELA CPC composites. Furthermore, the sustained release that was observed with the 
prolonged loaded scaffolds after 21 days can be attributed to the degradation of the gelatin 
microspheres.  
In SDS-page a very strong band of unaltered BSA was observed after 3 days in release medium with 
the instant loaded scaffolds, while for the prolonged loaded scaffolds and also for later time points the 
BSA signal was much weaker and bands of higher molecular weight were observed. This result 
indicates that indeed the BSA in the instant loaded scaffolds was more loosely bonded to the gelatin 
than in the prolonged loaded scaffolds. The occurrence of the signals at higher molecular weight 
implies that BSA/gelatin complexes were formed due to the electrostatic interaction between the 
protein structures(20). After 17 days these “complexes” were also observed with the instant loaded 
scaffolds, though with the prolonged loaded scaffolds only low molecular weight products were seen. 
This was partially due to a decrease in concentration below the detection limit. Degradation of the 
BSA in time is also a possibility because in literature(40) degradation of growth factors was observed 
with comparable calcium phosphate ceramics.  
Interpreting the results of the release and degradation assay, figure 10 gives a hypothetic model of the 
release mechanism. From the beginning a scaffold was obtained in which the BSA was distributed into 
the dry gelatin spheres, but also was present inside the surrounding calcium phosphate cement (A). 
After placing the composite into the release medium, the gelatin microspheres were swollen and 
showed a high release of gelatin chains and a delayed release of BSA into the medium. With the 
instant loaded scaffolds the release consisted of a high amount of unaltered BSA (B), while with the 
prolonged loaded scaffolds most likely also complexes between the gelatin and BSA were present as 
they bind electrostatically(8, 9, 20) (C). After releasing most of the loosely bonded protein, the release 
was continued due to the proteolytic degradation of the gelatin spheres(20). Here, the gelatin started to 
erode from the outside to the inside and especially with the prolonged loaded scaffolds small amounts 
of BSA or BSA/gelatin complexes were released into the medium (D,E). Furthermore, it can be 
hypothesized that after gelatin microsphere degradation, but also in an earlier stage, a small amount of 
the BSA that is (still) trapped inside the cement, diffuses out of the cement skeleton and gives a slow 
release in time (F) as was observed by multiple authors(18-19,  36, 39).  
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Figure 10. Representation of BSA release mechanism from GELA CPC; A= before release medium, B/C = dela-
yed initial release of BSA from instant/prolonged loaded scaffolds, D/E = release during gelatin microsphere 
degradation, F = release from cement after microsphere degradation. 
 
5. Conclusion  
A 10% gelatin type A microsphere CPC was formulated with sufficient cement setting and cohesion 
properties, a gelatin microsphere content (macroporosity) of 58% and a compression strength of 18.5 
MPa. In vitro degradation of the GELA CPC followed a surface-like erosion mechanism, in which a 
mass loss of 5% was obtained and the compression strength and E-modulus significantly decreased 
after 84 days in proteolytic medium. In vitro BSA release was tailored by loading gelatin microspheres 
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with BSA for a short (instant) or longer (prolonged) period before mixing them with the cement. 
Results showed a BSA release of more than 40% within 21 days with the instant loaded scaffolds, 
while prolonged loaded scaffolds showed a slower but sustained release. Differences were caused by 
weaker electrostatic interactions between the gelatin spheres and the BSA with the instant loaded 
scaffolds. SDS-PAGE also revealed differences in BSA structure between both loading mechanisms. 
Overall, 10wt% GELA microspheres can be used to generate in situ macroporosity into an injectable 
calcium phosphate cement and tailor release properties from these gelatin microsphere CPC 
composites. 
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1. Introduction 
Calcium phosphate cements (CPCs) are commonly used as bone-filling materials in the field of 
dentistry, orthopedic and post-operative surgery. These cements have proven be biocompatible and 
osteoconductive and due to the in-situ setting abilities, a perfect fit with the site defect can be 
accomplished(1-2). One disadvantage is the high density and slow degradability of the material, which 
makes it less applicable for tissue engineering purposes(3). Therefore, in earlier studies by our group 
microspheres made of poly(lactic-co-glycolic acid) (PLGA)(4-8) and gelatin(9-10) were added to an 
apatite cement. These microsphere CPCs exhibited good injectability characteristics and setting 
properties. During in vitro/in vivo degradation of the spheres, porosity increased concomitantly, 
yielding a structure of spherical pores and a decrease in mechanical strength. PLGA microspheres 
produced an acidic environment due to the hydrolysis of the ester groups(8). On the other hand, gelatin 
microspheres degraded gradually by proteolysis and no additional decrease in pH was observed(9). 
Drug release studies with microsphere CPC were also performed as the addition of osteoinductive 
drugs can improve bone remodeling at the implant site(11-12). The drug was incorporated or adsorbed 
onto the microspheres to give a release pattern that differs from the usual diffusion dependent release 
from calcium phosphate cements(13-14). In vitro/in vivo release data of bone morphogenic protein-2 
(BMP-2) from PLGA microsphere CPC overall showed a pattern that was characterized by a small 
burst release, followed by a period of slow, sustained release(4-5). Furthermore, by changing the 
molecular weight of the polymer release was tailored within certain ranges as low molecular weight 
PLGA microsphere CPC showed a significant higher release after 4 weeks in vivo(5). In an in vitro 
release study using gelatin microsphere CPC(10), microspheres were loaded with bovine serum albumin 
(BSA) and release from the microsphere CPC was monitored for 9 weeks. Two loading methods were 
applied; BSA was loaded onto the microspheres directly before mixing (instant loading) or 24 h before 
mixing (prolonged loading) to establish a strong electrostatic bond between the basic gelatin (type A, 
pI = 7.0-9.0) and the acidic BSA (pI = 5.0)(15). Results showed a release pattern without initial burst 
and a delayed release after 3 days that decreased in time. Release up to three weeks was significantly 
higher with the instant loaded scaffolds, whereas the prolonged loaded scaffolds exhibited a more 
sustained release. Structure analysis by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) showed peaks of intact BSA after 3, 7 and 17 days. Gelatin microsphere CPC therefore 
seems to be a suitable scaffold for drug delivery, however, growth factors like BMP-2, transforming 
growth factor-β (TGF-β), vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor (bFGF) can show a completely different release pattern than BSA(1). In addition, there exist two 
types of gelatin; type A (pI = 7.0-9.0) and type B (pI = 4.5-5.0) that due to their opposite isoelectric 
point exhibit different electrostatic interactions with various drugs/proteins(15). 
The goal of this study was to determine the release characteristics of gelatin type A or type B 
microsphere CPC by loading the scaffolds with various types of growth factor (TGF-β, bFGF and 
BMP-2) and applying two loading mechanisms. Also, different amounts of growth factor were loaded 
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onto the gelatin microspheres to investigate whether release from these composites is concentration 
dependent. Release was measured by labeling the growth factors with 125I  after which radioactivity of 
the loaded composites and release medium (phosphate buffered saline, PBS) was monitored for a total 
of 6 weeks. 
 
2. Materials and Methods 
2.1. Materials 
Cell culture tested gelatin type A (GELA) (pI = 7.0-9.0, bloom = 300) and gelatin type B (GELB) (pI 
= 4.7-5.2, bloom = 225) (Sigma-Aldrich, St. Louis, USA) were used for the fabrication of the 
microspheres. The calcium phosphate cement used is commercially available under the product name 
Calcibon® (Biomet Merck, Darmstadt, Germany) and consists of 61% α-tricalcium phosphate (α–
TCP), 26% Ca2HPO4, 10% CaCO3 and 3% precipitated hydroxyapatite (pHA). Collagenase 1A 
(Sigma) was used as gelatin degrading enzyme. Recombinant human transforming growth factor β1 
(TGF-β1, pI = 9.5), basic fibroblast growth factor (bFGF, pI = 9.6) and bone morphogenic protein-2 
(BMP-2, pI = 8.5) (R&D systems Europe Ltd., Abingdon, UK) were the growth factors used in the 
release experiment. 
 
2.2. Methods 
2.2.1. Preparation of gelatin microspheres 
2.5 g of GELA or GELB was dissolved in 25 ml ddH2O at an elevated temperature (30 min at 60°C). 
The resulting clear solution was added slowly (10 ml pipette) to a 250 ml three-necked round bottom 
flask containing 125 ml olive oil while stirring at 500 rpm (Teflon upper stirrer). During stirring, the 
round bottom flask was put in an ice bath. After 30 min, 50 ml of chilled acetone (4°C) and 
glutaraldehyde (0.5 ml = 6.25 mM) was added slowly. The solution was stirred for another hour. 
Microspheres were collected by filtration (D3, Schott Duran, Mainz, Germany) and washed several 
times with acetone (approx. 1 l) to remove residual olive oil. Following this, microspheres were stored 
in a drying chamber until further use. Morphology of the microspheres was visualized by scanning 
electron microscopy (SEM) (JEOL 6400-LINK AN 10000 at 10 kV) and is shown in Figure 1. 
Average size of the microspheres is given in Table 1 and was determined using digital image software 
(Leica Qwin®, Leica Microsystems AG, Wetzlar, Germany). 
 
Table 1. Average size gelatin microspheres (n=200) 
Average size (µm)  
dry swollen 
GELA microspheres 15.5 ± 13.8 37.4 ± 31.1 
GELB microspheres 8.4 ± 7.6 20.7 ± 14.6 
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Figure 1. Morphology microspheres by scanning electron microscopy; A = GELA microspheres, B = GELB 
microspheres (original magnification 100x) 
 
2.2.2. Radioiodination of growth factors 
TGF-β1, bFGF and BMP-2 were labeled with 125I according to the iodogen method(16). Briefly, in a 
500 µl eppendorf tube coated with 50 µg iodogen 10 µl of 0.5 M phosphate buffer saline (PBS) was 
added and adjusted to 100 µl with 50 mM PBS. Growth factor (8 µg) and 10-15 MBq 125I (Perkin-
Elmer, Boston, MA) was added and incubated at room temperature for 10 min. After that, 100 µl of 
saturated Tyrosine solution in PBS was added and labeling efficiency of the reaction was 36%, 13% 
and 43% for TGF-β1, bFGF and BMP-2 respectively. To remove the nonbound I125 activity, the 
reaction mixture was eluted with 0.1% BSA in PBS on a prerinsed disposable Sephadex G25M 
column (PD-10; Pharmacia, Uppsala, Sweden). The radiochemical purity of the 125I-labeled growth 
factors was determined by instant thin layer chromatography (ITLC) on Gelman ITLC-SG strips 
(Gelman Laboratories, Ann Arbor, MI, USA) with 0.1M citrate, pH 5.0 as a mobile phase. The 
radiochemical purity of the growth factors is presented in Table 2. 
 
Table 2. Radiochemical purity 125I-labeled  growth factors 
 TGF-β1 bFGF BMP-2 
Radiochemical 
purity 
95.6% 83.9% 97.8% 
 
2.2.3. Preparation of gelatin microsphere/calcium phosphate cement composites 
For the release study, 10wt% gelatin type A microsphere CPCs (GELA CPCs) and 5wt% gelatin type 
B microsphere CPCs (GELB CPCs) were prepared as described in previous studies(9-10). The weight% 
of microspheres inside the cement corresponds to the maximum amount of microspheres that can be 
incorporated to still obtain a composite with manageable handling properties(10). TGF-β1, bFGF and 
BMP-2 was loaded onto the composites by two loading methods where growth factor was mixed with 
the cement directly after loading them to the microspheres (instant loading), or following a period of 
swelling before cement was added (prolonged loading). Briefly, growth factor loaded 5/10 wt% gelatin 
microsphere CPCs were made by adding a growth factor solution in PBS (300/560 µl) to 50/100 mg of 
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dry gelatin microspheres inside a BSA coated 2 ml syringe. With instant loading, after 15 s vigorously 
stirring using a Silamat® (Vivadent, Schaan, LIE) mixing apparatus, 950/900 mg calcium phosphate 
cement was added and the constituents were stirred again for 15 s or until an equal distribution of 
spheres inside the cement was obtained. With the prolonged loaded composites, the gelatin 
microspheres were allowed to swell for 24 h at 4°C before they were mixed with the cement. 
Following both procedures, 280 µl of 1% Na2HPO4 was added and after 15s of stirring, the resulting 
paste was injected into Teflon moulds (cylindrical, d = 4.5 mm, h = 9.0 mm). Samples were hardened 
at room temperature overnight. SEM-micrographs of the gelatin microsphere CPCs are given in Figure 
2. Growth factor-loaded samples without microspheres (CPC) were used as control and prepared by 
adding a growth factor solution to preset cement samples (adsorbed). Calculated amount of growth 
factor per sample is 50 ng. Furthermore, drug entrapment efficiency was determined by measuring the 
γ-irradiation of the preset samples after which it was divided by the γ-irradiation of the corresponding 
calculated amount of labeled growth factor. 
 
 
Figure 2. Morphology gelatin microsphere CPCs; A = 10% GELA CPC, B = 5% GELB CPC (original 
magnification 100x) 
 
Table 3. Vol% of microspheres inside gelatin microsphere CPC 
Formulation Volume % of microspheres 
5%   GELA CPC 48.7 ± 1.8 % 
10% GELA CPC 57.5 ± 1.4 % 
5%   GELB CPC 48.4 ± 1.8 % 
 
With BMP-2 some supplementary studies were performed. To investigate whether growth factor 
release is concentration dependent, different amounts of BMP-2 were incorporated into the cement. 
Next to 50 ng of 125I-labbeled BMP-2 per scaffold, samples were loaded with 500 ng and 5 µg of 
BMP-2 applying hot/cold ratios of 1/10 and 1/100. Furthermore to investigate the effect on drug 
release of the total amount/volume of incorporated microspheres, with BMP-2 also a 5wt% GELA 
CPC was formulated. Volume% of gelatin microspheres inside the 5 and 10wt% GELA CPC(10) and 
5wt% GELB CPC is presented in Table 3. Finally, in addition to the adsorbed CPC controls, CPC 
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samples were prepared where BMP-2 was dissolved into the liquid hardener (1% Na2HPO4) during 
cement preparation (incorporated). 
 
2.2.4. Release study 
Samples were placed in 3 ml PBS containing 373 ng/ml collagenase 1A(17) inside 10 ml polypropylene 
tubes. Tubes were put in a water bath containing a rotating plate (70 rpm) at 37°C. Medium was 
renewed every 3-4 days. At the same time, γ-irradiation of the sample/medium was measured for a 
total of 6 weeks. Samples were taken and measured in triplicate (n = 3). 
 
2.2.5. Statistical analysis 
Data were presented as mean ± standard deviation. Significant differences were determined using 
analysis of variance (ANOVA). Results were considered significant if p<0.05. Calculations were 
performed using GraphPad Instat®. 
 
3. Results 
The drug entrapment efficiencies of the samples are given in Table 4. For all types of gelatin 
microsphere CPC, drug entrapment efficiencies were around 70-75%. Differences in entrapment 
efficiency between instant and prolonged loaded scaffolds were observed, though no clear trend was 
observed. CPC controls where the BSA was adsorbed exhibited higher entrapment efficiencies (82-
94%) than the gelatin microsphere CPC, though the incorporated CPC showed an efficiency of only 
51%. 
 
Table 4. Entrapment efficiency gelatin microsphere CPC and CPC as percentage of calculated amount of growth 
factor (1x = 50 ng, 10x = 500 ng, 100x = 5 µg) 
BMP-2  TGF-β1 bFGF 
1x 10x 100x 
CPC (adsorbed) 81.7 ± 3.4 82.3 ± 3.1 93.7 ± 4.2 90.7 ± 4.7 88.5 ± 2.9 
10% GelA CPC instant 74.8 ± 1.8 75.7 ± 2.6 77.7 ± 2.3 78.8 ± 1.5 75.7 ± 1.9 
10% GelA CPC prolonged 66.8 ± 1.7 76.1 ± 0.5 71.0 ± 2.0 72.1 ± 1.3 68.3 ± 1.6 
5%   GelB CPC instant 72.4 ± 2.8 69.4 ± 0.4 77.8 ± 2.4 81.0 ± 4.3 73.1 ± 4.4 
5%   GelB CPC prolonged 68.5 ± 0.2 68.8 ± 1.6 71.4 ± 0.9 71.1 ± 1.0 70.0 ± 1.3 
CPC (incorporated) - - 50.9 ± 2.3 - - 
5%   GelA CPC instant  - - 69.8 ± 1.5 - - 
5%   GelA CPC prolonged - - 75.8 ± 1.8 - - 
 
The release pattern for the CPC is given in Figure 3. Overall, CPC where the drug was adsorbed onto 
the surface exhibited a release pattern consisting of an initial burst, followed by a sustained release that 
was slowly diminishing in time. The release pattern of both BMP-2 and bFGF was similar, whereas 
the TGF-β1 showed a significant lower initial burst and sustained release. In contrast to the BMP-2 
adsorbed CPC, release from the BMP-2 incorporated cement did not show an initial burst. 
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Furthermore, sustained release was comparable to the BMP-2 adsorbed cement though release 
efficiency (Table 5), due to the initial burst, was significantly lower (p<0.001).  
 
 
Figure 3. Growth factor release from CPC, *** = p < 0.001 
 
Table 5. Release efficiency after 6 weeks of gelatin microsphere CPC and CPC as percentage of actual loaded 
protein (1x = 50 ng, 10x = 500 ng, 100x = 5 µg) 
BMP-2  TGF-β1 bFGF 
1x 10x 100x 
CPC (adsorbed) 33.5 ± 1.4 63.9 ± 4.4 62.5 ± 5.4 56.2 ± 2.8 57.4 ± 2.3 
10% GelA CPC instant 13.3 ± 0.3 50.5 ± 1.2 28.8 ± 0.3 30.5 ± 1.0 29.2 ± 0.5 
10% GelA CPC prolonged 17.8 ± 0.5 54.3 ± 1.4 32.5 ± 1.4 32.0 ± 0.8 34.2 ± 1.4 
5%   GelB CPC instant 13.8 ± 0.2 53.7 ± 0.4 27.1 ± 0.3 28.0 ± 1.0 28.3 ± 0.6 
5%   GelB CPC prolonged 14.4 ± 0.4 50.7 ± 1.0 28.1 ± 0.4 28.0 ± 0.6 28.3 ± 0.2 
CPC (incorporated) - - 28.3 ± 1.0 - - 
5%   GelA CPC instant  - - 20.7 ± 0.3 - - 
5%   GelA CPC prolonged - - 18.6 ± 0.3 - - 
 
Similar to the CPC samples, both 10% GELA CPCs (Figure 4) and 5% GELB CPCs (Figure 5) 
exhibited a pattern consisting of a (small) initial burst followed by sustained release of the growth 
factor. Also here, release was dependent on the type of growth factor, where bFGF exhibited a higher 
burst release than BMP-2 or TGF-β1. Sustained release and release efficiency (Table 5) was in the 
following order; bFGF > BMP-2 >> TGF-β1. The 10% GELA CPC also showed a significant higher 
sustained release from the prolonged loaded scaffolds when compared to the instant loaded scaffolds 
for all growth factors. With TGF-β1 the prolonged loaded scaffolds experienced a 33% higher release 
after 6 weeks, whereas with bFGF and BMP-2 this was 8 and 13%. The 5% GELB CPC did not show 
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such a trend, as with bFGF the instant loaded scaffolds showed a significant higher release (p<0.01), 
and differences between instant and prolonged loaded scaffolds with BMP-2 and TGF-β1 were small. 
 
Figure 4. Growth factor release from 10% GELA CPC, * = p < 0.05, *** = p < 0.001 
 
 
Figure 5. Growth factor release from 5% GELB CPC, * = p < 0.05, ** = p < 0.01 
 
In Figure 6 the BMP-2 release from all formulations is depicted. It was observed that sustained release 
from the 5% GELA CPC was significantly lower (p<0.001) than the 10% GELA CPC, 5% GELB CPC 
and CPC controls. Furthermore, sustained release from the incorporated CPC was identical to the 5% 
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GELB CPC and instant loaded 10% GELA CPC, though slower than the prolonged loaded 10% GELA 
CPC. 
 
Figure 6. BMP-2 release from gelatin microsphere CPC and CPC 
 
Figure 7 shows the absolute release from the BMP-2 loaded composites. The release patterns at the 
different BMP-2 concentrations were identical for all formulations and exhibited respectively a 10/100 
fold increase in burst or sustained release and absolute release after 6 weeks (Table 5) when implants 
were loaded with a 10/100 fold higher amount of BMP-2.  
 
4. Discussion 
In the present study, growth factor release from injectable calcium phosphate cements with 
incorporated gelatin microspheres was investigated. For this purpose, TGF-β1, bFGF or BMP-2 were 
added to the gelatin microspheres before they were mixed with the cement using two loading methods. 
Furthermore, scaffolds were prepared using either type A or type B gelatin microspheres. In addition, 
for BMP-2 the effect of growth factor concentration and amount of incorporated microspheres on the 
release pattern was investigated. Samples without gelatin microspheres (CPC) were used as control 
where the growth factor was adsorbed onto the scaffolds or added to the liquid hardener (BMP-2). 
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Figure 7. Cumulative BMP-2 release from 10% GELA CPC, 5% GELB CPC and CPC with different amount of 
incorporated BMP-2 (1x = 50 ng, 10x = 500 ng, 100x = 5 µg) 
 
Results showed that the drug entrapment efficiency of the CPC controls was dependent on the loading 
method as the incorporated CPC sample clearly exhibited a significant lower efficiency than the 
adsorbed CPC samples. For the incorporated CPC sample, losses occurred when drug adsorbed to the 
syringe during mixing or when drug was absorbed to the Teflon mould during cement hardening. 
Entrapment efficiency of the gelatin microsphere composites was intermediate. This indicates that the 
electrostatic interaction between the drug and microspheres was strong enough to retain drug inside the 
spheres during mixing, however, part of the growth factor will be dispersed into the surrounding 
cement(15). 
With most formulations an initial burst release of the growth factor was observed. With the growth 
factor-adsorbed CPC most of the drug was located at the outside of the sample, which explains the 
high burst release(13-14). The CPC with incorporated BMP-2 did not show a burst release as the growth 
factor in this sample was dispersed more evenly through the cement, which is known for its protein-
binding capacity(13-14, 18). Occasionally, with the gelatin microsphere CPCs a substantial burst release 
was obtained. Whereas the BMP-2 and TGF-β1 loaded composites showed a burst release of 5-7%, 
with bFGF a burst release of 16-18% was observed. This burst release is probably due to the 
suboptimal radiochemical purity of I125 labelled bFGF, which was 84%. The radioactive preparation 
used in this experiment therefore contained 16% free Iodine-125 that is expected to exhibit a fast 
release from the scaffolds. Regarding this radiochemical purity, burst release from gelatin microsphere 
CPC was low. As gelatin scaffolds/microspheres often show a high burst release(15, 17, 19), the low burst 
observed here is a result of protein binding to the cement after release from the microspheres. 
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Following the burst release, with each growth factor a sustained release was observed. With the CPC 
controls, this sustained release is probably due to diffusion of drug through the cement(20,21) as the CPC 
does not show signs of degradation or dissolution(8-10). Figure 8 shows that BMP-2 release from the 
incorporated CPC is proportional to the square root of time, which is typical for a diffusion dependent 
release. Prolonged loaded 10% GELA CPC, however, shows a more linear sustained release. With the 
gelatin microsphere CPCs drug release can also be the result of the proteolytic degradation of 
microspheres. Supposedly degradation of gelatin microspheres inside the CPC is a gradual process 
from the outside of the implant to the inner part(10), though in these samples also an initial burst of free 
gelatin chains was observed. According to literature(15), electrostatically bonded growth factor releases 
concomitantly with release of gelatin degradation products. The observation that the release from the 
10% GELA CPC is more rapid than from the 5% GELA CPC indicates that a similar mechanism 
indeed occurs. Furthermore as the used collagenase specifically degrades collagen or gelatin(22), no 
proteolytic degradation of the growth factor is expected. 
 
Figure 8. BMP-2 release curves from BMP-2 incorporated CPC  and 10% GELA CPC with additional trend 
lines 
 
In most cases the magnitude of the sustained release from the gelatin microsphere CPC was 
comparable to the CPC samples, whereas it was significantly lower with 5% GELA CPC. This can be 
due to the fact that proteolytic gelatin degradation does not occur in a high extent for the 5% GELA 
CPC and most of the growth factor is retained in the gelatin microspheres. In previous degradation 
studies(9-10) it was concluded that due to the low interconnectivity of the microspheres inside a 5% 
gelatin microsphere CPC, the enzyme did not penetrate the composite as it experienced physical 
interactions with the surrounding cement. The release that is observed from the 5% GELA CPC is 
mostly due to diffusion from the cement, which is higher with the CPC controls. Figure 6 also shows 
Chapter 6__________________________________________________________________________________ 
 130
that BMP-2 release from the 5% GELB CPC is significantly higher than release from the 5% GELA 
CPC, whereas the vol% of microspheres inside the composite is similar (Table 3). This can be 
explained by a better distribution of the GELB microspheres into the cement, which are smaller in size 
than the GELA microspheres, leading to a higher interconnectivity and improved microsphere 
degradation. Also, the lower isoelectric point of gelatin type B can have caused the higher sustained 
release from the GELB CPC, as the used growth factors all have an isoelectric point of 8.5-9.5. The 
electrostatic interactions with the acidic GELB microspheres (pI = 4.5-5.0) will be stronger than with 
the GELA microspheres (pI = 7.0-9.0), leading to smaller losses to the surrounding cement during 
composite preparation. Similarly, an increase in the % of microspheres inside the GELB CPC is 
supposed to improve drug release from these composites. However, like food-grade gelatin 
microspheres in a previous study(9) with GELB microspheres the addition of more than 5wt% of 
microspheres renders a composite with insufficient setting properties. 
Apart from the implant material, the release test showed large differences in the sustained release of 
the various growth factors, i.e. showing a fast release of bFGF and a much slower release of TGF-β1. 
In agreement with other studies with cement or gelatin as scaffold material(15, 19, 23),release in this study 
was highly dependent on the type of growth factor. Intrinsic and physical parameters like the 
isoelectric point(15, 19), hydration(24) and size of the drug play an important role in drug release, 
however, these parameters not always have the same effect on the release pattern/efficiency. Charge 
distribution and chain conformation of the drug are markedly influenced by environmental conditions 
like buffer capacity (pH) and consistency of the medium(15, 24). Also the state of the cement surface 
changes when these environmental conditions alter, resulting in a more positively/negatively charged 
substrate(25). It is therefore not always straightforward to predict release from these calcium phosphate 
cements, despite the similarities between the drugs. 
In the previous BSA release study(10) it was shown that the loading method also can be used to tailor 
release from the 10% GELA CPCs. In accordance to this study, current results indeed showed that 
absorption of the growth factor for a longer period onto the microspheres (prolonged loading), led to a 
higher sustained release with these composites. The explanation for this phenomenon is a higher 
release from the gelatin microspheres during proteolytic degradation as result of stronger electrostatic 
interactions between the gelatin and growth factor, and less losses to the surrounding cement. 5% 
GELA CPC and 5% GELB CPC do not show this feature, or to a lesser extent. As discussed earlier, 
proteolytic degradation did not occur in a high extent for the 5% GELA CPC and therefore it is not 
surprising that with this formulation the prolonged loaded samples did not show a higher sustained 
release than the instant loaded samples. Furthermore, as electrostatic interactions between the gelatin 
and growth factors are expected to be stronger with GELB microspheres, these interactions already 
could be optimal using instant loading.  
Another feature that was observed in the BSA release study(10) was a substantial higher release from 
the instant loaded scaffolds within the first weeks due to weaker electrostatic interactions between the 
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drug and gelatin. In our study, in most cases growth factor release up to 3 weeks was similar for both 
instant and prolonged loaded samples. With bFGF loaded 5% GELB CPC there was a 10% higher 
release from the instant loaded scaffolds within the first weeks, though with BSA a 100% higher 
release was obtained. Comparison of both studies, the type of drug (BSA/growth factor), substrate 
medium (demineralized water/PBS) and drug concentration (1.5 mg/50-5000 ng) used during the 
release experiment all could have influenced drug release. The use of demineralized water in the BSA 
release study also resulted in a strong decrease of the pH. An increase in drug concentration can 
influence release properties as protein-binding sites are saturable(26). Increasing BMP-2 loading from 
50 ng to 5 µg in this study did not lead to a different release pattern or efficiency, but a proportional 
increase in absolute release. Within this range, sustained release from the gelatin microsphere CPCs 
and CPC controls therefore can be tuned to a certain therapeutic amount per week. 
 
5. Conclusion 
Gelatin microsphere / calcium phosphate cement composites can be applied for the sustained release of 
growth factors. The composites showed release efficiencies of 14-55% and release patterns consisting 
of a small initial burst followed by a sustained release up to 6 weeks. CPC controls showed a higher 
burst release as well as release efficiency when drug was adsorbed at the outside of the sample, but a 
comparable pattern and release efficiency when drug was incorporated during cement preparation. 
Sustained release from the gelatin microsphere CPCs was highly dependent on the type of growth 
factor but was also dependent on the total volume of microspheres and type of gelatin. Also the 
loading mechanism was important, as instant loaded 10% GELA CPC showed a significant higher 
sustained release than prolonged loaded composites. Furthermore, release patterns/efficiencies from 
the gelatin microsphere composites and CPC controls did not differ significantly when BMP-2 
concentration was increased with a factor of 10 -100. 
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1. Introduction 
Calcium phosphate cements are used in clinical practice for filling up bone defects because of their 
biocompatibility, osteoconductivity and perfect fit with the surrounding tissue when injected in situ(1). 
For bone tissue engineering purposes, resorption of dense cement is too slow(2). Therefore, 
(macro)porosity is often introduced to enable bone ingrowth into the material concomitantly 
improving the bioresorption(3). Incorporation of poly(lactic-co-glycolic) acid (PLGA) or gelatin 
microspheres in calcium phosphate cements(4-6) has proven to introduce macroporosity during in situ 
degradation of the microspheres without unacceptably affecting the handling properties or cement 
setting. A rationale for this construct is that bone ingrowth compensates for the loss of mechanical 
strength, which occurs as a result of microsphere degradation. Furthermore, these microspheres can be 
used as drug delivery vesicles for osteoinductive growth factors(7-8), thereby improving the often 
marginal release from these cements.  
Despite the favorable release of growth factors we observed also that inclusion of PLGA microspheres 
was associated with a loss of mechanical strength of the set cement as well as the production of acidic 
degradation products(4). The subsequent replacement of PLGA with gelatin microspheres resulted in a 
more gradual degradation, which occurred from the outer to the inner part of the cement composite, 
where degradation was dependent on the type and amount of incorporated microspheres(5-6). 
Unfortunately, the gelatin degrading enzyme (collagenase) experienced physical interactions with the 
surrounding calcium phosphate cement, delaying degradation of microspheres at the inner parts. 
Another setback is that gelatin exhibits biomimetic properties(9). As a consequence, the microspheres 
became often completely covered by a calcium phosphate precipitate that decreased the 
interconnectivity of the spheres and thereby also penetration of the enzyme.  
Poly(trimethylene carbonate) (PTMC, Figure 1) is a flexible, biodegradable polymer that in contrast to 
PLA/PLGA does not produce acidic degradation products(10). PTMC degrades via surface erosion, i.e. 
degradation occurs only at the surface resulting in a decrease of size/radius of the material(11). Studies 
have shown that this process is driven by enzymatic degradation where degradation rates can be 
increased by increasing the molecular weight of the polymer(11-12).  It can be hypothesized that upon 
the introduction of PTMC microspheres(13) into an injectable calcium phosphate cement a controlled 
degradation pattern will occur without the problems as observed with gelatin. Furthermore, the rubber-
like properties of PTMC can possibly also be used to improve the initial mechanical properties of the 
cement. 
 
 
 
 
 
 
Figure 1. Chemical structure of poly(trimethylene carbonate) 
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In view of the above mentioned, the goal of this study was to formulate a PTMC microsphere/calcium 
phosphate cement composite (PTMC CPC) with appropriate handling properties and to investigate the 
mechanical properties and in vitro degradation characteristics. Therefore, 12.5 wt % and 25 wt% 
PTMC CPCs were prepared using PTMC with molecular weights of 52.7 kg⋅mol-1 and 176.2 kg⋅mol-1. 
Setting time, porosity and mechanical characteristics of the different formulations were determined. 
For the in vitro degradation assay, samples were subjected to enzyme containing medium (lipase) or 
phosphate buffered saline (PBS). The pH of the medium was monitored and samples were assayed on 
mass loss, compression strength, E-modulus, chemical consistency (FTIR, XRD) and morphology 
(SEM). 
 
2. Materials and Methods  
2.1. Materials 
PTMC53 (Mn = 52.7 kg⋅mol-1, Mw = 84.1 kg⋅mol-1, PDI = 1.60) and PTMC176 (Mn = 176.2 kg⋅mol-1, Mw 
= 265.2 kg⋅mol-1, PDI = 1.51) were synthesized by ring opening polymerization(13) and used for the 
preparation of the microspheres. The applied CaP cement is commercially available under the product 
name Calcibon® and consists of 61 wt% α-TCP, 26 wt% CaHPO4, 10 wt% CaCO3 and 3 wt% pHA. 
Lipase from Thermomyces lanuginosus (EC 3.1.1.3., minimum 100000 units/g, Sigma-Aldrich, St. 
Louis, USA) was used as PTMC degrading enzyme solution. 
 
2.2. Methods 
2.2.1. Preparation of PTMC microspheres 
PTMC microspheres were prepared by a single emulsion method. Briefly, a 1 wt% of PTMC176 and 
respectively 2 wt% of PTMC53 solution in dichloromethane was emulsified in an aqueous phase 
containing 2% PVA. The stirring speeds were respectively 1000 rpm and 800 rpm. After evaporation 
of dichloromethane, microparticles were solidified, and then purified by centrifugation and re-
dispersed in the PVA-containing aqueous phase. 
Morphology of the PTMC53 and PTMC176 microspheres was determined by scanning electron 
microscopy (SEM, JEOL 6400-LINK AN 10000 at 10 kV); samples were dried on carbon tape and 
sputtered with gold-palladium prior to measurement. In addition, morphology of the microspheres was 
also visualized by light microscopy (Leica Microsystems AG, Wetzlar, GER) after which particle size 
distributions were determined using digital image software (Leica Qwin, Leica). 
 
2.2.2. Preparation of PTMC CPC 
PTMC microsphere/calcium phosphate cements (PTMC CPCs, 12.5 and 25 wt%) of both PTMC53 and 
PTMC176 polymers were prepared. For this, the amount of PTMC microspheres inside the suspension 
was pooled and microsphere suspensions containing 125/250 mg of microspheres were centrifuged 
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and decanted. Then, 290/260 μl of 1% Na2HPO4 was added to the microspheres and the resulting 
suspension was added to 875/750 mg of CPC inside a 2 ml syringe and stirred vigorously for 15s using 
a Silamat® mixing device (Vivadent, Schaan, Liechtenstein). Cement paste was injected into a Teflon 
mold (cylinders 4.5*9.0 mm) and samples were left to set at room temperature over night. The applied 
concentration and amount of liquid hardener for both 12.5 and 25 wt% PTMC CPCs was sufficient to 
accomplish a fully injectable calcium phosphate cement(4). After drying, cross-sections of the 
composites were made and the morphology was determined by SEM. 
 
2.2.3. Setting time 
Initial and final setting time was assessed using custom available Gillmore needles (ASTM C266). 
Therefore, a bronze block containing 6 holes (6 mm in diameter, 12 mm in height) was used as a 
mould and placed in a water bath at body temperature (37˚C). Samples were mixed and injected into 
the mould in a retrograde fashion, after which the initial and final setting time was determined(4). Tests 
were done in triplicate. 
 
2.2.4. Porosity 
The macro- and total porosity of preset samples was determined. Macroporosity is the porosity 
generated by the PTMC microspheres and corresponds to the vol% of microspheres. The total porosity 
is the macroporosity plus the original microporosity of the cement.  
To measure these parameters, both PTMC CPC samples and CPC samples of a known volume were 
placed in an oven at 650°C for 2 h. After burning out the PTMC or moisture, samples were weighed 
and equation 1 and 2 were used for the derivation of the total porosity and the macroporosity. 
%100*)
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ρε −=         Equation 1
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m−=ε         Equation 2 
Legend: εtot = total porosity (%), εmacro = macroporosity (%), m = average mass sample (g, n=3), mmacro = average 
mass macroporous sample (after burning out PTMC) (g, n=3), mmicro = average mass microporous sample (CPC) 
(g, n=3), V = volume sample (cm3), ρHAP = density hydroxy apatite (g/cm3) 
 
2.2.5. Mechanical characteristics 
Preset PTMC CPC samples (cylinders, 4.5 mm diameter * 9.0 mm height) were soaked in PBS for 3 
days.  Subsequently, samples were dried over night in a freeze-dryer, placed in a testing bench (858 
MiniBionixII®, MTS Corp., Eden Prairie, MN, USA) and compression strength, E-modulus and strain-
at yield (ε) along the vertical axis (height) of the specimens was measured at 0.5 mm/min crosshead 
speed. 
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2.2.6. Degradation assay 
For the degradation assay, preset 12.5/25 wt% PTMC53 CPC and PTMC176 CPC samples were put in 3 
ml of a 1:2 lipase/demineralized water solution or PBS (pH = 7.4) for a total of 6 and 12 weeks 
respectively. Sample medium was refreshed every week. At day 3, 7, 14, 28, 42 and 84, five samples 
of each formulation were subjected to analysis as summarized below. CPC samples were taken as 
reference. 
pH measurement 
Corresponding to an earlier performed study using PLGA microsphere/calcium phosphate cement 
composites(4), the pH of the PBS medium was monitored to observe whether conditioning in PBS leads 
to the formation of acidic compounds.  
Mass loss 
Sample weight was measured after removal from the incubation medium and freeze-drying over night. 
Mass loss was determined using Equation 3. 
%100*
0
0
m
mm
R nL
−=         Equation 3 
Legend: RL = mass loss sample on t = n (%), m0 = mass sample on t = 0 (g), mn  = mass sample on t = n (g) 
 
Mechanical characteristics 
Compression strength and E-modulus of dried samples was determined by placing the samples in a 
testing bench as described earlier. 
IR spectroscopy 
A fraction of the PTMC CPCs samples was grinded and measured by attenuated reflectance Fourier 
transform infrared spectroscopy (ATR-FTIR, Perkin-Elmer, Fremont, CA, USA). Concentration of 
PTMC inside the samples was determined analogous to Featherstone et al(14). In brief, the extinction of 
a typical PTMC absorption band (C=O, 1750 cm-1) and a calcium phosphate absorption band (PO4, 
1050 cm-1) of the PTMC CPC was determined using Equation 4. The resulting ratio of both extinctions 
(EC=O/EPO4) is linear with the percentage of PTMC inside the cement. Therefore, composites with 
different contents of PTMC CPC (5, 10, 15, 20, 25 and 30 wt%) were prepared and used to make a 
standard curve.  
peaksample
baseline
T
TE
_
log=                    Equation 4  
Legend: E = extinction, Tbaseline = transmission baseline, Tsample-peak = transmission sample peak 
 
Thermogravimetric analysis 
Samples for the FTIR standard curve were calibrated using thermogravimetric analysis (TGA 7, 
Perkin-Elmer). For this assay, 30 mg of sample was placed in the instrument where it was kept at 50°C 
for 2 min before scanning it from 50°C to 650°C at a rate of 10°C per min. Finally, the sample was 
kept at 650°C for 2 min before it was cooled down. 
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X-ray diffraction spectroscopy 
The composition of the cement inside the composites was determined by powder X-ray diffraction 
(XRD, Philips, PW 3710, Almelo, The Netherlands). Therefore, the same grinded samples were used 
as for FTIR. 
Morphology 
Cross-sections of the samples were prepared, morphology of the cement and microspheres at the 
surface and inner part of the composite was monitored at different magnifications by SEM. 
 
2.2.7. Statistical analysis 
Data were arranged as mean ± standard deviation. Significant differences were determined using 
analysis of variance (ANOVA). Results were considered significant if p<0.05. Calculations were 
performed using GraphPad Instat® (GraphPad Software Inc., San Diego, Ca, USA). 
 
3. Results 
3.1. Preparation of PTMC microspheres 
Investigation by SEM and light microscopy revealed that microspheres of both PTMC53 and PTMC176 
polymers showed a spherical structure with a smooth surface. Average size of the microspheres was 
higher for the PTMC53 polymer (28.6 μm, Table 1) compared to the PTMC176 polymer (15.3 μm). 
PTMC176 microspheres showed a narrow particle size distribution with a maximum particle size < 
40μm, whereas PTMC53 microspheres showed a much broader particle size distribution with a 
maximum size up to 90 μm.  
 
Table 1. Physical/mechanical properties PTMC CPCs and CPC 
Formulation CPC PTMC53 CPC PTMC176 CPC 
Average size 
microspheres (μm) 
- 28.63 ± 16.70 15.30 ± 6.21 
PTMC microspheres 
(wt%) 
0% 12.5% 25% 12.5% 25% 
Mass samples (mg) 262.7 ± 6.1 200.0 ± 6.3 178.9 ± 6.7 198.1 ± 6.7 177.5 ± 6.7 
Initial setting time (s) 108.3 ± 5.8 105.0 ± 0.0 183.3 ± 31.8 110.0 ± 8.7 170.0 ± 34.6 
Final setting time (s) 235.0 ± 31.2 480.0 ± 17.3 > 1200* 480.0 ± 42.4 >1200* 
Total porosity (%) 40.8 ± 1.3 57.3 ± 0.5 69.6 ± 0.6 62.5 ± 1.5 70.0 ± 0.4 
Macroporosity (%) 0 27.9 ± 1.4 48.7 ± 1.4 36.7 ± 1.9 49.3 ± 1.3 
Compression strength 
(MPa, n=7) 
64.4 ± 16.6 19.0 ± 3.1 15.5 ± 2.6 23.9 ± 4.8 15.3 ± 1.6 
E-modulus 
(GPa, n=7) 
5.44 ± 1.33 1.14 ± 0.23 0.68 ± 0.13 1.60 ± 0.62 1.13 ± 0.27 
Strain-at-yield  
(ε, mm, n=7) 
0.186 ± 
0.011 
0.299 ± 
0.034 
0.386 ± 
0.116 
0.215 ± 
0.021 
0.271 ± 
0.071 
* Experiment stopped after 20 min, the specimens harden within 1 day 
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3.2. Preparation/Mechanical properties of PTMC CPC 
Figure 2 shows SEM micrographs of the as-prepared 25 wt% PTMC53 CPC and after burning out of 
the microspheres for the porosity measurements. From the left picture, it can be observed that spheres 
inside the cement were present with a thin layer of calcium phosphate precipitate onto the surface. The 
right picture shows that the pores formed by the microspheres are spherical and have a homogenous 
distribution inside the cement. 
 
 
Figure 2. Morphology 25 wt% PTMC53 CPC as-prepared (left) and after burning out polymer (right), arrows 
indicate microspheres or pores (original magnification 100×) 
 
 
Results of the setting time, porosity measurements and mechanical characteristics of the composites 
are shown in Table 1. Initial setting time of both PTMC CPC composites was similar to the original 
CPC, whereas final setting time was significantly increased with the 12.5 wt% PTMC CPC and 25 
wt% PTMC CPC. Porosity measurements showed a total porosity of ± 60% and 70% with the 12.5 
wt% and 25 wt% PTMC CPC, while the microporosity of the original cement reached values up to 
40%. Calculated macroporosity (% spheres inside the cement) increased with increasing amount of 
microspheres, and reached 49% with both 25 wt% PTMC CPCs. For the 12.5 wt% PTMC CPC 
samples, macroporosity differed significantly (p<0.05) between both PTMC53 and PTMC176 
composites.  
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Figure 3. A. Stretching of PTMC microspheres at fracture interface (original magnification 200× (left) and 500× 
(right)), B. Stress-strain curves of CPC and 12.5/25 wt% PTMC CPCs 
 
Compression strength and E-modulus of the PTMC CPCs were significantly lower compared with 
CPC and decreased with increasing amount of microspheres (p<0.05). The E-modulus was dependent 
on the molecular weight of the PTMC used for the microspheres as significant higher values were 
observed for PTMC176 CPC as compared to PTMC53 CPC. Strain-at-yield(ε) of the PTMC CPC 
samples increased with increasing amount of PTMC microspheres and was significantly higher 
(p<0.05) than the CPC. Also, for PTMC53 CPCs a higher ε was observed (p<0.05) than the PTMC176 
CPCs. Furthermore, under high compression PTMC CPC did not fracture into separate smaller pieces 
but was kept together by the elongated microspheres as depicted in Figure 3A. From stress/strain 
curves of compression strength measurements (Figure 3B), the same phenomenon was observed with 
especially the 25 wt% PTMC CPC as compression strength remained at a constant level after reaching 
yield strengths. 
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Figure 4. Results degradation in PBS;  A. pH change of medium per week, B. Mass change in time, C. 
Compression strength in time, D. E-modulus in time 
 
3.3. Degradation in PBS 
Results for the degradation of PTMC CPC in PBS are given in Figures 4-7. Release of acidic products 
from the CPC into the medium (Figure 4A) resulted in a pH of 6.6 after 21-42 days. Thereafter, the pH 
decrease was less and the pH slowly returned to its original value after 84 days. The PTMC CPC 
formulations showed a pattern similar to CPC, but exhibited an overall smaller decrease in pH. For the 
25 wt% PTMC CPCs, also a faster increase in pH after 14-28 days was observed. The mass change of 
the samples in time (Figure 4B) showed an initial increase in mass of 1.5-3.0% for all samples after 3 
days incubation time, after which the mass slowly decreased in time. Though changes in mass were 
small, significant differences (p<0.05) between the formulations were observed and the initial mass 
increase was in the following order: CPC > 12.5 wt% PTMC CPC > 25 wt% PTMC CPC. 
Compression strength and E-modulus of the PTMC CPC and CPC samples (Figure 4C-D) was 
constant over time, but, at t = 14 and 28 days values with the 12.5 wt% PTMC53 CPC were slightly 
higher. Furthermore, compression strength of the 25 wt% PTMC CPCs showed a significant decrease 
after 84 days (p<0.005).  
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Figure 5. SEM-micrographs of 12.5 wt% and 25 wt% PTMC53 CPC / PTMC176 CPC samples at t = 42 days in 
PBS, arrows denote PTMC microspheres/shells (orig. magn. 100× and 500×) 
 
SEM-micrographs of the PTMC CPC composites (Figure 5) show spherical pores and microsphere 
structures that are scattered evenly through the cement. For the 12.5 wt% PTMC CPC, these 
pores/spheres are isolated inside the cement, whereas for 25 wt% PTMC CPC there is a tight packing. 
However, interconnections between pores are very scarce. Due to the different microsphere sizes, there 
is a slight difference in pore size between the PTMC53 CPC and PTMC176 CPC. No clear differences in 
morphology were observed between samples taken at t =  42 days and other time points (data not 
shown).  
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Figure 6. Weight% of PTMC 
in samples as measured by 
FTIR as function of incubation 
time in PBS 
 
 
 
 
 
 
 
 
FTIR was performed to quantitatively determine the amount of PTMC inside the composites. Standard 
curves that were analyzed with FTIR (and calibrated with TGA) showed a linear relationship between 
the EC=O/EPO4 ratio and PTMC content (r2 > 0.98) for both PTMC53 and PTMC176 polymers. Using 
these standard curves, the percentage of PTMC inside the composites was calculated as is shown in 
Figure 6. In PBS, both PTMC53 and PTMC176 CPCs showed a similar trend and a slight increase in 
%PTMC over time with the 25 wt% PTMC CPCs was determined, whereas the 12.5 wt% PTMC 
CPCs showed a slight decrease of PTMC content after 84 days. Investigation of the cement structure 
of the PTMC CPCs by X-ray diffraction (Figure 7, PBS) revealed that the cement starting compounds 
(α-TCP, monetite) disappeared within 14 days of incubation, with only the endproduct (apatite) 
remaining.  
 
3.4. Degradation in lipase solution 
Results of the degradation of PTMC CPC in lipase solution are depicted in Figures 7-11. Mass change 
of the PTMC CPCs in time (Figure 8A) showed different curves for both 12.5 wt% and 25 wt% PTMC 
CPCs. For 12.5 wt% PTMC CPC, there was an initial increase in mass of 2% after 3 days that 
significantly increased to 3.5% after 42 days (p<0.005). The 25 wt% PTMC CPC samples showed a 
decrease in mass with 1.1-1.7 wt% after 7 days after which also a slight increase in mass was 
observed. Compression strength (Figure 8B) of the 25 wt% PTMC CPC (5-10 MPa) at most time 
points was significantly lower than for the 12.5 wt% PTMC CPC (15-22 MPa) and did not show a 
clear trend in time.  The E-modulus of both systems (data not shown) showed a similar trend as the 
compression strength, though less significant differences were observed.  
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Figure 7. XRD spectra of cement starting material and 25 wt% PTMC53 CPC after 3 and 14 days in PBS and 
lipase solution, legend figures: A = apatite,  o= α-TCP, * = monetite 
 
 
Figure 8. Degradation of PTMC CPC in lipase solution; A. Mass change in time, B. Compression strength in 
time  
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Figure 9. SEM-micrographs of 25 wt% PTMC53 CPC and PTMC176 CPC samples at t = 3, 42 days in lipase 
solution, arrows denote PTMC microspheres/shells (orig. magn. 100× and 500×) 
 
SEM micrographs of 25 wt% PTMC CPCs (Figure 9) at day 3 show an open porous structure at the 
outside of the samples, whereas in the inside microspheres were present. A similar morphology was 
observed after 42 days, though the amount of microspheres present in the middle was markedly 
reduced. Conversely, with the 12.5 wt% PTMC CPC (Figure 10) a lot of microspheres were visible at t 
= 3 and 42 days and only at the upper 200μm of the samples the amount of microspheres was reduced. 
Furthermore, the cement microstructure of especially the 25 wt% PTMC CPCs showed a strikingly 
high porosity.  
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Figure 10. SEM-micrographs of 12.5 wt% PTMC53 CPC and PTMC176 CPC samples at t = 3, 42 days in lipase 
solution, arrows denote PTMC microspheres/shells (orig. magn. 100× and 500×) 
 
Results from FTIR spectroscopy are given in Figure 11A-B. Figure 11A gives a representation of the 
acquired IR spectra with 25wt% PTMC53 CPC after t = 7, 14, 28 and 42 days. A distinct decrease of 
peak intensity of all separate PTMC peaks was observed with increasing degradation times, whereas 
the PO4-peak of the CaP cement remained constant. Furthermore, a peak at 1650 cm-1 was present, that 
was absent for PTMC CPC in PBS medium, showing a slight increase in time. As this wavelength 
corresponds to the C=O stretch of proteins/amides, this peak may indicate the presence of lipase inside 
the scaffolds. Figure 11B shows the wt% of PTMC inside the composite as a function of degradation 
time. For both 25 wt% PTMC CPC samples, a significant decrease in the wt% of PTMC was observed 
from 25 wt% to 5-8 wt% at 42 days that was faster with the PTMC53 CPC. The composition of the 
_____________________Introduction of enzymatically degradable PTMC microspheres into an injectable CPC 
 149
12.5 wt% PTMC CPCs did vary less in time, although also a small decrease in the wt% of PTMC was 
noted. Finally, the analysis of the cement by XRD (Figure 7, lipase) revealed that after 14 days of 
incubation peaks of monetite and α-TCP were still present, though also here cement was converted 
into apatite. 
 
Figure 11.  A. IR-spectra of 25wt% PTMC53 CPC in lipase solution after t = 7, 14, 28 and 42 days, B. Weight% 
of PTMC in samples as measured by FTIR as function of incubation time in lipase solution 
 
4. Discussion 
In this study, physical/mechanical properties and in vitro degradation characteristics of injectable 
calcium phosphate cement with incorporated PTMC microspheres was investigated. Therefore, 12.5 
wt% and 25 wt% PTMC53 and PTMC176 microsphere/ calcium phosphate cement composites were 
formulated, which were tested on setting properties, mechanical strength and macroporosity.  
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Furthermore, preset samples were incubated in PBS/lipase and assayed for weight loss, mechanical 
strength, morphology and composition (XRD, FTIR). 
The used poly(trimethylene carbonate) is a polymer with a glass transition temperature (Tg) ~ -
20°C(15). Consequently, at room and body temperature PTMC behaves as a rubber-like polymer. 
During preparation of polymeric microsphere CPC composites, (freeze-)dried microspheres are usually 
mixed with calcium phosphate cement powder to obtain a good distribution of the microspheres, after 
which liquid hardener is added(4). Due to its low Tg, freeze-dried PTMC microspheres agglomerate and 
therefore cannot be mixed with the cement powder. Therefore, to obtain a PTMC CPC, microspheres 
were added to the liquid hardener during cement preparation as described in the materials and methods 
section, which resulted in a well distributed microsphere composite. In agreement with previous 
studies using PLGA and gelatin microspheres(4-5), setting time was increased upon the addition of 
PTMC microspheres. When compared to conventional CPC(16) setting time increased due to an 
increase in liquid/powder ratio as extra aqueous phase was still present after carefully decanting the 
PVA solution above the PTMC microspheres. Also with PLGA microspheres(4) and gelatin 
microspheres(5) extra aqueous phase was present to improve the injectability of the composite (PLGA) 
or as a result of the preparation method (pre-swollen gelatin microspheres). Another parameter that 
influenced the setting of the PTMC CPC is the large volume of microspheres of especially 25 wt% 
PTMC CPC that hampers the entanglement of calcium phosphate crystals (setting process)(17). 
Furthermore, even after the cement has set, imprints of the Gilmore needle were still visible as a result 
of plastic deformation of the composite(18).  
For the degradation study PBS as well as a lipase solution were used. Though in PBS no degradation 
of the microspheres is expected, this study was necessary to compare the current results with 
microsphere CPC specimens in previous experiments(4-6). Comparable to in vitro studies with pure 
PTMC specimens(11), the lipase solution was used to determine whether microspheres within a calcium 
phosphate scaffold can degrade in the presence of a PTMC degrading enzyme. Although it has to be 
emphasized that in a bony environment the concentration of lipase will be much lower, implantation of 
solid PTMC scaffolds in the tibia and femur of rabbits(11) also resulted in a sustained surface erosion of 
the polymer indicating the presence of PTMC degrading enzymes. 
Results of the pH assay for the degradation in PBS showed that a higher amount of incorporated 
PTMC microspheres results in a smaller pH decrease, indicating that the cement is the major source of 
acidic (degradation) products(4, 19). Furthermore, results of the PBS study showed that there was no 
sign of PTMC degradation as an initial mass increase of 1.5-2.5% was measured, while the 
compression strength/E-modulus remained constant during the first 6 weeks of incubation. 
Nevertheless, after the first week the mass of the samples gradually decreased in time and also the 
compression strength decreased slightly after 12 weeks of incubation. As the same trend is observed 
with the CPC control, cement dissolution/degradation over time is the most plausible explanation. The 
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initial mass increase was also observed in previous studies(5, 6) and is caused by precipitation of salts 
from the PBS solution. 
SEM pictures of the 25 wt% PTMC CPC specimens that were incubated in lipase solution showed an 
interconnected structure of macropores, which confirms that the microspheres have been degraded. At 
early time points (t = 3 days) this porosity was mostly present at the outer parts whereas at later time 
points also at the inner radius the amount of microspheres was reduced. This result is comparable to 
that for the gelatin microsphere CPC in a previous experiment(6) and indicates a similar pattern with 
microspheres degrading from the outer to the inner part of the implants. Also results with IR showed a 
slow decrease in the wt% of PTMC within the composite, confirming a sustained degradation of the 
PTMC polymer. Both analyses showed that degradation of PTMC (microspheres) in the 12.5 wt% 
composites was much slower. This corresponds to studies with gelatin microspheres(5-6), and is caused 
by the low or non-existent interconnectivity of the microspheres that delays the penetration of lipase 
into the composite.  
A striking observation in the IR spectra is that for 25 wt% PTMC CPC, the PTMC53 microspheres 
inside the cement degrade faster than the PTMC176 microspheres, whereas the highest molecular 
weight PTMC degrades faster in separate degradation experiments(11). As PTMC176 microspheres were 
significantly smaller than the PTMC53 microspheres, they also contained a relatively higher amount of 
hydrophilic PVA at the surface(20). This may form a barrier for enzymatic degradation as the enzymes 
are more active at hydrophobic surfaces. The difference in size of the PTMC53 and PTMC176 
microspheres was related to different parameters that were applied in their preparation. 
The results from the mass assay do not corroborate with the IR and SEM results. If mass decrease 
would be in agreement with these results, the mass of 25 wt% PTMC CPC should have decreased with 
15-20% after 6 weeks. However, only an initial decrease in mass was observed followed by a slow 
increase in mass. The reason for this phenomenon is that within this system there are two processes 
occurring at the same time, i.e. degradation of PTMC microspheres and adsorption of organic 
components (lipase) from the medium. Next to the appearance of a typical protein/amide-peak in IR 
spectra(21), occasionally a layer of precipitate at the surface of the sample was observed in SEM and the 
cement itself turned from white to yellow (color of lipase medium) in time.  
For both 12.5 wt% and 25 wt% PTMC CPC either in PBS or in lipase solution, the compression 
strength/E-modulus remained constant in time. While in PBS there is no PTMC degradation, the 
compression strength of the PTMC CPC is expected to be constant. However, in lipase solution 25 
wt% PTMC CPC should show a decrease in compression strength(4-6) as the polymer is slowly 
degrading. Comparing the compression strengths of samples exposed to lipase solution with that of 
samples in PBS, 25 wt% PTMC CPC samples (but also 12.5 wt% PTMC CPC) have a lower value 
from the beginning (3 days) in lipase and no gradual decrease. This is probably due to the fact that the 
PTMC microspheres degrade by surface erosion(11) thereby detaching themselves from the surrounding 
cement. As a consequence, the compression strength decreases immediately after the start of 
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microsphere degradation. A slower cement conversion rate in lipase solution as can be suggested from 
Figure 7 is also an explanation for a lower initial mechanical strength, though in both media the 
cement was highly converted into apatite after 14 days.  
Finally, the introduction of a rubber-like PTMC into a calcium phosphate cement for tissue 
engineering possibly can be used to improve the mechanical properties of the cement, i.e. overcome 
brittleness(22), as a higher strain-at-yield was obtained with an increasing percentage of PTMC. Also 
the toughness of the cement increased as composites did not fracture after reaching the yield strength 
but were kept together by the elongated microspheres. Similar mechanical characteristics are also 
observed using fiber-containing calcium phosphate cements(23-24). Compared to these fiber-containing 
cements, microsphere/calcium phosphate cement composites are more easily to process with respect to 
injectability and polymer distribution and therefore can form an attractive alternative. 
 
5. Conclusion 
Calcium phosphate cements incorporated with well distributed PTMC microspheres were formulated 
and showed initial setting times of ± 2-3 min and compression strengths of 15-24 MPa. Gradual 
degradation of the incorporated microspheres occurred from the outer to the inner part of the 
composite when they were incubated in lipase solution, but not in PBS. The incorporation of PTMC 
microspheres in CPC improved the toughness of the material, preventing it from fracturing into 
smaller pieces.  
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1. Introduction  
Most of the currently available calcium phosphate cements (CPCs) convert after application in a bone 
defect into apatite, which is a calcium phosphate phase that is similar to the inorganic part of bone. A 
disadvantage of this end-product is its high stability and therefore this material shows only a slow 
osteoclastic depending resorption in time(1). Although, a faster degrading brushite cement(2-3) can be 
selected to solve this problem, another approach is the introduction of macroporosity(4) into the apatite 
cement. The consequential increase of surface area results in an increased resorption rate of the 
cement. Macroporosity can be generated by the addition of foaming agents to the cement such as 
sodium bicarbonate(5-6), bovine serum albumin(7), water soluble crystals(8) and by the introduction of 
biodegradadable microspheres(9-11). This last method has the advantage that the mechanical strength of 
the microspheres contributes to the initial strength of the ceramic scaffold(12). Additionally, these 
microspheres can be applied as drug delivery vehicle for osteoinductive growth factors(10).  
Previous studies have already shown that indeed injectable and setting CPCs can be produced upon the 
introduction of microspheres composed of poly(lactic-co-glycolic acid) (PLGA)(12), gelatin(13) and 
poly(trimethylene carbonate) (PTMC)(14). In vitro incubation of these composites in phosphate 
buffered saline or enzyme-containing media(12, 14, 15) results in an interconnected, macroporous calcium 
phosphate matrix after microsphere degradation. The in vitro degradation mechanisms of the different 
microsphere/calcium phosphate formulations in these studies were varied by using polymers with 
unique degradation or erosion mechanisms (Table 1)(16). For example, gelatin and PTMC 
microsphere/CPC composites(14, 15) were found to show a gradual degradation of the microspheres from 
the outer to the inner parts of the composite as the cement delays enzyme diffusion through the 
material. On the other hand, in PLGA microsphere containing cements(12), microspheres degraded 
throughout the cement as a result of hydrolytic cleavage of the polymer chains. Furthermore, 
compared to the bulk erosion mechanism of PLGA and gelatin microspheres(12, 15), surface erosion of 
the PTMC microspheres(16) resulted in a fast decrease of compression strength as they detached from 
the cement matrix(14). In an in vivo situation, conditions are different regarding fluid flow, buffer 
capacity and enzyme activity(17), and therefore it can be hypothesized that the microsphere composites 
degrade then in a different manner.  
 
Table 1. Degradation/erosion pattern biodegradable polymers 
 PLGA Gelatin PTMC 
Degradation Hydrolysis Enzymatic Enzymatic 
Erosion Bulk erosion Bulk erosion Surface erosion 
 
The goal of this study is to investigate the in vivo degradation behavior and tissue response of 
microsphere/calcium phosphate cement composites (microsphere CPCs) with different microsphere 
degradation and erosion mechanisms. As a model, microsphere CPCs composed of calcium phosphate 
cement containing either PLGA microspheres, gelatin microspheres or PTMC microspheres were 
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formulated and implanted subcutaneously in the back of New Zealand white rabbits. Additionally, to 
investigate the influence of the type of gelatin, both porcine (type A) and bovine (type B) gelatin 
microspheres were introduced into the cement. PTMC microspheres with a relatively low molecular 
weight of 40.0 kg⋅mol-1 and 444.2 kg⋅mol-1 were incorporated into the cement as previous 
experiments(16) showed that higher molecular weight PTMC exhibits a higher erosion rate. Finally, 
also a composite of cement with incorporated gelatin and PLGA microspheres was formulated to 
investigate whether the degradation of one type of microspheres influenced the degradation of the 
other type of microspheres.  
 
2. Materials and Methods 
2.1. Materials 
Poly(lactic-co-glycolic acid) (PLGA, L/G : 54/46, Mn = 34.7 kg⋅mol-1, Mw = 54.2 kg⋅mol-1, PDI = 
1.56, Purac, Gorinchem, The Netherlands), gelatin (porcine (type A): pI = 7.0-9.0; bovine (type B): pI 
= 4.5-5.0, both Acros, Geel, Belgium) and poly(trimethylene carbonate)(16) (LMW PTMC: Mn = 40.0 
kg⋅mol-1, Mw = 68.7 kg⋅mol-1, PDI = 1.72, HMW PTMC: Mn = 444.2 kg⋅mol-1, Mw = 599.0 kg⋅mol-1, 
PDI =1.35) were used for the preparation of the microspheres. Poly(vinyl alcohol) (PVA, 88% 
hydrolyzed, Mw = 22 kg⋅mol-1, Acros) was used as stabilizer during microsphere preparation. The 
calcium phosphate cement (Calcibon®, Biomet Merck, Darmstadt, Germany) is commercially 
available and consists of 61% α-TCP, 26% DCPA, 10% CaCO3 and 3% pHA. The applied cement 
liquid was a 1% w/v Na2HPO4 solution in demineralized water (ddH2O).  
 
2.2. Methods 
2.2.1. Preparation of PLGA microspheres 
PLGA microspheres were prepared by a water-in-oil-in-water (w/o/w)-double emulsion solvent 
evaporation technique(18). 1.0 g of PLGA was dissolved in 4 ml of dichloromethane (DCM) in a 50 ml 
glass test tube. 500µl of demineralized water (ddH2O) was added while vortexing vigorously for 1 
min, subsequently adding 6 ml of a 0.3% w/v poly(vinyl alcohol) (PVA) solution in ddH2O and 
continuing vortexing for another 1 min. The content of the tube was transferred to a 1000 ml beaker 
and stirred by a magnetic stirring bar, followed by adding another 394 ml of 0.3% PVA and 400 ml of 
a 2% isopropyl alcohol (IPA) solution. The suspension was stirred for 1 hr, the formed microspheres 
were allowed to settle for 15 min and the solution was decanted. The remaining suspension was 
centrifuged and the microspheres were washed three times with ddH2O. Finally the microspheres were 
frozen, freeze-dried for 24 hr (-40°C, 0.13 mbar) and stored under argon at -20°C. 
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2.2.2. Preparation of gelatin microspheres 
Gelatin microspheres were prepared using an established technique(19). Briefly, 2.5 g of gelatin type A 
(GELA) / gelatin type B (GELB) was dissolved in 25 ml ddH2O at an elevated temperature (30 min at 
60°C). The resulting clear solution was added slowly (10 ml pipette) to a 250 ml three-necked round 
bottom flask containing 125 ml olive oil (Acros) while stirring at 500 rpm (Teflon upper stirrer). The 
round bottomed flask was cooled using an ice bath and after 30 min, 50 ml of chilled acetone (4°C) 
and glutaraldehyde (0.5 ml = 6.25 mM) was added gently. The solution was stirred for another 1h, 
after which the microspheres were collected by filtration (paper filter, D3, Schott Duran, Mainz, 
Germany) and washed several times with acetone (~1 L) to remove residual olive oil. Thereafter, the 
microspheres were stored in a vacuum exicator. 
 
2.2.3. Preparation of PTMC microspheres 
PTMC microspheres were prepared by a single emulsion method(20). 1% w/v of HMW PTMC and 
respectively 2% w/v of LMW PTMC solutions in dichloromethane were emulsified in an aqueous 
phase containing 2% PVA. The stirring speeds were respectively 1000 rpm and 800 rpm. After 
evaporation of dichloromethane, microparticles were formed, which were purified by centrifugation 
and redispersed in the PVA-containing aqueous phase. 
 
2.2.4. Preparation of microsphere/calcium phosphate cement composites 
Before the microsphere/calcium phosphate cement composites were prepared, calcium phosphate 
cement powder was sterilized by gamma-irradiation (25 kGy, Isotron, Ede, The Netherlands). 
Microspheres were sterilized by UV (254 nm) to prohibit extensive degradation of the PLGA(21) or 
crosslinking of the PTMC polymer. Subsequently, cement composites were prepared and stored in a 
sterile environment. Briefly, for the preparation of the microsphere/calcium phosphate cement 
composites, (freeze-)dried PLGA microspheres or swollen gelatin microspheres (560 µl ddH2O/100 
mg dry spheres) were mixed with the calcium phosphate cement powder before liquid hardener (1% 
Na2HPO4) was added. Alternatively, PTMC microspheres were dispersed into the liquid hardener 
before adding the cement powder(14). The resulting mixtures were stirred vigorously for 15 s using a 
Silamat® mixing device (Vivadent, Schaan, Liechtenstein) and injected into Teflon molds with 
cylindrical holes (4.5 mm diameter, 9.0 mm length) and hardened at room temperature over night.  
Properties of the resulting calcium phosphate cement composites with PLGA microspheres (PLGA 
CPC), gelatin type A microspheres (GELA CPC), gelatin type B microspheres (GELB CPC), LMW 
PTMC microspheres (LMW PTMC CPC) and HMW PTMC microspheres (HMW PTMC CPC) are 
summarized in Table 2(12,14,15). In addition, a composite material was prepared which contained both 
PLGA and gelatin type A microspheres (PLGA/GELA CPC). To compare the in vivo response and 
degradation for all composites, macroporosity(4) (volume percentage of microspheres) was kept in the 
range of 48-57 %.  
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Table 2. Properties microsphere CPCs(12,14,15) 
Name PLGA 
CPC  
GELA 
CPC  
GELB 
CPC  
GELA/ 
PLGA CPC  
LMW  
PTMC CPC  
HMW 
PTMC  CPC  
Average size 
microspheres 
(µm) 
33 ± 17 37 ± 31 21 ± 15 33 ± 17, 
37 ± 31 
29 ± 17 15 ± 6 
Wt % 
microspheres 
20 % 10 % 5 % 5 + 10 % 25 % 25 % 
Vol % 
microspheres 
48 % 57 % 48 % 53 % 49 % 49 % 
 
2.2.5. Surgical procedure and implant retrieval 
Eighteen 6-month old female New Zealand white rabbits of 3-4 kg were used in this experiment.  
Surgery was performed under total anesthesia. Before surgery, the back of the rabbits was shaven, 
washed with alcohol and disinfected with iodine. Subsequently, at both sides of the vertical column, 
three 1.5 cm long incisions were made through the full thickness of the skin. Lateral pockets for 
subcutaneous implantation were made by blunt dissection with scissors. One implant of each 
formulation was inserted into each subcutaneous pocket, after which the pockets were closed with 
Vicryl 4.0 sutures. After 4, 8 and 12 weeks, 6 rabbits were sacrificed by CO2 suffocation. Three 
specimens of each material and time point were used for physicochemical characterization and 
histology. For physicochemical analysis, the tissue that surrounded the samples was removed. Then, 
the specimens were stored in water. For histological examination, samples including their surrounding 
tissues were fixated in a 4% formaldehyde solution for 1 week, dehydrated by a series of alcohol 
dilutions and embedded in methyl methacrylate. After polymerization, undecalcified 10µm thick 
sections of the implant were prepared by a modified sawing microtome technique(22). Three sections 
per implant were made and stained by methylene blue/basic fuchsin.  
 
2.2.6. Physicochemical analysis 
Mechanical strength 
After implant retrieval, wet samples were subjected to compression strength measurements. Therefore, 
they were placed in a testing bench (858 MiniBionixII®, MTS Corp., Eden Prairie, MN, USA) and 
compression strength along the vertical axis (height) of the specimens was measured at 0.5 mm/min 
crosshead speed. Samples before implantation (after 1 day setting) were used as reference. 
Molecular weight 
Gel permeation chromatography (GPC) was used to determine the molecular weight of the polymer 
microspheres at different implantation time points. For the PTMC CPCs, GPC analysis was difficult, 
therefore only PLGA polymer inside the PLGA CPC and PLGA/GELA CPC was measured with GPC. 
For analysis, samples were grinded and extracted with 3 ml of THF. The resulting suspension was 
filtered using 13 mm GHP 0.2µm Acrodisk® filters (Waters). The HPLC system consists of a L2130 
HPLC pump, a L-2400 UV detector and a L-2490 RI Detector (Hitachi corp., Tokyo, JPN). The GPC 
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column was a 4.6*300 mm Styragel® HR 4E column with a 4.6*30 mm Styragel® guard column 
(Waters Corp., Milford, MA, USA). Tetrahydrofuran (THF) was used as eluent, flow rate was 0.35 
ml/min. To obtain a calibration curve, polystyrene standards (SM-105, Shodex corp., Tokyo, JPN) 
were used. For the calculation of the number and weight average molecular weight (Mn/Mw) of the 
PLGA, Mark-Houwink constants of PLGA 50:50 (a = 0.761, K = 1.07*10-2, THF, 22.5°C)(23) and PS 
(a = 0.717, K = 1.17*10-2, THF, 25°C) were used.  
Infrared spectroscopy 
For the PTMC CPCs, a fraction of the samples was grinded and measured by attenuated total 
reflectance Fourier transform infrared spectroscopy (ATR-FTIR, Perkin Elmer, Fremont, CA, USA). 
A method derived from Featherstone et al(24) was used to quantitatively determine the content of 
PTMC in the composites in time and was also applied in a previous experiment(14). Briefly, the 
extinction of a characteristic PTMC peak (C=O, 1750 cm-1) and calcium phosphate peak (PO4, 1050 
cm-1) was determined using Equation 1. According to this method, the ratio of both extinctions 
(EC=O/EPO4) forms a linear relationship with the percentage of PTMC within the composites. For this, a 
standard curve was made using samples with different PTMC/cement compositions and calibrated 
with thermogravimetric analysis (TGA). This resulted in a linear relationship for both low and high 
molecular weight polymers (r2 > 0.98), which was used to determine the amount of PTMC in the 
samples.  
peaksample
baseline
T
TE
_
log=          Equation 1  
Legend: E = extinction, Tbaseline = transmission baseline, Tsample peak = transmission sample peak 
 
X-ray diffraction 
The calcium phosphate cement composition of the microsphere/CPC formulations was determined by 
powder X-ray diffraction (XRD, Philips, PW 3710, Almelo, The Netherlands). The same grinded 
samples were used as for FTIR. 
SEM 
The morphology of the different microsphere/CPC formulations was investigated by scanning electron 
microscopy (SEM, JEOL 6400-LINK AN 10000 at 10 kV). Samples were dried on carbon tape and 
sputtered with gold prior to measurement. Magnifications of 250/500x were used to visualize 
microsphere degradation. 
 
2.2.7. Histological examination 
After sectioning of the histological samples, tissue response and microsphere degradation was 
examined by light microscopy (Leica Microsystems AG, Wetzlar, Germany). A histological grading 
scale for soft-tissue implants(25) was used to evaluate the tissue response surrounding the implant 
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(reaction zone) and at the implant surface (interface) (Table 3). Two observers conducted the scoring 
separately and reached consensus on the final score. 
 
Table 3. Histological grading scale of the tissue reaction(25) 
Evaluation Response Score 
1-4 fibroblasts 4 
5-9 fibroblasts 3 
10-30 fibroblasts 2 
 
Capsule 
Quantitatively 
> 30 fibroblasts 1 
Capsule is fibrous, mature, not dense, resembling connective or fat 
tissue in the non-injured regions 
4 
Capsule tissue is fibrous but immature, showing 
fibroblasts and little collagen 
3 
Capsule tissue is granulous and dense, containing both fibroblasts 
and many inflammatory cells 
2 
 
 
 
Capsule 
Qualitatively 
Capsule consists of masses of inflammatory cells with little or no 
signs of connective tissue organization 
1 
Fibroblasts contact the implant surface without the presence of 
macrophages or leucocytes 
4 
Scattered foci of macrophages and leucocytes are present 3 
One layer of macrophages and leucocytes are present 2 
 
Interface 
Qualitatively 
Multiple layers of macrophages and leucocytes are present 1 
 
2.2.8. Statistical analysis 
Data were arranged as mean ± standard deviation. Significant differences were determined using 
analysis of variance (ANOVA). Results were considered significant if p<0.05. Calculations were 
performed using GraphPad Instat® (GraphPad Software Inc., San Diego, Ca, USA). 
 
3. Results 
3.1. Implant retrieval 
During the experiment one rabbit died as a result of a bacterial infection. Hence, of the 8 weeks group 
one implant of each formulation was lost. The other seventeen rabbits remained in a good health and 
did not show any wound complications. At the end of the implantation periods, a total of one hundred 
and two implants (17 of each formulation) were retrieved. At retrieval, the implants were all covered 
by an intact fibrous tissue capsule. 
 
3.2. Physicochemical analysis 
Results of the compression strength measurements after 4, 8 and 12 weeks of implantation are depicted 
in Figure 1. In most cases compression strength decreased gradually during implantation time. For the 
PLGA CPC, PLGA/GELA CPC and HMW PTMC CPC, compression strength was significantly 
decreased after 12 weeks of implantation. For the GELB CPC compression strength significantly 
decreased from 11MPa initially to 4 MPa at 8 weeks of implantation, which was followed by a small 
increase in compression strength at 12 weeks.  
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Figure 1. Compression strength of samples of different microsphere/calcium phosphate cement formulations as a 
function of implantation period 
 
Results of gel permeation chromatography (Figure 2) show that the number average molecular weight 
(Mn) of the PLGA polymer inside the PLGA CPC and PLGA/GELA CPC gradually decreased to ~ 
5000 g/mol at 8 weeks of implantation. At 12 weeks not enough PLGA polymer was left for GPC 
analysis.  
 
Figure 2. Number average 
molecular weight of PLGA 
of the PLGA CPC and 
PLGA/GELA CPC as a 
function of implantation 
period 
 
 
 
 
 
 
 
 
ATR-FTIR (Figure 3) revealed that the PTMC CPCs exhibited microsphere degradation after 4-12 
weeks as the percentage of PTMC inside the composites significantly decreased to ~ 70% of its 
original value. Between the low and high molecular weight PTMC, no significant differences in 
degradation rate were observed. The spectrograms also indicated that after subcutaneous implantation 
an additional peak appeared at 1650 cm-1 corresponding to the C=O stretch of proteins(26). 
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Figure 3. Determination of the amount of PTMC in the PTMC CPCs; A. IR spectra HMW PTMC CPC of star-
ting material and at t=12 weeks, B. amount of PTMC as % of initial amount of PTMC  in both LMW PTMC 
CPC  and HMW PTMC CPC scaffolds as a function of implantation period, *** = p<0.005 
 
In the SEM-micrographs (Figures 4-5), degradation of the PLGA was observed for both PLGA CPC 
and PLGA/GELA CPC samples as characterized by a deformation of the microspheres at 4 weeks and 
complete disappearance of the microspheres at 8 and 12 weeks of implantation.  
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Figure 4. SEM-micrographs of PLGA CPC, GELA CPC and GELB CPC samples at t = 0, 4 and 12 weeks of 
implantation (original magnification 500x) 
 
 
Figure 5. SEM-micrographs of PLGA/GELA CPC, LMW PTMC CPC and HMW PTMC CPC  after t = 0, 4 and 
12 weeks of implantation (original magnifications 250 and 500x 
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In the GELA CPC, GELB CPC and PLGA/GELA CPC, gelatin shells were still visible at 12 weeks of 
implantation. In time, the morphology of the gelatin microspheres changed. Initially, the microspheres 
had a thick shell(13, 15), but at 8 and 12 weeks the thickness decreased slowly, which was also associated 
with deformations of the shell wall. The occurrence of gelatin degradation was further confirmed by 
the observation that at 12 weeks the composites showed a distinctive higher porosity than after 4 
weeks (Figure 6). In all gelatin microsphere containing CPCs also some proof of tissue ingrowth was 
observed as is visualized in Figures 6C and 6D. 
 
 
Figure 6. SEM micrographs of GELA CPC at t = 4 (A) and 12 weeks (B) of implantation, close-up picture 
GELA CPC at  t = 4 weeks of implantation (C) and SEM micrograph of PLGA/GELA CPC at t = 8 weeks of 
implantation (D) (arrows denote tissue ingrowth, original magnifications 100x and 250x) 
 
The PTMC CPCs showed the presence of microsphere structures at all time points. However, 
microspheres were deformed plastically in LMW PTMC CPC. In the HMW PTMC CPC, the 
microspheres maintained a spherical structure although the diameter of the spheres decreased during 
implantation resulting in an empty space between the microsphere and the surrounding spherical hole. 
Furthermore, it was observed that in HMW PTMC CPC, spheres were often fused together (Figure 7). 
At a fracture plane, HMW PTMC microspheres were found to have become interconnected, while in 
the LMW PTMC CPC the polymer showed elongation without the retention of microsphere structure. 
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Figure 7. SEM micrographs LMW PTMC CPC at t=4 weeks of implantation indicating stretching of the material 
at a fracture plane (A + B, original magn. 1000 and 430x), agglomeration of HMW PTMC microspheres (C, ori-
ginal magn 500x) and agglomerated HMW PTMC microspheres at fracture interface (D, original magn 700x) 
 
 
Figure 8. XRD-
spectra of GELB 
CPC featuring 
cement powder, 
starting material 
(t=0) and samples 
after 4, 8 and 12 
weeks of implant-
tation 
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Finally, investigation of the cement composition with XRD showed that for all microsphere CPCs, 
monetite and α-TCP signals completely disappeared within the 12 week implantation period implying 
that the cement has been transformed into apatite. Typical XRD-spectra were shown in Figure 8. 
 
Figure 9A. Histological sections PLGA CPCs at 4, 8 and 
12 weeks of subcutaneous implantation, C = cement, M = 
microsphere, F = fibrous capsule, arrows denote tissue 
ingrowth in microspheres (bar represents 25µm). See also 
page 198 for color figure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3. Histological examination 
Light microscopical pictures of the various histological specimens are depicted in Figures 9A-B. After 
4 weeks of implantation, the surface of the implants showed a rough appearance with spherical cavities 
corresponding to degraded microspheres and irregular shaped calcium phosphate particles. Tissue 
response to all microsphere CPC/formulations was similar, and revealed a fibrous capsule of typically 
> 10 layers that was composed of aligned fibroblasts and other cells. In more than 50% of the samples, 
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this fibrous capsule contained some inflammatory cells. Occasionally, between the fibrous capsule and 
cement surface multiple layers of inflammatory cells were observed, which could be associated with 
the presence of multi-nucleated cells at the cement surface. At places where the implant showed a 
smooth surface, little or no inflammatory response was seen. For the GELA CPC, GELB CPC and 
GELA/PLGA CPC, cells were seen in the microsphere cavities till a distance of >100µm below the 
implant surface.  
 
 
Figure 9B. Histological sections of microsphere CPCs after 12 weeks of implantation; PLGA CPC (1), GELA 
CPC (2), GELB CPC (3), PLGA/GELA CPC (4), LMW PTMC  CPC (5) and HMW PTMC CPC (6), arrows 
denote tissue ingrowth with GELB CPC, dashed arrow denotes shell gelatin microsphere (bar represents 100 
µm). See also page 199 for color figure. 
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The 8 and 12 week specimens showed a gradual decrease in fibrous capsule thickness, especially for 
PLGA CPC and GELB CPC. Tissue ingrowth into the various microsphere/CPC formulations 
increased during implantation time. Tissue response at these time points was similar to the 4 weeks 
samples. 
Besides differences in tissue response, some distinct differences regarding structure or microsphere 
degradation were visible with light microscopy. At t = 4 weeks all gelatin microsphere CPCs looked 
similar and microspheres were evenly spread throughout the material. Gelatin microspheres could be 
easily distinguished from the surrounding cement or pores because they adsorbed high quantities of 
dye. Morphology did not change for GELA CPC after t = 8 and 12 weeks, while for the PLGA/GELA 
CPC and GELB CPC the microspheres at the outer parts of the samples slowly degraded in time. 
Furthermore, for the HMW PTMC CPC, the cement at the outer parts was fractured at all time points, 
while for the other microsphere/CPC formulations the cement structure was intact.  
 
 
Figure 10.  Histological scoring of samples after 4, 8 and 12 weeks of implantation; A. Capsule quantitatively, 
B. Capsule qualitatively, C. Interface qualitatively; * = p<0.05 
 
Histological grading results are given in Figure 10. For all microsphere CPCs, fibrous capsule 
thickness scored between 2-2.5 at week 4 and appeared to show a gradual decrease over time. 
Significant differences in capsule thickness were found between the PLGA CPC and PLGA/GELA 
CPC after 8 and 12 weeks (p<0.05). The fibrous capsule quality was similar for most 
microsphere/CPC formulations and time points (an average scoring of 2.5), but for the GELB CPC and 
PLGA CPC a statistically slightly higher capsule quality (p<0.05) was obtained compared to both 
PTMC CPCs after 8 and 12 weeks respectively. The implant interface quality data showed an average 
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score of 1.5-2.0 for all groups and time points, which did not change over time. Further, the interface 
data did not show significant differences between the various microsphere/CPC formulations. 
 
4. Discussion 
In this study, composites of calcium phosphate cements with incorporated PLGA, gelatin or PTMC 
microspheres were implanted subcutaneously into the back of rabbits to investigate the in vivo 
degradation characteristics and to evaluate the biocompatibility of these materials. In in vitro 
conditions, macroporosity was generated by various microsphere degradation and erosion mechanisms 
after incubation of PLGA CPC in phosphate buffered saline (PBS)(12), or incubation of gelatin CPC 
and PTMC CPC in enzyme containing media(14,15). Although in an in vivo environment gelatin and 
PTMC degrading enzymes are present, degradation patterns can be different due to an altered fluid 
flow, buffer capacity and enzyme activity.  
Results from GPC analysis show that the molecular weight (Mn and Mw) of PLGA microspheres 
within the composites decreased continuously from the beginning, and were substantially degraded 
within 12 weeks of implantation. This degradation pattern was confirmed by compression strength 
data that showed a continuous and significant decrease over time. Also the SEM micrographs 
confirmed the complete disappearance of the microspheres after 8 and 12 weeks, whereas at 4 weeks 
microspheres are still present. These results correspond to an earlier performed in vitro degradation 
study(12) where microspheres prepared from PLGA with a similar molecular weight were applied. 
Evidently, the degradation mechanism of PLGA (hydrolysis, bulk erosion) is also valid in an in vivo 
environment. 
For gelatin microsphere CPCs it is difficult to investigate the microsphere degradation because both 
GPC and FTIR cannot be applied. Although water-phase GPC is available to investigate the molecular 
weight of proteins, gelatin consists of a wide range of different molecular weights and does not give a 
clear Gaussian distribution. Holland et al(19) used the microsphere swelling characteristics to determine 
hydrogel degradation, but in the gelatin CPCs microspheres are trapped inside a stiff calcium 
phosphate matrix. In addition, FTIR cannot be used to investigate in vivo microsphere degradation as 
gelatin does not give sharp, distinctive peaks and the percentage (5-10wt%) of microspheres is small 
compared to the cement phase. Furthermore, additional proteins that are absorbed by the cement will 
give a signal at the same place (1650 cm-1) as gelatin, as was also visible in the FTIR-curves of HMW 
PTMC CPC.  
Despite the fact that it is difficult to quantify gelatin microsphere degradation inside these composites, 
the gelatin microspheres do show degradation as next to the decrease in compression strength, a 
distinct increase in porosity of the composite was observed in SEM. Histological examination 
provided a better indication of the degradation mechanism for both GELB CPCs and PLGA/GELA 
CPCs. It was observed that microsphere degradation proceeded from the outside to the center of the 
material, which corresponds to the in vitro degradation behavior(15). It has to be noticed that GELA 
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CPC did not show this degradation pattern, as probably caused by the overall thicker shell of these 
microspheres, which is more difficult to degrade completely. Apparently, the combination of GELA 
and PLGA microspheres enhances the GELA microsphere degradation. This can be due to the higher 
porosity as generated after PLGA microsphere degradation that facilitates enzyme diffusion into the 
composite.  
Histological evaluation and investigation by SEM confirmed the ingrowth of cells at a distance of 
>100 µm into the GELA CPC, GELB CPC and PLGA/GELA CPC composites, which indicates that 
the porosity generated by the microspheres was interconnected(27). Nevertheless, cell ingrowth never 
reached the center of the implant as was observed by Link et al(28) with PLGA CPC.  A too small size 
of the PLGA microspheres(28) or the formation of calcium phosphate precipitate in or onto the gelatin 
microspheres(13, 15) could have hampered connectivity of the pores in our study and hindered tissue 
ingrowth.  
Analysis with FTIR revealed that both LMW PTMC CPCs and HMW PTMC CPCs showed 
microsphere degradation as the percentage of PTMC inside the composites significantly decreased 
upon subcutaneous implantation. Furthermore, SEM-investigation showed that the HMW PTMC 
microspheres became smaller than the surrounding spherical hole, which indicates the occurrence of 
surface erosion of the microspheres.  
No significant differences in degradation rate between the LMW PTMC and HMW PTMC were 
observed and both formulations exhibited about 30% degradation at 12 weeks of implantation. 
Alternatively, studies by Zhang et al(16) where PTMC disks were implanted in the femur and tibia of 
rabbits, have shown that the highest molecular weight PTMC exhibits a faster in vivo degradation as 
the enzymes (lipases) degrade hydrophobic polymers, i.e. ones with higher molecular weights, faster 
than the lower molecular weight polymers. In a previous in vitro degradation experiment with PTMC 
CPCs in lipase solution(14), the highest molecular weight polymer microspheres (PTMC176, Mn = 176 
kDa) degraded even slower than the lower molecular weight microspheres (PTMC53, Mn = 53 kDa). 
The explanation for this observation was that the presence of a hydrophilic layer of poly(vinyl alcohol) 
(PVA) at the surface of the microspheres delayed PTMC degradation of the smaller HMW PTMC 
microspheres. In our study, the difference in molecular weight between the low and high molecular 
weight PTMC polymer (40 kDa to 444 kDa) was larger than in the previous experiment. Alternatively, 
also different environments or enzyme sources could have influenced the in vivo degradation of these 
PTMC CPC composites.  
In agreement with our previous in vitro degradation experiment, elongation of PTMC microspheres at 
a fracture surface was observed in SEM-micrographs(14). For the HMW PTMC CPCs, also 
agglomeration of the microspheres was observed. This is beneficial for tissue ingrowth as 
interconnections between pores will be present after microsphere degradation. Cracks that were 
observed in the HMW PTMC histology samples after incubation were due to swelling of the polymer 
in acetone and methyl methacrylate. 
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Finally, the histological grading data revealed that especially the implant interface of all 
microsphere/cement formulations showed a moderate inflammatory response as inflammatory cells 
were present between the fibrous tissue capsule and cement surface. This was in contrast to previous 
studies where CPC(29) or PLGA CPC(28) was subcutaneously implanted in goats as well as rats and only 
a limited inflammatory response was observed. The thickness of the fibrous capsule, however, was 
similar to these studies. An explanation for the higher inflammatory response at the implant interface 
can be found in the irregular shaped surface of the microsphere/calcium phosphate cement 
composites(29) that was caused by microsphere degradation. Also the animal model can influence the 
inflammatory response as the morphology of the skin and subcutaneous tissue of the rabbit are 
different compared with the rat and goat. Furthermore as all composites showed a similar tissue 
response, likely degradation products of the microspheres like lactic acid, or remaining gelatin(30) or 
glutaraldehyde(31) did not contribute to the inflammatory response. 
 
5. Conclusion 
Composites composed of calcium phosphate cement with incorporated PLGA, gelatin or PTMC 
microspheres showed in vivo degradation of the microspheres with corresponding decrease in 
mechanical strength. PLGA microspheres exhibited bulk erosion throughout the composites, whereas 
with gelatin type B degradation of the microspheres started at the outside and gradually proceeded to 
the inner part. Furthermore, with HMW PTMC, surface erosion of microspheres over time was 
observed. Histological analysis revealed that for all composites a similar tissue response was observed 
with a decreasing capsule thickness over time and a moderate inflammatory response between the 
fibrous capsule and cement surface. Overall, microsphere CPCs can be used to generate porous 
scaffolds in an in vivo environment after degradation of microspheres with various degradation/erosion 
mechanisms.  
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1. Closing remarks 
Calcium phosphate cement is a promising material for bone tissue engineering purposes due to its 
osteoconductive properties and perfect fit with the surrounding tissue when injected in situ. In 
addition, the calcium phosphate cement as used in this thesis has a very short setting time, good 
cohesion properties and high compression strength.  
 
1.1. Clinical performance 
In view of the above mentioned, the first challenge was to develop a microsphere/calcium phosphate 
cement composite with a comparable clinical performance as the original calcium phosphate cement. 
In previous studies, the clinical performance of PLGA microsphere/ calcium phosphate cement 
composites (PLGA CPCs) with respect to injectability and setting time was not an issue as the applied 
animal models (cranial defects, rats) acquired preset cement composites. In our studies with PLGA 
CPC, it was important not to deviate from the optimal L/P ratio (L/P =0.32) of the cement to obtain a 
microsphere/calcium phosphate cement composite with good setting and cohesion properties as well as 
high compression strengths. The optimal L/P ratio could be maintained upon incorporation of 10wt% 
PLGA microspheres and a composite with good injectability properties was achieved. On the other 
hand, upon the addition of 20wt% of PLGA microspheres L/P ratio had to be increased because the 
stiff PLGA microspheres affected the injectability properties, which resulted in a significant increase 
of the final setting time. Further, a 1% solution of Na2HPO4 was shown to be the best accelerator. 
For both gelatin and PTMC microspheres the same mixing parameters were used (low L/P ratio, 1% 
Na2HPO4), but still some extra changes were necessary. As gelatin is a hydrogel, microspheres had to 
be added in a swollen state to the cement to achieve a good distribution of microspheres and to avoid 
swelling of the microspheres after implantation. Also with respect to drug loading, microspheres had 
to be swollen first to prevent extensive binding of the protein to the cement. The high compressibility 
of these swollen microspheres improved injectability of the gelatin microsphere CPCs, but increased 
the final setting time even more than for the PLGA microspheres. Initial setting time only increased 
gradually, which enabled us to prepare a >50 vol% gelatin type A microsphere/calcium phosphate 
cement composite with an initial setting time of only 4 min. Furthermore, setting time of the gelatin 
microsphere CPCs was highly dependent on the type of microspheres and microsphere size as the use 
of smaller type B gelatin microspheres resulted in even more problems with cement setting. 
Incorporation of PTMC microspheres produced similar properties as the gelatin microsphere CPC with 
respect to setting time. Handling properties with these PTMC CPCs were hampered by the 
thermoplastic properties of the polymer, which acquired storage and processing of the microspheres in 
aqueous solution.  
Final mechanical properties of the microsphere CPCs (compression strength, E-modulus) were less 
than the original cement, but still a minimal compressive strength of 14 MPa was obtained. Upon 
degradation of the microspheres, compression strength decreased in all CPCs. For the PTMC 
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microsphere CPCs, some improvement of the elastic properties was observed as the strain-at-yield and 
toughness of the composite increased upon the addition of a higher percentage of PTMC microspheres. 
After brittle fracture of the cement, microspheres were elongated and kept the individual pieces 
together. 
 
1.2. Degradation 
The in vitro and in vivo degradation of these microsphere CPCs was also tailored, because 
microspheres were incorporated with different degradation and erosion mechanisms. Furthermore, the 
individual polymers as chosen for the preparation of the microspheres (PLGA, gelatin and PTMC) also 
showed a degradation pattern that can be customized by altering the molecular weight or crosslinking 
density. Overall, the PLGA microsphere CPC showed the highest applicability as porogen. 
Degradation rates of the PLGA microspheres were highly dependent on the molecular weight and 
produced a concomitant porosity through the composite. The production of acidic degradation 
products appeared even to increase the in vitro cement dissolution.  
Gelatin microspheres showed a more gradual degradation, i.e. the microspheres degraded from the 
outside to the center of the composite. Such a degradation mechanism has to be preferred, because it 
fits to the process of bone formation (ingrowth). On the other hand, a high amount of gelatin 
microspheres was needed to produce porosity as gelatin degrading enzymes have a strong affinity with 
the cement. Calcium phosphate precipitate onto the biomimetic gelatin also hampered 
interconnectivity of the microspheres. The crosslinking density of the gelatin microspheres did not 
influence in vitro degradation inside the composites, but it has to be noticed that non-crosslinked 
microspheres were not stable upon mixing.  
In the in vitro study, PTMC CPC showed a similar degradation mechanism as gelatin. The surface 
erosion of the PTMC microspheres resulted in a fast decrease of the compression strength of the 
PTMC CPC. However, the in vivo degradation was substantially different and was characterized by a 
gradual decrease in compression strength and slower overall degradation. This discrepancy between in 
vitro and in vivo results was due to the high amount of PTMC degrading enzyme as used in the in vitro 
degradation experiment. The molecular weight of the PTMC microspheres did not influence 
degradation in a high extent, which can be caused by the presence of hydrophilic PVA at the surface of 
the microspheres.  
 
1.3. Drug delivery 
In this study, the different microspheres were also used as a drug delivery vehicle for osteoinductive 
growth factors. With PLGA, previous studies have already shown to provide a sustained in vivo 
release of growth factor with an additional enhancement of bone ingrowth. The current in vitro BSA 
release study questions whether PLGA microspheres are indeed the most suitable vehicle for drug 
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delivery, because no retention of BSA structure was observed and release (from the cement) was 
hampered by the pH decrease.  
Gelatin microspheres showed a more favorable in vitro release pattern with even a linear sustained 
release in time, which was tailored by changing the type of gelatin, amount of microspheres and 
loading mechanism. BSA release from the gelatin type A microsphere CPC, also showed retention of 
protein structure and substantial higher release efficiencies than the PLGA CPC. Compared to the 
PLGA CPC, the loading mechanism for the gelatin microsphere CPCs is also more favorable as 
microspheres are loaded directly before mixing with the cement powder without any substantial loss or 
exposure to organic solvents. A drawback is the low binding efficiency between the gelatin 
microspheres and growth factors or drugs, which results in substantial dispersion of the drug through 
the cement during composite preparation.  
PTMC microspheres can also be used as a vehicle for drug delivery, but the present preparation 
process of the PTMC CPCs where microspheres are stored in aqueous solutions is not optimal for drug 
entrapment efficiency and has to be altered before further exploration of their use in CPC. 
 
1.4. General conclusions 
To conclude, this thesis shows that calcium phosphate cement with various biodegradable 
microspheres can produce macroporosity during in vitro/in vivo degradation and still possesses 
appropriate clinical handling properties. Furthermore, the in situ formation of macroporosity and drug 
release characteristics of the different microsphere composites can be tailored by choosing a polymer 
with a different degradation or erosion pattern. 
 
2. Future perspectives 
In view of the studies performed in this thesis some future perspectives can be given regarding the 
final application of a microsphere CPC for tissue engineering purposes.  
 
2.1. Combinations of different types of microspheres 
The various studies as presented in this thesis have shown that the addition of various types of 
microspheres into CPC results in a wide range of degradation patterns and alters the handling 
properties of the CPC. Therefore, by combining different kinds of microspheres into one specific 
composite it is possible to obtain a composite with customized degradation rates, release 
characteristics and handling properties. Especially, the following combinations of microspheres are 
worth further investigation: 
• PLGA and gelatin (type A or B) microsphere CPC 
A combination of PLGA with gelatin microspheres, as already tested in our in vivo experiment can 
combine the tailored degradation rates of the PLGA with the sustained drug release characteristics 
of the gelatin. Furthermore, the porosity generated after PLGA degradation can improve gelatin 
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microsphere degradation and alternatively the remaining gelatin microspheres provide mechanical 
strength to the inner parts of the cement. Also, such a mix is favorable for the handling properties 
of the CPC, since the flexible gelatin microspheres will compensate for the decreased injectability 
of the PLGA microspheres, and even will allow the incorporation of a high amount of large 
microspheres (several 100 µm’s) without the problems of clogging at the syringe opening.  
• PLGA and PTMC microsphere CPC   
Similar to the previous composite, a combination of PLGA microspheres with PTMC 
microspheres is an interesting option. The unique elastic properties of the PTMC microspheres 
will improve the mechanical properties of the CPC.  
• Gelatin type A and gelatin type B microsphere CPC 
Incorporation of gelatin type A and type B microspheres in one composite can be used for the 
sustained release of basic and/or acidic growth factors. Also, the opposite charge of the different 
gelatins can be used to form interconnections between the microspheres. 
Another promising combination is the use of different molecular weights of PLGA microspheres. The 
formation of macroporosity could be modified in this way, but to obtain an interconnective matrix 
after microsphere degradation the faster degrading microspheres have to be situated at the outside of 
the composite and the slower degrading microspheres at the center.  
 
2.2. Other adjustment of microsphere CPC 
Besides the combination of different types of microspheres, also others adjustments can be made to 
improve the handling properties, degradation and release characteristics of the microsphere CPCs.  
When the material is injected in situ the presence of blood and body fluids hampers occasionally the 
setting reaction and influences the cohesion of the composite. For gelatin microsphere CPC the 
amount of liquid hardener added during the second step can be decreased within a certain range, which 
will result in a viscous, but still injectable paste. In case of bleeding at the implant site, cohesion will 
then be retained as the blood will be adsorbed by the gelatin.  
One of the most important parameters for degradation of the included polymeric microspheres and 
subsequent tissue ingrowth is the interconnectivity of the pores. In addition to the use of a high amount 
(vol%) of microspheres, interconnections between microspheres (pores) can also be obtained by 
agglomeration of microspheres. Evidence of this mechanism has been found with (HMW) PTMC 
microspheres and is probably caused by the plastic deformation of the polymer during cement mixing.  
From the gelatin release study, we can also conclude that when the drug is adsorbed onto the cement, 
the cement scaffold itself can be a suitable drug delivery vehicle. Depending on the final clinical 
application of the injectable CPC, a possibility is the addition of a growth factor solution after in situ 
initial setting of the material.  
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2.3. Modifications in study design 
Some modifications in the design of the in vitro or in vivo studies can be made, which will provide 
more insight in the clinical performance, degradation characteristics and drug release kinetics of these 
composites.  
Previous in vitro studies have shown that the used calcium phosphate cement reaches its maximum 
compression strength after 3 days of incubation in a liquid environment. From the performed in vivo 
study it can be questioned whether this is indeed true in an in vivo environment as proteins that are 
present in the body fluids can interfere with the setting reaction and resulting mechanical properties. A 
simple test where preset disks or injectable materials are incubated in cell-culture medium or 
(simulated) body fluid already can provide a lot of information about these issues. Besides 
compression strength measurements, also other mechanical tests can be performed on the different 
microsphere CPCs, like three-point bending, which will provide more information about the added 
(elastic) properties of the microspheres.  
Further, a flow perfusion system has to be applied during in vitro degradation and release studies to 
mimic more accurately the in vivo conditions. As such a system acquires the use of a high volume of 
medium, release from these composites can be analyzed by measuring the retention of a (radioactive) 
labeled drug.  
Finally, other in vivo investigations are necessary, which include the application of different injectable 
microsphere CPCs in a wide variety of clinically relevant bone defects.  In addition to the histological 
examination, techniques like gel permeation chromatography (GPC) and attenuated total reflectance 
Fourier transform infrared spectroscopy (ATR-FTIR) have to be used to evaluate PLGA and PTMC 
microsphere degradation in vivo.  
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1. Summary and address to the aims 
In the field of dentistry, plastic and reconstructive surgery and orthopedics, calcium phosphate 
ceramics/cements are promising implant materials that are often applied for filling bone defects. 
Especially calcium phosphate cements have a high potential as next to their osteoconductivity they 
exhibit a perfect contact with the surrounding tissue when injected in situ. A disadvantage is the slow 
resorbability of these materials, thereby causing difficulties with respect to brittle fracture after longer 
implantation periods. Tissue engineering is a new field of science that aims to develop implants that 
can restore, maintain or improve the functions of the original tissue by the use of combining expertise 
on medical science, biology and engineering. By the use of a construct that is biodegradable, forms a 
suitable matrix for tissue (in)growth and is a vehicle for growth factors one can synthesize an implant 
that is gradually replaced by the hosts own tissue thereby prohibiting post-operative failure of the 
implant. The introduction of macroporosity is one way to make a calcium phosphate cement more 
suitable for tissue engineering purposes as it promotes bone ingrowth and increases bioresorption of 
the material. The resulting macroporosity should be interconnected and large enough to guide tissue 
ingrowth, however, should not decease the clinical performance of the cement with respect to handling 
properties, setting and mechanical strength.  
The main goal of this research was to develop a calcium phosphate cement that is suitable for bone 
tissue engineering purposes and furthermore still possesses a good clinical performance. This was 
done by the incorporation of biodegradable microspheres where porosity is formed after microsphere 
degradation. Secondly, these microspheres can be used as delivery vehicle for osteoinductive drugs. 
 
1.1. Injectable PLGA microsphere/calcium phosphate cement composites: physical properties and 
degradation characteristics  
In chapter 2 we aimed to develop poly(lactic-co-glycolic)acid (PLGA) microsphere/calcium phosphate 
cement composites (PLGA CPCs) with appropriate setting/cohesive properties and good 
mechanical/physical characteristics. Secondly, we investigated the in vitro degradation characteristics 
of preset samples. Therefore, 10/90 and 20/80 dry wt% PLGA microsphere/calcium phosphate cement 
composites were prepared as well as CPC controls. Injectability, setting time, cohesive properties and 
porosity were determined. Also, a 12-week degradation study in PBS (37°C) was performed. Results 
showed that injectability decreased with an increase in PLGA microsphere content. Initial and final 
setting time of the PLGA CPC was higher than the original CPC. Porosity of the different formulations 
was 40.8% (CPC), 60.2% (10/90) and 69.3% (20/80). The degradation study showed distinct mass loss 
and a pH decrease of the surrounding medium starting from week 6 with the 10/90 and 20/80 
formulations, indicating PLGA erosion. Compression strength of the PLGA CPC samples decreased 
siginificantly in time, the CPC control remained constant. After 12 weeks, both PLGA CPC 
formulations showed a structure of spherical pores and compression strengths of 12.2MPa (10/90) and 
4.3 MPa (20/80) were obtained. Signs of cement degradation were also found with the 20/80 
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formulation. In conclusion: all physical parameters were well within workable ranges with both 10/90 
and 20/80 PLGA microsphere/calcium phosphate cement composites. After 12 weeks the PLGA was 
totally degraded and a highly porous scaffold remained. 
 
1.2. PLGA microsphere/calcium phosphate cement composites for tissue engineering: in vitro 
release and degradation characteristics  
In chapter 3 we tried to elucidate the drug release mechanism of PLGA CPC. Therefore, both in vitro 
degradation characteristics and drug release pattern of the PLGA CPC were determined using bovine 
serum albumin (BSA) as a model protein. Two loading mechanisms were applied; BSA was adsorbed 
onto the microspheres or incorporated into the microspheres during double-emulsion. BSA release 
from PLGA microspheres and CPC was also measured and used as reference. Results show fast 
degrading polymer microspheres, which produced a macroporous scaffold within 4 weeks but also 
showed a concomitant release of acidic degradation products. BSA release from the PLGA CPC was 
similar to the CPC samples and showed a pattern consisting of a small initial release, followed by a 
period of almost no sustained release. Separate PLGA microspheres exhibited a high burst release and 
release efficiency that was higher with the adsorbed samples. For the PLGA CPC samples, the BSA 
readsorbed to the cement surface after being released from the microspheres. This process was 
mediated by the pH decrease during microsphere degradation. 
 
1.3. Introduction of gelatin microspheres into an injectable calcium phosphate cement   
In chapter 4 we developed gelatin microsphere/calcium phosphate cement composites and investigated 
their handling properties and in vitro degradation characteristics. Therefore, setting time and 
injectability were determined and an in vitro degradation study was performed. Samples were assayed 
on mass, compression strength, E-modulus and morphology. A supplementary degradation test with 
gelatin microspheres was performed to investigate the influence of physical conditions inside the 
cement on microsphere stability. Results showed that the gelatin microsphere CPCs were easy to inject 
and showed initial setting times of less than 3 min. After 12 weeks in vitro degradation no increase in 
macroporosity was observed, which was supported by the small mass loss and stabilizing mechanical 
strength. Even a clear densification of the composite was observed. Explanations for the lack of 
macroporosity were recristallization of the cement onto or inside the gelatin spheres and a delayed 
degradation of gelatin microspheres inside the scaffold. The supplementary degradation test showed 
that the pH is a factor in the delayed gelatin microsphere degradation. Also differences in degradation 
rate between types of gelatin were observed. Overall, the introduction of gelatin microspheres into 
CPC renders composites with good handling properties, though the degradation characteristics should 
be further investigated to generate a macroporous scaffold. 
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1.4. Porcine gelatin microsphere/calcium phosphate cement composites: in vitro degradation and 
protein release  
In chapter 5 a porcine gelatin (type A) microsphere/calcium phosphate cement composite was 
formulated. Secondly, the in vitro degradation and release characteristics of preset composites were 
investigated. Therefore, the in vitro degradation of 10wt% gelatin type A microsphere CPCs (GELA 
CPCs) was followed for 12 weeks in proteolytic medium. Composites were loaded with bovine serum 
albumin (BSA) by swelling of gelatin microspheres in a BSA solution for a short (instant) and longer 
(prolonged) period. In vitro BSA-release was analyzed by reversed-phase high performance liquid 
chromatography (RP-HPLC), structural stability of BSA was monitored by SDS-PAGE. Results of the 
degradation test for the GELA CPC showed a gradual decrease in mass, compression strength and E-
modulus. Morphology investigation showed that degradation of the spheres started at the surface of the 
composite and gradually proceeded to the inner part. From the release assay it was concluded that the 
BSA release pattern of GELA CPCs can be altered within certain ranges by changing the loading 
mechanism. No initial burst was observed and release efficiencies up to 43% after 63 days were 
obtained. From these results we can conclude that GELA microspheres can be used to generate in situ 
macroporosity into an injectable calcium phosphate cement and tailor release properties from these 
gelatin microsphere CPC composites. 
 
1.5. In vitro growth factor release from injectable calcium phosphate cements containing gelatin 
microspheres  
In chapter 6 we investigated the in vitro growth factor release from various gelatin microsphere CPCs. 
For this, recombinant human TGF-β1, bFGF and BMP-2 were labeled with 125I and loaded onto gelatin 
type A/type B microspheres for a short (instant) and longer (prolonged) time before mixing them with 
the cement. Radioactivity of the resulting 5 or 10wt% gelatin microsphere CPC composites was 
monitored for 6 weeks when subjected to proteolytic medium. Drug-loaded CPC was used as control. 
Results showed that release pattern/efficiency of gelatin microsphere CPCs and CPC controls was 
highly dependent on the type of growth factor but unaffected by the amount of growth factor. With 
gelatin microsphere CPC, release was also dependent on the type of gelatin, total volume of 
incorporated microspheres and loading method. 
 
1.6. Introduction of enzymatically degradable poly(trimethylene carbonate) microspheres into an 
injectable calcium phosphate cement  
In chapter 7 we developed calcium phosphate cements with incorporated enzymatically degradable 
PTMC microspheres (PTMC CPCs) and investigated their physical/mechanical properties and in vitro 
degradation characteristics. Therefore, composites were tested on setting time and mechanical strength 
as well as subjected to phosphate buffered saline (PBS) and enzyme containing medium. PTMC CPCs 
(12.5 and 25wt%) with molecular weights of  52.7 kg⋅mol-1 and 176.2 kg⋅mol-1 were prepared, which 
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showed initial setting times similar to the original CPC. Though compression strength decreased upon 
incorporation of PTMC microspheres, elastic properties were improved as strain-at-yield increased 
with increasing content of microspheres. Sustained degradation of the microspheres inside the PTMC 
CPC occurred when incubated in the enzymatic environment, but not in PBS, which resulted in an 
interconnected macroporosity for the 25 wt% composites.  
 
1.7. In vivo degradability of calcium phosphate cement with incorporated biodegradable 
microspheres  
In chapter 8 we investigated the influence of the microsphere degradation or erosion mechanism on the 
in vivo degradation of microsphere/calcium phosphate cement composites (microsphere CPCs) for 
tissue engineering. Microspheres composed of poly(lactic-co-glycolic acid) (PLGA), gelatin and 
poly(trimethylene carbonate) (PTMC) were used as models and the resulting microsphere CPCs were 
implanted subcutaneously for 4, 8 and 12 weeks in the back of New Zealand white rabbits. Besides 
degradation, the soft tissue response to these formulations was evaluated. After retrieval, specimens 
were analyzed by physicochemical characterization and histological analysis. 
Results showed that all microsphere CPCs exhibited microsphere degradation after 12 weeks of 
subcutaneous implantation, which was accompanied by a decrease in compression strength. The 
PLGA microspheres exhibited bulk erosion throughout the whole composite, whereas in the case of 
gelatin degradation of the microspheres preceded from the outside to the center of the composite. High 
molecular weight PTMC microspheres exhibited surface erosion, which resulted in decreasing 
microsphere sizes. All composites showed a similar tissue response with a decreasing capsule 
thickness over time and a persisting moderate inflammatory response at the implant interface. In 
conclusion: microsphere CPCs can be used to generate porous scaffolds in an in vivo environment 
after degradation of microspheres with various degradation/erosion mechanisms. 
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1. Samenvatting en realisatie van de doelstellingen 
Op het gebied van de tandheelkunde, plastische en reconstructieve chirurgie en orthopedie 
zijn calcium fosfaat cementen/keramieken veelbelovende materialen die vaak worden 
toegepast voor het opvullen van botdefecten. Met name calcium fosfaat cementen (CPC’s) 
hebben een goede potentie omdat ze naast osteoconductiviteit een perfect contact hebben met 
het onringende weefsel wanneer ze in situ worden geinjecteerd. Een nadeel van deze 
cementen is de langzame degradatie waardoor problemen kunnen optreden zoals een brosse 
breuk na langere implantatieperioden. Tissue Engineering is een nieuw wetenschapsgebied 
waarbij het doel is om implantaten te maken die de functies van het originele weefsel kunnen 
vervangen, behouden of verbeteren door het samenvoegen van expertise op het gebied van 
medicijnen en natuurwetenschappen. Door het gebruik van een biologisch degradeerbaar 
construct dat een geschikte matrix vormt voor weefselingroei en een vector vormt voor 
groeifactoren, kan men een implantaat maken dat langzaam wordt vervangen door het eigen 
weefsel en zo post-operatieve complicaties kan voorkomen. Het introduceren van 
macroporositeit is een manier om calcium fosfaat cement geschikt te maken voor tissue 
engineering omdat het de ingroei van bot vergemakkelijkt en degradatie versnelt. De 
verkregen macroporositeit zou hierbij interconnectief en groot genoeg moeten zijn voor 
botingroei, hoewel, het mag ook niet de performance van het cement verminderen betreffende 
hanteerbaarheid, uitharding en mechanische sterkte. 
Het doel van dit onderzoek was het ontwikkelen van een calcium fosfaat cement dat geschikt 
is voor tissue engineering en tevens een goede clinische performance bezit. Dit werd bereikt 
door het incorpereren van biodegradeerbare microsferen in cement, waar porositeit verkregen 
wordt na degradatie van de microsferen. Tevens kunnen deze microsferen gebruikt worden als 
vector voor osteoinductieve groeifactoren.  
 
1.1. Injecteerbare PLGA microsfeer/calcium fosfaat cement composieten: physische 
eigenschappen en degradatie karakterististieken  
Het doel van hoofdstuk 2 was het ontwikkelen van een poly(melk-co-glycol)zuur (PLGA) 
microsfeer/calcium fosfaat cement composiet (PLGA CPC) met geschikte uithardings,- en 
cohesieve eigenschappen en goede mechanische/ physische karakteristieken. Tevens 
onderzochten we de in vitro degradatie van uitgeharde samples. 10/90 en 20/80 wt% PLGA 
CPC’s en CPC (referentie) werden gesynthetiseerd waarvan de injecteerbaarheid, uithardtijd 
en cohesieve eigenschappen werden bepaald. Ook werd er een degradatiestudie uitgevoerd in 
PBS (37°C) voor 12 weken. Resultaten lieten een afname in injecteerbaarheid zien met een 
grotere hoeveelheid geincorpereerde PLGA microsferen. Initiele en finale uithardtijd van het 
PLGA CPC waren hoger dan die van het originele CPC. Porositeit van de verschillende 
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formuleringen was 40.8% (CPC), 60.2% (10/90) en 69.3% (20/80). Na 6 weken liet de 
degradatiestudie voor beide formuleringen een duidelijke afname in massa zien en pH van het 
omringende medium, wat indicatief is voor PLGA degradatie. De compressiesterkte van de 
PLGA CPC samples in de tijd liet een siginificante afname zien, waar de CPC controle 
constant bleef. Na 12 weken was bij beide PLGA CPC formuleringen een structuur van 
sferische porien zichtbaar en werden compressiesterktes van 12.2MPa (10/90) en 4.3 MPa 
(20/80) verkregen. De 20/80 formulering liet ook tekens van cement degradatie zien. In 
conclusie: alle mechanische/fysische parameters zijn binnen clinisch aanvaardbare waarden 
voor beide 10/90 en 20/80 PLGA microsfeer/calcium fosfaat cement composieten. Na 12 
weken was het PLGA volledig degradadeerd resulterend in een poreuze matrix.  
 
1.2. PLGA microsfeer/calcium fosfaat cement composieten voor tissue engineering: in vitro 
afgifte en degradatie eigenschappen  
In hoofdstuk 3 probeerden we het mechanisme van eiwit/medicijnen afgifte uit het PLGA 
CPC op te helderen. Daarvoor werden zowel de in vitro degradatie eigenschappen bepaald als 
het eiwit/medicijnen afgifte patroon van het PLGA CPC met behulp van albumine (BSA) als 
model eiwit. Twee ladingsmechanismen werden toegepast; BSA werd geadsorbeerd op de 
microsferen of geincludeerd tijdens de microsfeer synthese (dubbele emulsie). BSA afgifte uit 
PLGA microsferen en CPC werd ook gemeten en gebruikt als referentie. De resultaten lieten 
microsferen  zien die snel degradeerden en een poreuze matrix vormden binnen 4 weken maar 
tevens zure degradatieproducten produceerden. BSA afgifte uit the PLGA CPC was indentiek 
aan het CPC en bestond uit een kleine initiele afgifte gevolgd door een periode waarbij de 
afgifte minimaal was. Afzonderlijke PLGA microsferen lieten een hoge initiele afgifte en 
efficientie zien, welke het hoogst was bij de samples waar BSA was geadsorbeerd op de 
microsferen. In het algemeen kan men concluderen dat voor het PLGA CPC, BSA weer 
adsorbeert op het cementoppervlak na afgifte uit de microsferen. Dit proces wordt 
gecatalyseerd door de pH afname tijdens de degradatie van de microsferen. 
 
1.3. De introductie van gelatine microsferen in een injecteerbaar calcium fosfaat cement  
Hoofdstuk 4 beschijft de ontwikkeling van gelatine microsfeer/calcium fosfaat cement 
composieten (gelatine microsfeer CPC’s), waarbij is gekeken naar de clinische toepasbaarheid 
en in vitro degradatie-eigenschappen van deze materialen. Hiervoor werden de uithardtijd en 
injecteerbaarheid van het composiet bepaald en werd er een in vitro degradatiestudie 
uitgevoerd waarbij samples werden onderzocht op massa, compressiesterkte, E-modulus en 
morfologie. Een supplementaire degradatietest met gelatine microsferen werd uitgevoerd om 
de invloed van fysiche omstandigheden in het cement, zoals pH en calcium concentratie, op 
de stabiliteit van de microsferen te onderzoeken. Resultaten toonden aan dat het gelatine 
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microsfeer CPC makkelijk te injecteren was en een initiele uithardtijd had van minder dan 3 
minuten. Na 12 weken in vitro degradatie was er geen toename in macroporositeit. Dit werd 
gestaafd door de kleine afname in massa en stabiele mechanische sterkte. Er werd zelfs een 
duidelijke verdichting van het composiet geconstateerd. De uitleg voor het gebrek aan 
macroporositeit was kristallisatie van het cement op de gelatine microsferen en een vertraagde 
degradatie van de microsferen in het cement. De supplementaire degradatietest liet zien dat de 
pH een belangrijke factor is in deze vertraagde degradatie. Daarnaast werden er ook 
verschillen in degradatiesnelheid geobserveerd tussen verschillende soorten gelatines. 
Concluderend, de introductie van gelatine microsferen in CPC levert composieten met een 
goede hanteerbaarheid, hoewel de degradatie-eigenschappen verbeterd moeten worden om 
een macroporeuze matrix te produceren. 
 
1.4. Gelatine type A microsfeer/calcium fosfaat cement composieten: in vitro degradatie en 
eiwitafgifte 
In hoofdstuk 5 werd er een gelatine type A microsfeer/calcium fosfaat cement composiet 
geformuleerd waarvan de in vitro degradatie-eigenschappen en het eiwit/medicijn-
afgiftepatroon werden onderzocht. Hiervoor werd de in vitro degradatie van 10wt% gelatine 
type A microsfeer CPC (GELA CPC) gevolgd voor in totaal 12 weken in proteolytisch 
medium. Daarnaast werden composieten geladen met albumine (BSA) door gelatine 
microsferen te zwellen in een BSA oplossing voor een korte (instantane) en langere 
(verlengde) periode. In vitro BSA-afgifte werd geanalyseerd door reversed-phase high 
performance liquid chromatography (RP-HPLC), structurele stabiliteit van het BSA werd 
gevolgd met behulp van SDS-PAGE. Resultaten van de degradatietest voor het GELA CPC 
vertoonden een geleidelijke afname in massa, compressiesterkte en E-modulus in de loop van 
de tijd. Morfologisch onderzoek toonde aan dat de degradatie van de microsferen begon aan 
het oppervlak van het composiet en geleidelijk doorzette naar het midden. Resultaten van het 
BSA-afgifte experiment lieten zien dat het BSA-afgiftepatroon uit het GELA CPC kan 
worden gevarieerd door het veranderen van het ladingsmechanisme. Geen initiele afgifte 
werd geconstateerd en na 63 dagen werden efficienties van 43% verkregen. Gelatine  type A 
microsferen kunnen dus gebruikt worden om in situ macroporositeit te verkrijgen in een 
injecteerbaar calcium fosfaat cement en kunnen tevens gebruikt worden om 
eiwit/medicijnafgifte te reguleren van deze gelatine microsfeer/CPC composieten.  
 
1.5. In vitro afgifte van groeifactoren uit een injecteerbaar gelatine microsfeer/calcium 
fosfaat cement composiet 
In hoofdstuk 6 werd de in vitro afgifte van groeifactoren uit verschillende gelatine 
microsfeer/calcium fosfaat cement composieten onderzocht. Hiervoor werd recombinant 
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humaan TGF-β1, bFGF and BMP-2 gelabeled met 125I en geladen in gelatine type A/type B 
microsferen voor een korte (instantane) en langere (verlengde) periode. Radioactiviteit van de 
resulterende 5 of 10wt% gelatine microsfeer CPC’s werd gevolgd voor 6 weken in proteo-
lytisch medium. Groeifactor-geladen CPC werd gebruikt als referentie. Resultaten toonden 
aan dat het afgifte patroon en de efficientie afhankelijk waren van het type groeifactor maar 
niet afhankelijk van de hoeveelheid geladen groeifactor. De afgifte uit de gelatine microsfeer 
CPC’s was ook afhankelijk van het type gelatine, het totale volume aan geincorpereerde 
microsferen en het ladingsmechanisme.  
 
1.6. Introductie van enzymatisch degradeerbare poly(trimethyleen carbonaat) microsferen 
in een injecteerbaar calcium fosfaat cement  
In hoofdstuk 7 werd er een poly(trimethyleen carbonaat) PTMC microsfeer/calcium fosfaat 
cement composiet geformuleerd waarvan de fysische/mechanische eigenschappen en in vitro 
degradatie eigenschappen werden onderzocht. Hiervoor werden composieten getest op 
uithardtijd en mechanische sterkte alsook geincubeerd in fosfaat gebufferde zoutoplossing 
(PBS) en enzym bevattend medium. PTMC CPC’s  (12.5 en 25 wt%) met molecuulgewichten 
van 52.7 kg⋅mol-1 en 176.2 kg⋅mol-1 werden gesynthetiseerd met een uithardtijd identiek aan 
het originele CPC. Alhoewel de compressiesterkte afnam met de introductie van PTMC 
microsferen, vertoonden de elastische eigenschappen een verbetering doordat de strain-at-
yield toenam met een toename in hoeveelheid geincorpereerde microsferen. Geleidelijke 
degradatie van de microsferen in het PTMC CPC vond plaats in het enzymatisch milieu, maar 
niet in PBS, resulterend in een interconnectieve, macroporeuze matrix voor de 25wt% 
composieten.  
 
1.7. In vivo degradatie van calcium fosfaat cement geincorpereerd met biodegradeerbare 
microsferen  
In hoofdstuk 8 is gekeken naar de invloed van het microsfeer degradatie/erosie mechanisme 
op de in vivo degradatie van microsfeer/calcium fosfaat cement composieten voor tissue 
engineering. Microsferen gemaakt van PLGA, gelatine en PTMC werden hiervoor gebruikt 
als model en subcutaan geimplanteerd voor 4, 8 en 12 weken in een konijnenstudie. Behalve 
degradatie werd ook de (zachte) weefsel reactie op deze formuleringen onderzocht. Na het 
verkrijgen van de specimens werden ze geanalyseerd op physicochemische eigenschappen en 
histologie.   
Resultaten lieten zien dat alle formuleringen degradatie vertoonden na 12 weken subcutane 
implantatie. Het PLGA CPC vertoonde bulkerosie van de microsferen door het hele 
implantaat, terwijl gelatine microspheren eerst degradeerden aan de oppervalkte van het 
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composiet. Hoog moleculair gewicht PTMC microsferen vertoonden oppervlakte-erosie, 
resulterend in een afname van de microsfeerdiameter. Uit histologisch onderzoek kwam naar 
voren dat alle composieten een vergelijkbare weefselreactie vertoonden met een afname in 
kapseldikte en een gematigde inflammatiereactie op het implantaatoppervlak. Concluderend, 
de onderzochte microsfeer/CPC formuleringen kunnen gerbruikt worden om een poreuze 
matrix te genereren na microsfeer degradatie in een  in vivo omgeving.  
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Color Figures 
 
Figure 9A. Histological sections 
PLGA CPCs at 4, 8 and 12 weeks of 
subcutaneous implantation, C = 
cement, M = microsphere, F = fibrous 
capsule, arrows denote tissue 
ingrowth in microspheres (bar 
represents 25µm) 
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Figure 9B. Histological sections of microsphere CPCs after 12 weeks of implantation; PLGA CPC (1), 
GELA CPC (2), GELB CPC (3), PLGA/GELA CPC (4), LMW PTMC  CPC (5) and HMW PTMC 
CPC (6), arrows denote tissue ingrowth with GELB CPC, dashed arrow denotes shell gelatin micro-
sphere (bar represents 100 µm). 
 
 
